BIOCRYST PHARMACEUTICALS INC
FORM 10-K
(Annual Report)
Filed 3/14/2007 For Period Ending 12/31/2006
Address
2190 PARKWAY LAKE DR
BIRMINGHAM, Alabama 35244
Telephone
CIK
Industry
Sector
Fiscal Year
205-444-4600
0000882796
Biotechnology & Drugs
Healthcare
12/31
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended December 31, 2006
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
For the transition period from to .
OR
(cid:3)
(cid:1)
Commission File Number 000-23186
BIOCRYST PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of other jurisdiction of
incorporation or organization)
62-1413174
(I.R.S. employer identification no.)
2190 Parkway Lake Drive; Birmingham, Alabama 35244
(Address of principal executive offices)
(205) 444-4600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, $.01 Par Value
Name of each exchange on which registered
The NASDAQ Stock Global Market LLC
Securities registered pursuant to Section 12(g) of the Act:
Title of each class
None
Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes (cid:1) No (cid:3) .
Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Yes (cid:1) No (cid:3) .
Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes (cid:3) No (cid:1) .
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (Section 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
(cid:3) .
Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of
“accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act). (Check One):
Large accelerated filer (cid:1) Accelerated filer (cid:3) Non-accelerated filer (cid:1)
Indicate by a check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).
Yes (cid:1) No (cid:3) .
The Registrant estimates that the aggregate market value of the Common Stock on June 30, 2006 (based upon the closing price shown on the
NASDAQ Global Market SM on June 30, 2006) held by non-affiliates was approximately $298,330,997. For this computation, the Registrant
has excluded the market value of all shares of its Common Stock reported as beneficially owned by officers, directors and certain significant
stockholders of the Registrant. Such exclusion shall not be deemed to constitute an admission that any such stockholder is an affiliate of the
Registrant.
The number of shares of Common Stock, par value $.01, of the Registrant outstanding as of March 7, 2007 was 29,342,854 shares.
Portions of the Registrant’s definitive Proxy Statement to be filed in connection with the solicitation of proxies for its 2006 Annual Meeting of
Stockholders are incorporated by reference into Items 10, 11, 12, 13 and 14 under Part III hereof.
DOCUMENTS INCORPORATED BY REFERENCE
TABLE OF CONTENTS
PART I
ITEM 1. BUSINESS
ITEM 1A. RISK FACTORS
ITEM 1B. UNRESOLVED STAFF COMMENTS
ITEM 2. PROPERTIES
ITEM 3. LEGAL PROCEEDINGS
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
ITEM 6. SELECTED FINANCIAL DATA
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATION
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
ITEM 9A. CONTROLS AND PROCEDURES
ITEM 9B. OTHER INFORMATION
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
ITEM 11. EXECUTIVE COMPENSATION
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
SIGNATURES
INDEX TO EXHIBITS
EX-10.12 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT
EX-23 CONSENT OF ERNST & YOUNG
EX-31.1 SECTION 302 CERTIFICATION OF THE CEO
EX-31.2 SECTION 302 CERTIFICATION OF THE CFO
EX-32.1 SECTION 906 CERTIFICATION OF THE CEO
EX-32.2 SECTION 906 CERTIFICATION OF CFO
Table of Contents
PART I
ITEM 1. BUSINESS
Forward-Looking Statements and Risk Factors
This report includes forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives or assumptions
of future events or performance are contained or incorporated by reference in this report. We have based these forward-looking statements on
our current expectations about future events. While we believe these expectations are reasonable, forward-looking statements are inherently
subject to risks and uncertainties, many of which are beyond our control. Our actual results may differ materially from those suggested by these
forward-looking statements for various reasons, including those discussed in this report under the heading “Risk Factors” beginning at page 17.
Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking
statements included in this report are made only as of the date hereof. We do not undertake and specifically decline any obligation to update
any of these statements or to publicly announce the results of any revisions to any forward looking statements to reflect future events or
developments. When used in the report, unless otherwise indicated, “we,” “our” and “us” refers to BioCryst Pharmaceuticals, Inc.
Overview
BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes
involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. BioCryst integrates the necessary disciplines of biology,
crystallography, medicinal chemistry and computer modeling to effectively use structure-based drug design to discover and develop small
molecule pharmaceuticals.
Our lead product candidate, Fodosine™, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase
(“PNP”). The compound is currently in a Phase IIb trial, which is planned to be a pivotal trial, for patients with T-cell acute lymphoblastic
leukemia (“T-ALL”). The trial is being conducted under a special protocol assessment (“SPA”) negotiated with the U.S. Food and Drug
Administration (“FDA”). Additionally, Fodosine™ is currently being studied in a Phase I/II trial with an oral formulation in cutaneous T-cell
lymphoma (“CTCL”) and we are in active discussions with the FDA to determine what would be required to initiate a pivotal trial in CTCL
during 2007. Fodosine™ has been granted Orphan Drug status by the FDA for three indications: T-cell non-Hodgkin’s lymphoma, including
CTCL; chronic lymphocytic leukemia (“CLL”) and related leukemias including T-cell prolymphocytic leukemia, adult T-cell leukemia, and
hairy cell leukemia; and for treatment of B-cell acute lymphoblastic leukemia (“B-ALL”). Additionally the FDA has granted “fast track” status
to the development of Fodosine™ for the treatment of relapsed or refractory T-cell leukemia. In February 2006, we announced an exclusive
licensing agreement with Mundipharma International Holdings Limited (“Mundipharma”) to develop and commercialize Fodosine™ in
markets across Europe, Asia and Australasia for use in oncology.
Our second most advanced drug candidate is peramivir, an inhibitor of influenza neuraminidase. We re-initiated clinical development of
peramivir during 2006 with a focus on intravenous and intramuscular delivery. During 2006, we tested peramivir in multiple Phase I trials in
healthy volunteers and early in 2007 we initiated a Phase II trial with the intramuscular formulation. In January 2007, we announced the U.S.
Department of Health and Human Services (“HHS”) had awarded the Company a $102.6 million, four-year contract for the advanced
development of peramivir. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other
product approval requirements.
In November 2005, the Company announced it had entered into an exclusive worldwide licensing agreement with F.Hoffmann-La Roche
Ltd and Hoffmann-La Roche Inc. (“Roche”) to develop and commercialize BCX-4208, our second generation PNP inhibitor for the prevention
of acute rejection in transplantation and for the treatment of autoimmune diseases.
BioCryst is a Delaware corporation originally founded in 1986. Our principal office is located at 2190 Parkway Lake Drive, Birmingham,
Alabama 35244, and our telephone number is (205) 444-4600. For more information about BioCryst, please visit our website at
www.biocryst.com. The information on our website is not incorporated into this Form 10-K.
1
Table of Contents
Our Business Strategy
Our business strategy is to use structure-based drug design technologies to develop innovative, small-molecule pharmaceuticals to treat a
variety of diseases and disorders. We focus our drug discovery efforts on building potent, selective inhibitors of enzymes associated with
targeted diseases. Enzymes are proteins that cause or enable biological reactions necessary for the progression of the disease or disorder. The
specific enzymes on which we focus are called enzyme targets. We aim to design compounds that will inhibit an enzyme target by fitting the
active site of a particular enzyme. Inhibition means interfering with the functioning of an enzyme target, thereby stopping or slowing the
progression of the disease or disorder. The principal elements of our strategy are:
•
Select and License Promising Enzyme Targets for the Discovery of Small-Molecule Pharmaceuticals. We use our technical expertise
and network of academic and industry contacts to evaluate and select promising enzyme targets to license for the discovery of small-
molecule pharmaceuticals. We choose enzyme targets that meet as many of the following criteria as possible:
– serve important functions in disease pathways;
– have known animal or cell-based models that would be indicative of results in humans;
– address large potential markets or niche areas with significant unmet medical need; and
– have multiple potential clinical applications.
•
Focus on High Value-Added Structure-Based Drug Design Technologies. We focus our drug discovery activities and expenditures on
applications of structure-based drug design technologies to design and develop drug candidates. Structure-based drug design is a process
by which we design a drug candidate through detailed analysis of the enzyme target, which the drug candidate must inhibit in order to
stop the progression of the disease or disorder. We believe that structure-based drug design is a powerful tool for efficient development of
small-molecule drug candidates that have the potential to be safe, effective and relatively inexpensive to manufacture. Our structure-
based drug design technologies typically allow us to design and synthesize multiple drug candidates that inhibit the same enzyme target.
We believe this strategy can lead to broad patent protection and enhance the competitive advantages of our compounds.
•
Develop or License Inhibitors that are Promising Candidates for Commercialization. We test multiple compounds to identify those that
are most promising for clinical development. We base our selection of promising development candidates on desirable product
characteristics, such as initial indications of safety and efficacy. We believe that this focused strategy allows us to eliminate unpromising
candidates from consideration sooner without incurring substantial clinical costs. In addition, we select drug candidates on the basis of
their potential for relatively efficient Phase I and Phase II clinical trials that require fewer patients to initially indicate safety and efficacy.
We will consider, however, more complex candidates with longer development cycles if we believe that they offer promising commercial
opportunities.
An important element of our business strategy is to control fixed costs and overhead through contracting and entering into license
agreements with other parties. We maintain a streamlined corporate infrastructure that focuses on our strongest areas of expertise. By
contracting with other specialty organizations, we believe that we can control costs, enable our drug candidates to reach the market more
quickly and reduce our business risk. Key elements of our contracting strategy include:
•
Entering Into Relationships with Academic Institutions and Biotechnology Companies. Many academic institutions and biotechnology
companies perform extensive research on the molecular and structural biology of potential drug development targets. By entering into
relationships with these institutions, we believe we can leverage this respective research to significantly reduce the time, cost and risks
involved in drug development. Our collaborative relationships with such organizations may lead to the licensing of one or more drug
targets or compounds. Upon licensing a drug target or promising compound from one of these institutions, the scientists from
2
Table of Contents
the institution typically become working partners as members of our structure-based drug design teams. We believe this makes us a more
attractive development partner to these scientists since they can continue to have some involvement in the continuing development of the
program. In addition, we collaborate with outside experts in a number of areas, including crystallography, molecular modeling,
combinatorial chemistry, biology, pharmacology, oncology, cardiology, immunology and infectious diseases. These collaborations enable
us to complement our internal capabilities without adding costly overhead. We believe this strategy allows us to save valuable time and
expense, and further diversify and strengthen our portfolio of drug candidates. An example of such a collaborative relationship is the
arrangement that we have with Albert Einstein College of Medicine of Yeshiva University (“AECOM”) and Industrial Research Limited
(“IRL”) who are the licensors of our PNP inhibitor programs.
•
Developing Drug Candidates or Licensing Them to Other Parties. We generally plan to advance drug candidates through initial and/or
early-stage drug development. For larger disease indications requiring complex clinical trials, our strategy is to license drug candidates to
pharmaceutical or biotechnology partners for final development and global marketing. We believe partnerships are a good source of
development payments, license fees, future event payments and royalties. They also reduce the costs and risks, and increase the
effectiveness, of late-stage product development, regulatory approval, manufacturing and marketing. We believe that focusing on
discovery and early-stage drug development while benefiting from our partners’ proven development and commercialization expertise
will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.
However, after establishing a lead product candidate, we are willing to license that candidate during any stage of the development process
we determine to be beneficial to the company and to the ultimate development and commercialization of that drug candidate. For some
smaller niche disease indications markets, we may choose to develop, manufacture, and where appropriate market and distribute any
approved drugs ourselves, such as Fodosine TM for certain T-cell and B-cell cancers in the U.S.
•
Entering into relationships with Contract Research Organizations (“CRO’s”). We outsource a significant portion of our R&D to third
parties in order to avoid fixed overhead and remain focused on our core competencies. For example, we rely heavily on others to
manufacture our products and on CRO’s for our clinical and regulatory operations. Using these vendors, we are able to capitalize on their
strengths and expertise without having to build such infrastructure internally.
Products in Development
The following table summarizes BioCryst’s most advanced projects as of February 28, 2007:
Program and Candidate Disease
Category/Indication
PNP Inhibitor (Fodosine™)
T-ALL
CLL
B-ALL
CTCL
Neuraminidase Inhibitor (peramivir)
Viral
PNP Inhibitor (BCX-4208)
Autoimmune diseases
Transplantation rejection
Hepatitis C Polymerase Inhibitors
Viral
Additional Products
Delivery Form
Development Stage
Worldwide Rights
i.v./oral
oral
i.v.
oral
i.v.
i.m.
oral
oral
Phase IIb
Phase II
Phase I/II
Phase I/II
Phase I
Phase II
Phase I
BioCryst/Mundipharma
BioCryst
Roche/BioCryst has
co-promotion rights
in the U.S. in
limited indications
Preclinical
BioCryst
In addition to the programs shown above, we also retain exclusive rights to potent inhibitors of parainfluenza neuraminidase and additional
PNP inhibitors. We will continue to evaluate and test each of these compounds to determine which should be taken into clinical testing.
3
Table of Contents
PNP Inhibitors
T-cell Related Diseases
Overview . The human immune system employs specialized cells, including T-cells, to control infection by recognizing and attacking
disease-causing viruses, bacteria and parasites. T-cells are an essential part of the body’s immune system that serve a dual purpose to both
orchestrate and participate in the body’s immune response. For the most part, this system works flawlessly to protect the body. However, when
T-cells multiply uncontrollably, T-cell proliferative diseases, such as T-cell cancers, can occur.
The link between T-cell proliferation and the purine nucleoside phosphorylase, or PNP, enzyme was first discovered approximately twenty-
five years ago when a patient, who was genetically deficient in PNP, exhibited limited T-cell activity, but reasonably normal activity of other
immune functions. In other patients lacking PNP activity, the T-cell population was selectively depleted; however, B-cell function tended to be
normal. Based on these findings and the results of cell culture studies, inhibiting PNP appears to produce selective suppression of T-cells
without significantly impairing the function of other cells.
Acute Lymphoblastic Leukemia . The most common form of leukemia in children is acute lymphoblastic leukemia (“ALL”). According to
the American Cancer Society, 5,200 new cases (adult and children combined) will be diagnosed in the United States in 2007 (T-cell and B-
cell). ALL results from an acquired injury to the DNA of a single cell in the bone marrow.
T-cell Lymphoma . Lymphoma is a general term for a group of cancers that originate in the lymphatic system. About 63,190 Americans will
be diagnosed with a non-Hodgkin’s lymphoma in 2007 and approximately 15% of these will be considered T-cell lymphomas. T-cell
lymphoma results when a T-lymphocyte (a type of white blood cell) undergoes a malignant change and begins to multiply, eventually crowding
out healthy cells and creating tumors, which enlarge the lymph nodes and invade other sites in the body. CTCL is a primary skin neoplasm and
accounts for nearly 50% of all T-cell malignancies.
T-cell Mediated Autoimmune Diseases. There are more than 80 clinically distinct autoimmune diseases such as psoriasis, rheumatoid
arthritis, multiple sclerosis, and Crohn’s disease, which appear to have activated T-cells as a major part of their pathogenesis. These diseases
occur when the immune system attacks the body’s own cells rather than invading microorganisms. Therefore, inhibition and/or elimination of
activated T-cells could have a beneficial effect on these diseases.
Transplant Rejection. The greatest threat to transplant patients is rejection of the transplanted organ by the body’s own immune system. For
this reason, transplant recipients must take drugs to suppress the immune response and prevent rejection usually for the rest of their lives. A
regimen combining several drugs is usually given and this treatment has to be continued indefinitely. For kidney transplant recipients, rejection
of the new kidney by the patient’s immune system can lead to loss of the transplanted organ and a return to dialysis. For heart, lung and liver
transplant patients, loss of the transplanted organ presents an immediate threat to life.
B-cell Related Cancers
Overview . There are two types of lymphocytes in the broadest sense – T-cells and B-cells. Although PNP inhibitors were developed
specifically to block the T-cells, recent work indicates that the same biochemical event – the intracellular accumulation of deoxyguanosine
triphosphate (dGTP) also occurs in malignant B-cells. Furthermore, work of Dr. Varsha Gandhi at MD Anderson Cancer Center has shown that
PNP inhibitors, when acting in vitro on B-cells from patients with CLL induce accumulation of dGTP with resultant apoptosis (cell death).
These studies open the possibility of treating CLL, B-ALL and B-cell non-Hodgkin’s Lymphoma (NHL) with Fodosine. Importantly, B-cell
malignancies are considerably more prevalent than are the T-cell leukemias and lymphomas.
4
Table of Contents
Our PNP Inhibitor(s)
PNP Inhibition . PNP is an enzyme that plays an important role in T-cell proliferation, because it is necessary to maintain normal DNA
synthesis in human T-cells. Selective inhibition of PNP causes certain nucleosides, including deoxyguanosine, to accumulate. As the
concentration of deoxyguanosine increases within T-cells, it is converted by specific enzymes to dGTP. A high concentration of dGTP in T-
cells causes an imbalance in the intra-cellular trinucleotide pool and thus causes cell death.
In June 2000, we licensed a series of potent PNP inhibitors from AECOM and IRL. The lead drug candidate from this collaboration,
Fodosine™, is a more potent inhibitor of human lymphocyte proliferation than other previously known PNP inhibitors. Clinical data in our past
and ongoing clinical trials, plus extensive preclinical studies indicate that Fodosine™ can modulate T-cell activities. Fodosine™ is an
investigational PNP inhibitor for the potential treatment of T-cell leukemias and lymphomas. In February 2006, we licensed Fodosine™ to
Mundipharma to develop and commercialize in markets across Europe, Asia and Australasia for use in oncology.
During 2002, we exercised the option to add a new compound, BCX-4208, to the series of inhibitors of PNP licensed from AECOM and
IRL. Preclinical results indicated that BCX-4208 was a more potent inhibitor than Fodosine™. We completed a Phase I single ascending dose
clinical trial and a Phase Ib multi-dose clinical trial, both in healthy volunteers. In November 2005, we licensed BCX-4208 to Roche for the
world wide development and commercialization in autoimmune diseases and transplant rejection.
PNP Inhibitor (Fodosine™)
Overview
The first clinical trial with an intravenous formulation of Fodosine™, which began in 2002, was a Phase I clinical trial that enrolled T-ALL
patients at the M.D. Anderson Cancer Center in Houston, Texas. Simultaneously, there were preclinical studies being conducted at the M.D.
Anderson Cancer Center which indicated that Fodosine™ induces the same biochemical changes in various other types of leukemia cells that
are responsible for the inhibition of T-leukemia cells. The results of these preclinical studies led us to expand beyond the single starting trial in
T-ALL by initiating additional clinical trials for refractory patients with B-ALL, CTCL, and hematologic malignancies. Based on the
encouraging results of these initial studies, we are working with our partner, Mundipharma, to develop a strategy for the simultaneous
development of Fodosine™ in multiple indications using intravenous, oral and combination dosing regimens.
Current Development Strategy (T-ALL, CTCL, B-ALL, and CLL)
Fodosine™ Clinical Development for Aggressive T-cell Malignancies . During 2004, we initiated a Phase IIa trial to enroll patients with
aggressive T-cell malignancies. Despite encouraging results observed with other T-cell specific agents, the prognosis for patients with relapsed
or refractory leukemia or lymphoma is poor and treatment options remain limited. The goal of the Phase IIa clinical trial was to determine the
therapeutic effect produced by Fodosine™ as it relates to the proposed mechanism of action in the inhibition of proliferating T-lymphocytes in
patients with T-ALL.
Based on the results of the Phase IIa trial, we have negotiated a SPA agreement with the FDA for the design of a multicenter, open-label,
non-randomized repeat-dose registration study to evaluate an intravenous treatment of Fodosine™ followed by an oral treatment of Fodosine™
in patients with relapsed or refractory T-ALL. This study is designed to determine the rate of complete remission achieved with Fodosine™
and will be a multinational trial which will include sites in the United States, Eastern and Western Europe and South America. We announced
the start of this trial in January 2007.
We have obtained orphan drug status for Fodosine™ in multiple indications in both the U.S. and Europe and the FDA has granted “fast
track” status to the development of Fodosine™ for the treatment of relapsed or refractory T-cell leukemia. Our current intent is to maintain
significant rights in this program and for BioCryst itself to potentially market and distribute Fodosine™ in the United States for treatment of T-
cell cancers.
5
Table of Contents
In 2004, we initiated a Phase I/II trial with an oral formulation of Fodosine™ for treatment of patients with CTCL. Based on the
encouraging results of this trial, we are in active discussions with the FDA to determine what would be required to initiate a pivotal trial in
CTCL during 2007.
In February 2006, we and Mundipharma entered into an exclusive license agreement to develop and commercialize Fodosine™, in markets
across Europe, Asia and Australasia for use in oncology. The agreement covers a number of markets in Asia and Australasia including Japan,
Australia, New Zealand, China and India. This collaboration should help maximize the global development, commercialization, and market
potential of Fodosine™ in a variety of serious medical conditions potentially including T-cell leukemia, CTCL, CLL, T-cell non-Hodgkin’s
lymphoma and B-cell non-Hodgkin’s lymphoma. Based on preclinical studies conducted at the M.D. Anderson Cancer Center which indicated
that Fodosine™ induces the same biochemical changes in various other types of leukemia cells that are responsible for the inhibition of T-
leukemia cells, we initiated two small clinical studies late in 2005 in B-cell leukemias, which are more prevalent than T-cell leukemias. First,
we initiated a Phase II trial with oral Fodosine™ in patients with CLL in an advanced stage and refractory to fludarabine, the current standard
of therapy. Next, we initiated a Phase I/II clinical trial of Fodosine™ to determine the safety of repeat doses of an intravenous (IV) formulation
of the drug in patients with B-ALL. We are completing the evaluation of patients from these trials and are reviewing the results with
Mundipharma to determine the best clinical strategy going forward.
PNP Inhibitor (BCX-4208)
Overview
During the fourth quarter of 2004, we began clinical development of BCX-4208, a second-generation PNP inhibitor, as a drug candidate for
the treatment of T-cell mediated autoimmune diseases, including psoriasis, and transplant rejection. Although BCX-4208 and Fodosine™ are
both investigational PNP inhibitors, BCX-4208 differs from Fodosine™ in significant ways. For example, BCX-4208 is more potent, and has
the ability to suppress PNP for longer periods of time. Thus, BCX-4208 has potential advantages over Fodosine™ for the treatment of diseases
requiring long-term, chronic administration of a PNP inhibitor.
Current Development Strategy
We completed our initial Phase I study, a single dose pharmacokinetic trial in healthy volunteers, early in 2005 and during the third quarter
of 2005, we initiated a Phase Ib multi dose trial in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of multiple oral
doses of BCX-4208. In November 2005, we and Roche announced an exclusive license agreement for the worldwide development and
commercialization of BCX-4208 for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. This
collaboration provided substantial strategic and economic benefit to us and also all the essential elements for the rapid, comprehensive and
competitive development of BCX-4208. The two companies have established a joint committee to set the clinical development strategy and the
future development program for BCX-4208.
We completed the dosing of subjects in the Phase Ib trial during 2006 and we are currently working with Roche to plan the further
development of BCX-4208 and anticipate that a Phase II trial will be initiated during 2007.
Neuraminidase Inhibitor
Influenza
Seasonal Influenza. Seasonal influenza, commonly known as the flu, is a viral infection characterized by symptoms including fever, cough,
sore throat, fatigue, headache, and/or chills. According to the U.S. Centers for Disease Control and Prevention (“CDC”), an estimated 5% to
20% of the American population suffers from influenza annually, more than 200,000 people are hospitalized from flu complications, and
approximately 36,000 people die. Influenza is particularly dangerous to the elderly, young children and people with certain health conditions.
Outbreaks of seasonal flu tend to follow predictable patterns usually occurring in the winter. New vaccines are developed annually based on
known flu strains and are usually available for the annual flu season. There are also antiviral treatments available for the treatment of people
infected with influenza.
6
Table of Contents
Avian Influenza . According to information from the CDC, avian influenza, or bird flu is an infection caused by viruses which occur
naturally among birds. This form of flu is very contagious among birds and can lead to serious illness and sometimes death. There are two main
forms of disease that infect domestic poultry, one a low pathogenic form and the other a highly pathogenic form. The latter form can cause
disease that affects multiple internal organs and with a mortality rate between 90-100% in these birds within 2 days.
While there are many different subtypes of the influenza A virus, only three subtypes are known to be currently circulating among humans.
Avian influenza A viruses are found chiefly in birds, but there have been confirmed cases of infection in humans, generally as a result of
contact with infected birds. These infections have led to symptoms ranging from those of normal flu to more severe and life threatening
conditions. Influenza A (“H5N1”) is a subtype of an influenza virus that is highly contagious among birds and can be very deadly to them. Of
the avian influenza viruses that have crossed the species barrier to infect humans, the H5N1 virus has caused the largest number of detected
cases of severe disease and death in humans. Thus far, this virus does not spread easily from one person to another, but as influenza A viruses
constantly change, they could mutate over time to have the ability to spread rapidly among humans.
Pandemic Influenza . Pandemic influenza is a global disease outbreak that occurs when a new influenza virus emerges so that people have
had no previous exposure. This situation occurs very rarely and only occurred three times in the 20 th century.
Influenza Prevention and Treatment . The development of effective therapeutics has challenged medical researchers due to the seasonal
variation in viral strains and the highly infectious nature of influenza. Patients, therefore, have limited treatment options. Amantadine and
rimantadine are used for treatment of influenza A but are ineffective against influenza B. In addition, these drugs cause some adverse side
effects, and the virus tends to develop resistance to these drugs. The CDC has recommended against the use of amantadine and rimantadine for
the treatment or prophylaxis of influenza in the United States until susceptibility to these antiviral medications has been re-established among
circulating influenza A viruses.
Vaccines are available against the disease but have limitations: people require advance vaccination; vaccines are limited by their specificity
to particular strains of the virus; and vaccines offer little protection if the vaccine is inaccurate. In addition, many people decline the required
injections because of fear and/or discomfort. The ability of the virus to change its structure to avoid the body’s natural defenses is a serious
obstacle to developing an effective vaccine against influenza. Different strains can arise when surface antigens on the virus (the portion of the
virus that causes an immune reaction in humans) undergo minor genetic mutations each year as the virus replicates. Because of this mutability,
the immunity acquired in response to infection by a particular strain of the virus does not provide adequate protection against viruses that
subsequently arise. The production of a new vaccine each year is not only complex and expensive, but also an inefficient method of global
disease control.
Inhibiting Influenza Neuraminidase. Research during the past two decades has seen dramatic advances in understanding the molecular
structure and function of the influenza virus. Considerable attention has been focused on the enzyme neuraminidase, which is located on the
surface of the virus. Neuraminidase assists in the release and spread of the flu virus by breaking the chemical strands that hold the new viruses
to the cell surface, allowing the replicated virus to spread and infect other cells. This process progresses until the host’s immune response can
produce enough antibodies to bring the infection under control. Inhibiting the neuraminidase enzyme keeps new viruses attached to the cell
surface, thereby preventing the spread of the virus and the further infection of other cells. The subsequent quantities of virus in the bloodstream
are not enough to cause disease but are sufficient to induce the body to mount an immune response.
In addition to our neuraminidase inhibitor drug candidate, both Roche, in collaboration with Gilead Sciences, and GlaxoSmithKline
(“GSK”) have neuraminidase inhibitors. Roche’s neuraminidase inhibitor is a twice-a-day, orally active neuraminidase inhibitor, while GSK’s
neuraminidase inhibitor is administered by dry powder inhaler twice a day. Both drugs are approved for marketing in the United States and
other countries for treatment of influenza. Roche’s neuraminidase inhibitor is also approved for prophylaxis use for prevention of influenza. In
addition to these companies with neuraminidase inhibitors, there are other companies working to develop additional antiviral drugs to be used
against various strains of influenza.
7
Table of Contents
Some studies in laboratories suggest that some of these neuraminidase inhibitor drugs should work in treating avian influenza infections in
humans, but additional studies are needed to demonstrate the effectiveness of these drugs.
Neuraminidase Inhibitor (peramivir)
Overview
Background. In 1987, scientists at The University of Alabama at Birmingham (“UAB”), in collaboration with our scientists, began
determining the molecular structure of the influenza neuraminidase enzyme from several different strains of influenza, using X-ray
crystallography. Subsequently, our scientists and UAB scientists developed numerous new inhibitors of these enzymes using structure-based
drug design. We licensed the influenza neuraminidase program from UAB in 1994 and proceeded to complete the studies of the enzyme’s
molecular structure needed to advance the development of neuraminidase inhibitors. The structure of the active site of influenza neuraminidase
is similar among different viral strains. Because of this similarity, we believe that our neuraminidase inhibitors may be effective in the
treatment and prevention of influenza, regardless of changes in the virus.
Current status of peramivir. Due to the recent international concern about a potential influenza pandemic that could be initiated by avian
strains of the virus, peramivir has received considerable attention, since it is positioned to be one of very few advanced antiviral alternatives
behind oseltamivir, or Tamiflu, for addressing a potential pandemic. As a result, we re-initiated the clinical development of peramivir during
2006.
Current Development Strategy
Preclinical studies comparing peramivir with other anti-influenza drugs have demonstrated that peramivir has outstanding broad-spectrum
potency against multiple strains of influenza, including the avian strain H5N1. In addition, peramivir retains activity against nearly all Tamiflu-
resistant strains of influenza that have been identified to date. We are currently focusing on injectable formulations of peramivir that may
achieve high blood levels that should be effective against most strains of influenza, including strains that may be resistant to Tamiflu. Our
investigational new drug application (“IND”) for i.v. peramivir became effective in December 2005 and for i.m. in November 2006. We
received fast track designation from the FDA in January 2006 and initiated a Phase I clinical trial with i.v. peramivir in March 2006. During
2006, we conducted multiple Phase I clinical trials in healthy volunteers in preparation for the Phase II trials to be initiated during the 2006-
2007 influenza season, which began with the initiation of a Phase II study with the i.m. formulation in January 2007.
Our plan is to develop two injectable formulations, including intravenous peramivir for treating acutely ill patients, and an intramuscular
injectable formulation for treatment of earlier-stage infected patients. We expect the clinical development for these injectable formulations to
follow a classical development pathway. Initial testing in patients infected with seasonal flu began with the initiation of the Phase II study with
the i.m. formulation in January 2007. Preclinical studies have indicated that a single injection of peramivir is effective at preventing death in
mice from infections with virulent strains of influenza. If this finding can be confirmed in clinical trials, we believe the i.m. formulation will
have considerable potential for treating patients with seasonal influenza infections, in addition to providing an effective mechanism for treating
large numbers of patients rapidly in the event of a flu pandemic.
Congress approved an appropriation of $3.8 billion for 2006 to support the development of various countermeasures for a flu pandemic. The
appropriation included funding for the development of new antiviral agents. In January 2007, we announced that HHS had awarded the
Company a $102.6 million, four-year contract for the advanced development of peramivir for U.S. licensure. Funding from the contract will
support manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure.
Hepatitis C Polymerase Inhibitors
Overview
Hepatitis C virus (“HCV”) infection has been described in the New England Journal of Medicine as the nation’s most common chronic
blood-borne infection. According to the World Health Organization, 3% of the world’s population are infected with HCV and are at risk of
developing liver cirrhosis and/or liver cancer. The CDC estimates there are an estimated 4.1 million Americans (approximately 1.6% of the
population) that have been infected with HCV,
8
Table of Contents
of whom 3.2 million are chronically infected. According to the CDC, as many as 55-85% of those infected with HCV will have chronic
infection and 70% of those will develop chronic liver disease. While there are several approved treatments for chronic HCV using a
combination therapy of interferon and ribavirin, there are some potentially severe side effects to these treatments.
Background . In June 2000, we licensed intellectual property from Emory University (“Emory”) related to the hepatitis C polymerase target
associated with hepatitis C viral infections. Under the original terms of the agreement, the research investigators from Emory provided us with
materials and technical insight into the target.
Current Development Strategy
We are targeting HCV polymerase through collaborative and in-house efforts. Specifically, we are focused on development of orally active
inhibitors against the RNA-dependent RNA polymerase. Competition for this target is less intense than for the HCV protease target and history
suggests the likelihood of designing a useful inhibitor against this target may be better than designing inhibitors against the protease.
We have designed, synthesized and screened potential compounds against HCV polymerase. Specifically, our scientists have measured the
potency and ability of potential drug candidates to block the replication of HCV polymerase in vitro, or in test tubes. These experiments
measure the potency of each selected compound’s ability to block replication. Advanced screening was also used to measure the fit of
promising compounds in the HCV polymerase active site using X-ray crystallography and computer molecular modeling. The goal has been to
identify a series of compounds that are potent in vitro inhibitors of the active site of the HCV polymerase for further testing and lead
optimization.
During 2005, we identified a lead compound, BCX-4678, for which we have made progress in the preclinical development, plus major
improvements in the large-scale synthesis. In addition, we have identified a number of other preclinical candidates for this therapeutic area and
we are currently evaluating and prioritizing which candidate(s) to bring into clinical development.
Structure-Based Drug Design
Structure-based drug design is a drug discovery approach by which we design synthetic compounds from detailed structural knowledge of
the active sites of enzyme targets associated with particular diseases. Enzymes are proteins that act as catalysts for many vital biological
reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme (the active site of an enzyme is the area into
which a chemical or biological molecule fits to initiate a biochemical reaction) and thereby interfere with the progression of disease.
Our structure-based drug design involves the application of both traditional biology and medicinal chemistry and an array of advanced
technologies. We use X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the
three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
We believe that structure-based drug design technologies are superior to drug screening techniques. By identifying the target enzyme in
advance and by discovering the chemical and molecular structure of the enzyme, we believe it is possible to design a better drug to interact
with the enzyme. In addition, the structural data obtained by X-ray crystallographic analysis allow additional analysis and compound
modification at each stage of the biological evaluation. This capability makes structure-based drug design a powerful tool for efficient
development of drugs that are highly specific for particular enzyme target sites.
Research and Development
We initiated our research and development program in 1986, with drug synthesis beginning in 1987. We have assembled a scientific
research staff with expertise in a broad base of advanced research technologies including protein biochemistry, X-ray crystallography,
chemistry and pharmacology. Our research facilities include protein biochemistry and organic synthesis laboratories, testing facilities, X-ray
crystallography, computer and graphics equipment and facilities to make drug candidates on a small scale for early stage clinical trials.
Beginning in June 2006, we began
9
Table of Contents
building an internal clinical development and regulatory team, based in Cary, North Carolina to manage the development strategy for our
products.
During the years ended December 31, 2006, 2005 and 2004, we spent $47.1, $23.6 and $18.9 million, respectively, on research and
development. Approximately $13.4, $9.1 and $8.0 million of those respective amounts were spent on in-house research and development, and
$33.7, $14.5 and $10.9 million, respectively were spent on contract research and development.
Collaboration and In-License Relationships
We seek to enter into collaborations with leading pharmaceutical and biotechnology companies when we feel it is advantageous to leverage
these companies’ resources to develop and commercialize our drug candidates on a global basis. This allows us to remain focused on our
strength of early stage discovery and development of drug candidates. To date, we have two major collaborations for the development and
commercialization of our lead PNP inhibitors and two collaborations for the development and commercialization of peramivir in certain
countries outside the U.S. In addition, in January 2007, we announced that HHS had awarded the Company a $102.6 million, four-year contract
for the advanced development of peramivir for U.S. licensure.
Another important component of our strategy is to augment our internal discovery programs through the selective in-licensing of potential
drug development targets or early stage compounds for these specific targets.
Corporate Alliances
Roche . In November 2005, we entered into an exclusive license with Roche for the development and commercialization of our second
generation PNP inhibitor, BCX-4208, for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases.
Under the terms of the agreement, Roche obtained worldwide rights to BCX-4208 in exchange for an up-front payment of $30 million, which
included a payment as reimbursement for a limited supply of material during the first 24 months of the collaboration. There could also be future
event payments for achieving specified development, regulatory and commercial milestones (including sales level milestones following a
product’s launch) for certain indications. In addition, we will receive royalties based on a percentage of net product sales, which varies
depending upon when certain indications receive NDA approval in a major market country and can vary by country depending on the patent
coverage or sales of generic compounds in a particular country. We licensed this compound and other PNP inhibitors from AECOM and IRL
and will owe sublicense payments to these third parties on the upfront payment, future event payments and royalties received by us for the
sublicense of these inhibitors.
Roche has a right of first negotiation, under certain conditions, on existing backup PNP inhibitors we develop through Phase IIb in
transplant rejection and autoimmune diseases, but any new PNP inhibitors are exempt from this agreement and we retain all rights to such
compounds. We retain the right to co-promote BCX-4208 in the U.S. for several indications. Roche has certain obligations under the terms of
the agreement to use commercially reasonable efforts to develop, manufacture and commercialize the licensed product. The agreement may be
terminated by either party following an uncured material breach by the other party or may be either fully or partially terminated by Roche
without cause under certain conditions and all rights, data, materials, products and other information would be transferred to us at no cost.
Mundipharma . In February 2006, we entered into an exclusive, royalty bearing right and license in the specified territory (primarily
Europe, Asia and Australasia) with Mundipharma for the development and commercialization of our lead PNP inhibitor, Fodosine™, for use in
oncology. Under the terms of the agreement, Mundipharma obtained oncology rights to Fodosine™ in the specified territory in exchange for a
$10 million up-front payment. Mundipharma will share 50% of the documented out of pocket development costs incurred by us in respect of
our current and planned trials as of the effective date of the agreement provided that Mundipharma’s maximum contribution to these trials shall
be $10 million. In addition, Mundipharma will conduct additional clinical trials at their own cost up to a maximum of $15 million. The license
provides for future event payments for achieving specified development, regulatory and commercial events (including certain sales level
amounts following a product’s launch) for certain indications. In addition, we will receive royalties based on a percentage of net product sales,
which varies depending upon when certain indications receive NDA approval in a major market country and can vary by country depending on
the patent
10
Table of Contents
coverage or sales of generic compounds in a particular country. Generally, all payments under the agreement are nonrefundable and non-
creditable, but they are subject to audit. We licensed this compound and other PNP inhibitors from AECOM and IRL and will owe sublicense
payments to these third parties on the upfront payment, future event payments and royalties received by us for the sublicense of these
inhibitors.
Within five years of the effective date of the agreement, Mundipharma will has a right of first negotiation on existing backup PNP inhibitors
we develop through Phase IIb in oncology, but any new PNP inhibitors are exempt from this agreement and we retain all rights to such
compounds. We retain the rights to Fodosine™ in the United States (“U.S.”) and Mundipharma is obligated by the terms of the agreement to
use commercially reasonable efforts to develop the licensed product in the territory specified by the agreement. The agreement will continue
for the commercial life of the licensed products, but may be terminated by either party following an uncured material breach by the other party
or in the event the pre-existing third party license with AECOM and IRL expires. It may be terminated by Mundipharma upon 60 days written
notice without cause or under certain other conditions as specified in the agreement and all rights, data, materials, products and other
information would be transferred to us at no cost. In the event we terminate the agreement for material default or insolvency, we could have to
pay Mundipharma 50% of the costs of any independent data owned by Mundipharma in accordance with the terms of the agreement.
Shionogi & Co., Ltd. In March 2007, the Company entered into an exclusive license agreement with Shionogi & Co., Ltd. (“Shionogi”) to
develop and commercialize the Company’s lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and
potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of
peramivir in Japan in exchange for a $14 million up-front payment. The license provides for future event payments for achieving specified
development, regulatory and commercial events (including certain sales level amounts following a product’s launch) for certain indications. In
addition, the Company will receive royalties based on a percentage of net product sales. Generally, all payments under the agreement are
nonrefundable and non-creditable, but they are subject to audit. The Company developed peramivir under a license from UAB and will owe
sublicense payments to them on the upfront payment and any future event payments and/or royalties received by the Company from Shionogi.
The Company retains all rights to commercialize peramivir in North America, Europe, and other countries outside of Korea and Japan.
Green Cross Corporation (“Green Cross”). In June 2006, the Company entered into an agreement with Green Cross to develop and
commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and
commercialization costs in Korea. The Company received a one-time license fee and may also receive future event payments as well as
royalties on product sales of peramivir. In addition, the Company will share in any profits resulting from the sale of peramivir to the Korean
government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for
development and any future marketing of peramivir products in Korea.
Academic Alliances
Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd, New Zealand . In June 2000, we licensed a series
of potent inhibitors of PNP from AECOM and IRL. The lead drug candidates from this collaboration are Fodosine™ and BCX-4208. We have
obtained worldwide exclusive rights to develop and ultimately distribute these compounds or any other drug candidates that might arise from
research on these inhibitors. We have agreed to pay certain milestone payments for future development of these inhibitors, certain royalties on
sales of any resulting product, and to share in future payments received from other third-party partners, if any. In addition, we have agreed to
pay an annual license fee that is non-refundable, but is creditable against actual royalties and other payments due to AECOM and IRL. This
agreement may be terminated by us at any time by giving 60 days advance notice or in the event of material uncured breach by AECOM and/or
IRL.
The University of Alabama at Birmingham . We have had a close relationship with UAB since our formation. Our Chairman, Dr. Charles E.
Bugg, was the previous Director of the UAB Center for Macromolecular Crystallography, and our President and Chief Operating Officer, Dr. J.
Claude Bennett, was the former President of UAB, the former Chairman of the Department of Medicine at UAB and a former Chairman of the
Department of Microbiology at UAB. Several of our early programs originated at UAB.
11
Table of Contents
We currently have agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements,
UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any discoveries
in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay royalties on sales of any
resulting product and to share in future payments received from other third-party partners. We have completed the research under both the
complement and influenza agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms
throughout the life of the last patent and are terminable by us upon three months notice and by UAB under certain circumstances. There is
currently no activity between us and UAB on these agreements, but when the Company licenses this technology, such as in the case of the
Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense fees or royalties on
amounts we receive.
Emory . In June 2000, we licensed intellectual property from Emory related to the HCV polymerase target associated with hepatitis C viral
infections. Under the original terms of the agreement, the research investigators from Emory provided us with materials and technical insight
into the target. We have agreed to pay Emory royalties on sales of any resulting product and to share in future payments received from other
third party partners, if any. We can terminate this agreement at any time by giving 90 days advance notice.
Government Contracts
In January 2007, we announced that HHS had awarded the Company a $102.6 million, four-year contract for the advanced development of
peramivir for U.S. licensure. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other
product approval requirements needed for U.S. licensure. HHS has indicated that antiviral drugs are an important element of their pandemic
influenza preparedness efforts and that their strategy includes not only stockpiling of existing antiviral drugs but also seeking out new antiviral
medications to further broaden their capabilities to treat and prevent all forms of influenza. Peramivir is in the same class of neuraminidase
inhibitors as oseltamivir (Tamiflu) and zanamivir (Relenza), all of which are antiviral drugs, but the method of delivery for peramivir will be
parenteral (i.m. and i.v.) as compared to the oral Tamiflu or inhaled Relenza. We are committed to working with HHS for the development of
these parenteral formulations of peramivir which could be especially useful in hospital settings or pandemic situations due to the ability to
achieve high levels of the drug rapidly throughout the body.
This contract is a cost-plus-fixed-fee contract, which is milestone-driven. HHS will make periodic assessments of progress and the
continuation of the contract is based on our performance, timeliness and quality of deliverables, and other factors. The government has rights
under certain contract clauses to terminate this contract.
Patents and Proprietary Information
Our success will depend in part on our ability to obtain and enforce patent protection for our products, methods, processes and other
proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the United
States and in other countries. We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and
patent applications which relate to compounds we are developing. We actively seek, when appropriate, protection for our products, proprietary
technology and proprietary information by means of U.S. and foreign patents, trademarks and contractual arrangements. In addition, we rely
upon trade secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology and products.
The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain
and solidify our proprietary position for our technology will depend on our success in obtaining effective patent claims and enforcing those
claims once granted. We do not know whether any of our patent applications or those patent applications that we license will result in the
issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated,
rendered unenforceable or circumvented, which could limit our ability to stop competitors from marketing related products or the length of
term of patent protection that we may have for our products. In addition, the rights granted under any issued patents may not provide us with
competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors may independently develop
similar technologies or duplicate any technology developed by us in a manner that does not infringe our patents or other intellectual property.
Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of
our drug candidates or those
12
Table of Contents
developed by our partners can be commercialized, any related patent may expire or remain in force for only a short period following
commercialization, thereby reducing any advantage of the patent.
As of February 20, 2007, we have been issued 28 U.S. patents that expire between 2009 and 2023 and that relate to our PNP, serine protease
and neuraminidase inhibitor compounds. We have licensed six additional composition of matter patents and two pending composition of matter
patents from AECOM and IRL for our PNP inhibitors, plus additional manufacturing patents related to these PNP inhibitors and one patent
from Emory related to hepatitis C. Additionally, we have 16 U.S. patent applications pending related to PNP, neuraminidase, RNA viral
polymerase, paramyxovirus neuraminidase, and serine protease inhibitors. Our pending applications may not result in issued patents, and our
patents may not provide us with sufficient protection against competitive products or otherwise be commercially viable.
Our success is also dependent upon the skills, knowledge and experience of our scientific and technical personnel, none of which is
patentable. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements,
which prohibit the disclosure of confidential information to anyone outside of our company and, where possible, requires disclosure and
assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade
secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of
such information.
Marketing and Sales
We currently plan to market, distribute and sell Fodosine™ in the U.S. for use in treatment of T-cell and B-cell cancers. Although our
general strategy is to rely on major marketing companies for worldwide commercialization of most products we may develop, we believe that
we can manage the highly specialized oncology market for Fodosine™ within the U.S. Most patients with advanced T-cell malignancies in the
U.S. are treated at major referral cancer centers, and many of these centers have been participating in our Fodosine™ clinical trials and will
thus be familiar with Fodosine™ if it reaches the market. However, we lack experience in marketing, distributing and selling pharmaceutical
products. Our general strategy is to rely on partners, licensees or arrangements with others to provide for the marketing, distribution and sales
of products we may develop. We may not be able to establish and maintain acceptable commercial arrangements with partners, licensees or
others to perform such activities.
Competition
The pharmaceutical and biotechnology industries are intensely competitive. Many companies, including biotechnology, chemical and
pharmaceutical companies, are actively engaged in activities similar to ours, including research and development of drugs for the treatment of
cancer, infectious, autoimmune, inflammatory and cardiovascular diseases and disorders. Many of these companies have substantially greater
financial and other resources, larger research and development staffs, and more extensive marketing and manufacturing organizations than we
do. In addition, some of them have considerable experience in preclinical testing, clinical trials and other regulatory approval procedures. For
example, in October 2005, the FDA announced the approval of Arranon (nelarabine) for the treatment of adults and children with T-cell acute
lymphoblastic leukemia. This drug was approved under the FDA’s orphan drug and accelerated approval (fast track) programs and is being
distributed and marketed by GSK. We are currently testing Fodosine™ in T-cell ALL and have also received both orphan drug and fast track
designation from the FDA. There are also academic institutions, governmental agencies and other research organizations that are conducting
research in areas in which we are working. They may also market commercial products, either on their own or through collaborative efforts.
We expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that complete
clinical trials, obtain required regulatory approvals and commence commercial sales of their products before their competitors may achieve a
significant competitive advantage. Such is the case with GSK’s Arranon for T-cell ALL and the current neuraminidase inhibitors marketed by
GSK and Roche for influenza. In addition, several pharmaceutical and biotechnology firms, including major pharmaceutical companies and
specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and in the fields of PNP,
HCV, influenza, and other therapeutic areas where we are focusing our drug discovery efforts.
13
Table of Contents
In order to compete successfully, we must develop proprietary positions in patented drugs for therapeutic markets that have not been
satisfactorily addressed by conventional research strategies and, in the process, expand our expertise in structure-based drug design. Our
products, even if successfully tested and developed, may not be adopted by physicians over other products and may not offer economically
feasible alternatives to other therapies.
Government Regulation
The FDA regulates the pharmaceutical and biotechnology industries in the U.S., and our drug candidates are subject to extensive and
rigorous domestic government regulations prior to commercialization. The FDA regulates, among other things, the development, testing,
manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical
products. In foreign countries, our products are also subject to extensive regulation by foreign governments. These government regulations will
be a significant factor in the production and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA
and other regulatory requirements at any stage during the regulatory process may subject us to sanctions, including:
•
delays;
•
warning letters;
•
fines;
•
product recalls or seizures;
•
injunctions;
•
penalties;
•
•
refusal of the FDA to review pending market approval applications or supplements to approval applications;
total or partial suspension of production;
•
civil penalties;
•
withdrawals of previously approved marketing applications; and
•
criminal prosecutions.
The regulatory review and approval process is lengthy, expensive and uncertain. Before obtaining regulatory approvals for the commercial
sale of any products, we or our partners must demonstrate that our product candidates are safe and effective for use in humans. The approval
process takes many years, substantial expenses may be incurred and significant time may be devoted to clinical development.
Before testing potential candidates in humans, we carry out laboratory and animal studies to determine safety and biological activity. After
completing preclinical trials, we must file an IND, including a proposal to begin clinical trials, with the FDA. We have filed thirteen INDs to
date and plan to file, or rely on future partners to file, additional INDs in the future as our potential drug candidates advance to that stage of
development. Thirty days after filing an IND, a Phase I human clinical trial can start, unless the FDA places a hold on the study.
Our Phase I trials are designed to determine safety in a small group of patients or healthy volunteers. We also assess tolerances and the
metabolic and pharmacologic actions of our drug candidates at different doses. After we complete the initial trials, we conduct Phase II trials to
assess safety and efficacy and establish the optimal dose in patients. If Phase II trials are successful, we or our partners conduct Phase III trials
to verify the results in a larger patient population. Phase III trials are required for FDA approval to market a drug. A Phase III trial may require
hundreds or even thousands of patients and is the most expensive to conduct. The goal in Phase III is to collect enough safety and efficacy data
to obtain FDA approval of a drug for treatment of a particular disease. For some clinical indications that are
14
Table of Contents
especially serious and for which there are no effective treatments, such as refractory cancers, conditional approval can be obtained following
Phase II trials.
Initiation and completion of the clinical trial phases are dependent on several factors including things that are beyond our control. For
example, the clinical trials cannot begin at a particular site until that site receives approval from its Institutional Review Board (“IRB”), which
reviews the protocol and related documents. This process can take from several weeks to several months. In addition, clinical trials are
dependent on patient enrollment, but the rate at which patients enroll in the study depends on:
•
•
•
•
•
•
willingness of investigators to participate in a study;
ability of clinical sites to obtain approval from their IRB;
the size of the patient population we intend to treat;
the availability of patients;
the willingness of patients to participate; and
the patients meeting the eligibility criteria.
Delays in planned patient enrollment may result in increased expense and longer development timelines.
After completion of the clinical trials of a product, we or our partners must submit a NDA to the FDA for marketing approval before
commercialization of the product. The FDA may not grant approval on a timely basis, if at all. The FDA, as a result of the Food and Drug
Administration Modernization Act of 1997, has six months to review and act upon license applications for priority therapeutics that are for life-
threatening or unmet medical needs. Standard reviews can take between one and two years, and can even take longer if significant questions
arise during the review process. The FDA may withdraw any required approvals, once obtained.
In addition to clinical development regulations, we and our contract manufacturers and partners must comply with the applicable FDA
current good manufacturing practice (“GMP”) regulations. GMP regulations include requirements relating to quality control and quality
assurance as well as the corresponding maintenance of records and documentation. Manufacturing facilities are subject to inspection by the
FDA. Such facilities must be approved before we can use them in commercial manufacturing of our potential products. We or our contract
manufacturers may not be able to comply with the applicable GMP requirements and other FDA regulatory requirements. If we or our contract
manufacturers fail to comply, our business, financial condition and results of operations will be materially adversely affected.
Human Resources
As of February 28, 2007, we had 85 employees, of whom 61 were engaged in research and development and 24 were in general and
administrative functions. Our scientific staff, 28 of whom hold Ph.D. or M.D. degrees, has diversified experience in biochemistry,
pharmacology, X-ray crystallography, synthetic organic chemistry, computational chemistry, and medicinal chemistry. We consider our
relations with our employees to be satisfactory.
Scientific Advisory Board and Consultants
Our scientific advisory board (“SAB”) is comprised of five scientific advisors who are leaders in certain of our core disciplines or who
otherwise have specific expertise in our therapeutic focus areas. The SAB meets as a group at scheduled meetings and consists of the following
individuals:
Albert F. LoBuglio, M.D. (Chairman)
Name
Director Emeritus and Distinguished Professor,
Comprehensive Cancer Center , University Of Alabama at
Birmingham
Position
15
Table of Contents
Gordon N. Gill, M.D.
Name
Lorraine J. Gudas, Ph.D.
Herbert A. Hauptman, Ph.D.
Hamilton O. Smith, M.D.
Professor of Medicine and Cellular and Molecular Medicine; Dean of Translational
Medicine, University of California, San Diego School of Medicine.
Position
Professor and Chairman, Department of Pharmacology Weill Medical College of
Cornell University, Revlon Pharmaceutical Professor of Pharmacology and
Toxicology.
President of the Hauptman-Woodward Medical Research Institute, Inc. (formerly the
Medical Foundation (Buffalo), Inc.), and Research Professor in Biophysical Sciences
and Distinguished Professor in Structural Biology at the State University of New
York (Buffalo). Recipient of the Nobel Prize in Chemistry (1985).
Professor, Molecular Biology and Genetics Department at The Johns Hopkins
University School of Medicine, retired, and Scientific Director of the Synthetic
Biology and Biological Energy Groups at the J. Craig Venter Institute in Rockville,
Maryland. Recipient of the Nobel Prize in Medicine (1978).
The SAB members are reimbursed for their expenses and receive periodic options to purchase shares of common stock. We also have
consulting agreements with a number of other scientists with expertise in our core disciplines or who are specialists in diseases or treatments on
which we focus. The SAB members and other consultants are all employed by or have consulting agreements with entities other than us, some
of which may compete with us in the future. They are expected to devote only a small portion of their time to our business, although no specific
time commitment has been established. They are not expected to participate actively in our affairs or in the development of our technology.
Several of the institutions with which the SAB members and the consultants are affiliated may adopt new regulations or policies that limit their
ability to consult with us. The loss of the services of the SAB members and the consultants could adversely affect us to the extent that we are
pursuing research or development in areas relevant to their expertise. To the extent members of our SAB members or the consultants have
consulting arrangements with or become employed by any of our competitors, we could be materially adversely affected.
Any inventions or processes independently discovered by the SAB members or the consultants may not become our property and will
probably remain the property of such persons or of such persons’ employers. In addition, the institutions with which they are affiliated may
make available the research services of their personnel, including the SAB members and the consultants, to our competitors pursuant to
sponsored research agreements. We require the SAB members and the consultants to enter into confidentiality agreements which prohibit the
disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas,
developments, discoveries or inventions. However, our competitors may gain access to trade secrets and other proprietary information
developed by us and disclosed to the SAB members and the consultants.
Available Information
We have available a website on the Internet. Our address is www.biocryst.com. We make available at our website our Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the
SEC. We also make available at our website copies of our audit committee charter, compensation committee charter, corporate governance and
nominating committee charter and our code of business conduct, which applies to all employees of BioCryst as well as the members of our
Board of Directors.
16
Table of Contents
ITEM 1A. RISK FACTORS
An investment in our stock involves a high degree of risk. You should consider carefully the following risks, along with all of the other
information included in our other filings with the Securities and Exchange Commission, before deciding to buy our common stock. Additional
risks and uncertainties not currently known to us or that we currently deem to be immaterial may also impair our business operations. If we
are unable to prevent events that have a negative effect from occurring, then our business may suffer. Negative events are likely to decrease
our revenue, increase our costs, make our financial results poorer and/or decrease our financial strength, and may cause our stock price to
decline. In that case, you may lose all or a part of your investment in our common stock.
Risks Relating to Our Business
We have incurred substantial losses since our inception in 1986, expect to continue to incur such losses, and may never be profitable.
Since our inception in 1986, we have not been profitable. We expect to incur additional losses for the foreseeable future, and our losses
could increase as our research and development efforts progress. As of December 31, 2006, our accumulated deficit was approximately
$195.5 million. To become profitable, we must successfully develop drug product candidates, enter into profitable agreements with other
parties and our product candidates must receive regulatory approval. We or these other parties must then successfully manufacture and market
our product candidates. It could be several years, if ever, before we receive royalties from any current or future license agreements or revenues
directly from product sales.
Because of the numerous risks and uncertainties associated with developing our product candidates and their potential for
commercialization, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain
profitability, the market value of our common stock will likely decline.
Our success depends upon our ability to advance our products through the various stages of development, especially through the clinical
trial process.
To receive the regulatory approvals necessary for the sale of our product candidates, we or our partners must demonstrate through
preclinical studies and clinical trials that each product candidate is safe and effective. The clinical trial process is complex and uncertain.
Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show
good results in the trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have a reasonable
commercial potential. We may suffer significant setbacks in pivotal clinical trials, even after earlier clinical trials show promising results. Any
of our product candidates may produce undesirable side effects in humans. These side effects could cause us or regulatory authorities to
interrupt, delay or halt clinical trials of a product candidate. These side effects could also result in the FDA or foreign regulatory authorities
refusing to approve the product candidate for any targeted indications. We, our partners, the FDA or foreign regulatory authorities may suspend
or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail to
demonstrate that our product candidates are safe or effective.
Our ability to successfully complete clinical trials is dependent upon many factors beyond our control, including:
•
•
•
•
our ability to find suitable clinical sites and investigators to enroll patients;
the availability of and willingness of patients to participate in our clinical trials;
difficulty in maintaining contact with patients to provide complete data after treatment;
our product candidates may not prove to be either safe or effective;
17
Table of Contents
•
•
manufacturing or quality problems could affect the supply of drug product for our trials;
delays or changes in requirements by governmental agencies.
Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant time to, preclinical testing
and clinical trials, yet cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials
require adequate supplies of drug and sufficient patient enrollment. Delays in patient enrollment can result in increased costs and longer
development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file
the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidate.
If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates
or continue our research and development programs.
To date, we have financed our operations primarily from sale of our equity securities and cash from collaborative and other research and
development agreements, and, to a lesser extent, interest. For the year, our cash, cash equivalents and marketable securities balance has
decreased from $60.0 million as of December 31, 2005 to $46.2 million as of December 31, 2006, primarily due to the monthly cash burn from
operations less the cash received from collaborations, which totaled to approximately $31.8 million net of sublicense fees.
With the award of the HHS contract to fund the development of peramivir and the current and planned trials for Fodosine™, we expect an
increase in our operating expenses for 2007. However, with the expected reimbursement from the HHS contract and our other partners, we are
projecting our net cash burn rate to average approximately $3.0 million per month in 2007. We caution that both our expenses and our cash
flows will vary significantly from quarter to quarter due to the nature of the trials in influenza and the reimbursement from HHS.
As our clinical programs continue to grow and patient enrollment increases, our costs will increase. Our current and planned clinical trials
plus the related manufacturing, personnel resources and testing required for supporting the development of our drug candidates will consume
significant capital resources and will increase our expenses. Our expenses, revenues and burn rate could vary significantly depending on many
factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our drug candidates, the
amount of funding we receive from HHS for peramivir, the amount of funding or assistance, if any, we receive from other governmental
agencies or other new partnerships with third parties for the development of our drug candidates, the progress and results of our current and
proposed clinical trials for our most advanced drug products, the progress made in the manufacturing of our lead products and the progression
of our other programs.
As of December 31, 2006, we had $46.2 million in cash, cash equivalents and marketable securities. With our currently available funds and
amounts to be received from HHS, Shionogi (and our other collaborators), we believe these resources will be sufficient to fund our operations
for at least the next twelve months. However, this is a forward looking statement, and there may be changes that would consume available
resources significantly before such time. Our long-term capital requirements and the adequacy of our available funds will depend upon many
factors, including:
•
•
•
•
•
•
our ability to perform under the contract with HHS and receive reimbursement;
the progress and magnitude of our research, drug discovery and development programs;
changes in existing collaborative relationships or government contracts;
our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies
and governmental agencies or other third parties;
the extent to which our partners, including governmental agencies will share in the costs associated with the development of our
programs or run the development programs themselves;
our ability to negotiate favorable development and marketing strategic alliances for our drug candidates;
18
Table of Contents
•
•
•
•
•
•
•
•
•
•
the scope and results of preclinical studies and clinical trials to identify and evaluate drug candidates;
our ability to enroll sites and patients in our clinical trials;
the scope of manufacturing of our drug candidates to support our preclinical research and clinical trials;
increases in personnel and related costs to support the development of our drug candidates;
the scope of validation for the manufacturing of our drug substance and drug products required for future NDA filings;
competitive and technological advances;
the time and costs involved in obtaining regulatory approvals;
the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;
our dependence on others for development and commercialization of our product candidates; and
successful commercialization of our products consistent with our licensing strategy.
We expect that we will be required to raise additional capital to complete the development and commercialization of our current product
candidates. Additional funding, whether through additional sales of securities or collaborative or other arrangements with corporate partners or
from other sources, including governmental agencies, in general and from the HHS contract specifically, may not be available when needed or
on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more
favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights
of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate
partners. Insufficient funds may require us to delay, scale-back or eliminate certain of our research and development programs.
If HHS were to eliminate or reduce funding from our contract, this would have a significant negative impact on our anticipated revenues
and cash flows and the development of peramivir.
Our projections of revenues and incoming cash flows for 2007 are substantially dependant upon HHS reimbursement for the costs related to
our peramivir program. If HHS were to eliminate or reduce the funding for this program, we would have to obtain additional funding for
development of this drug candidate or significantly reduce or stop the development effort.
In contracting with HHS, we are subject to various U.S. government contract requirements, including general clauses for a cost-
reimbursement research and development contract, which may limit our reimbursement or if we are found to be in violation could result in
contract termination. U.S. government contracts typically contain unfavorable termination provisions and are subject to audit and modification
by the government at its sole discretion. The U.S. government may terminate its contract with us either for its convenience or if we default by
failing to perform in accordance with the contract schedule and terms, which would have a significant negative impact on our cash flows and
operations.
Our contract with HHS has special contracting requirements, which create additional risks or reduction or loss of funding.
We have entered into a contract with HHS for the advanced development of our neuraminidase inhibitor, peramivir. In contracting with
HHS, we are subject to various U.S. government contract requirements, including general clauses for a cost-reimbursement research and
development contract. U.S. government contracts typically contain unfavorable termination provisions and are subject to audit and
modification by the government at its sole discretion, which subjects us to additional risks. These risks include the ability of the U.S.
government to unilaterally:
•
•
terminate or reduce the scope of our contract; and
audit and object to our contract-related costs and fees, including allocated indirect costs.
The U.S. government may terminate its contract with us either for its convenience or if we default by failing to perform in accordance with
the contract schedule and terms. Termination for convenience provisions generally enable
19
Table of Contents
us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination
for default provisions do not permit these recoveries.
As a U.S. government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting
practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. government may review the adequacy of,
and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating,
compensation and management information systems. Based on the results of its audits, the U.S. government may adjust our contract-related
costs and fees, including allocated indirect costs. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject
to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of
payments, fines and suspension or prohibition from doing business with the U.S. government. We could also suffer serious harm to our
reputation if allegations of impropriety were made against us. In addition, under U.S. government purchasing regulations, some of our costs
may not be reimbursable or allowed under our contracts. Further, as a U.S. government contractor, we are subject to an increased risk of
investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector
commercial companies.
If we fail to establish collaborative relationships to commercialize certain of our drug product candidates or if any partner terminates or
fails to perform its obligations under agreements with us, the commercialization of our product candidates could be delayed or terminated.
A key aspect of our business strategy is to enter into successful collaborative arrangements with pharmaceutical companies, research
institutions, the United States government and universities for the preclinical development, clinical development, regulatory approval,
marketing, domestic and international sales and distribution of our drug product candidates. Our general strategy is to rely upon other parties
for all of these steps so that we can focus exclusively on the key areas of our expertise. For some smaller niche markets, we may perform these
steps ourselves and outsource those functions where we do not have the internal expertise.
Currently, we have established collaborative relationships with four pharmaceutical companies, Roche, Mundipharma, Shionogi and Green
Cross for development and commercialization of BCX-4208, Fodosine™ and peramivir, respectively. The process of establishing and
implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty. Heavy reliance upon collaborative
relationships with these third parties for these critical functions presents several risks, including:
•
•
•
•
•
•
•
•
•
our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, a change in
business strategy, a change of control or other reasons;
our contracts for collaborative arrangements may expire;
our partners may choose to pursue alternative technologies, including those of our competitors;
we may have disputes with a partner that could lead to litigation or arbitration;
we do not have day to day control over the activities of our partners and have limited control over their decisions;
our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and
efficacy of our drug candidates, obtain regulatory approvals and achieve market acceptance of products developed from our drug
candidates;
our partners may not properly maintain or defend our intellectual property rights, where applicable, or they may utilize our
proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary
information or expose us to potential liability;
our partners may not devote sufficient capital or resources towards our product candidates; and
our partners may not comply with applicable government regulatory requirements.
20
Table of Contents
If any partner fails to fulfill its responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could
be delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility
of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue
further development of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative
sources of funding. Any delay in the development or commercialization of our compounds would severely affect our business, because if our
compounds do not progress through the development process or reach the market in a timely manner, or at all, we may not receive additional
future event payments and may never receive product or royalty payments.
If our contract research organizations do not successfully carry out their duties or if we lose our relationships with contract research
organizations, our drug development efforts could be delayed.
We depend on contract research organizations, third-party vendors and investigators for preclinical testing and clinical trials related to our
drug discovery and development efforts, including the HHS contract. We intend to depend on them to assist in our future discovery and
development efforts. These parties are not our employees and we cannot control the amount or timing of resources that they devote to our
programs. If they fail to devote sufficient time and resources to our drug development programs or if their performance is substandard, it will
delay the approval of our products. The parties with which we contract for execution of our clinical trials play a significant role in the conduct
of the trials and the subsequent collection and analysis of data. Their failure to meet their obligations could adversely affect clinical
development of our products. Moreover, these parties may also have relationships with other commercial entities, some of which may compete
with us. If they assist our competitors it could harm our competitive position.
If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another
comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all.
Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide
the same type or level of service as the original provider. In addition, any provider that we retain will be subject to current Good Laboratory
Practices (“cGLP”), current Good Manufacturing Practices (“cGMP”), or current Good Clinical Practices (“cGCP”), and similar foreign
standards and we do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards
are not adhered to by these providers, the development and commercialization of our product candidates could be delayed.
We have not commercialized any products or technologies and our future revenue generation is uncertain.
We have not yet commercialized any products or technologies, and we may never be able to do so. Our revenue from collaborative
agreements is dependent upon the status of our preclinical and clinical programs. If we fail to advance these programs to the point of being able
to enter into successful collaborations, we will not receive any future event or other collaborative payments.
Any future revenue directly from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory
approvals, manufacture, market and commercialize any approved drugs.
If our development collaborations with other parties fail, the development of our drug product candidates will be delayed or stopped.
We rely heavily upon other parties for many important stages of our drug development programs, including:
•
•
•
•
discovery of proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called
enzyme targets;
licensing or design of enzyme inhibitors for development as drug product candidates;
execution of some preclinical studies and late-stage development for our compounds and product candidates;
management of our clinical trials, including medical monitoring and data management;
21
Table of Contents
•
•
•
•
execution of additional toxicology studies that may be required to obtain approval for our product candidates;
manufacturing the starting materials and drug substance required to formulate our drug products and the drug products to be used in
both our clinical trials and toxicology studies;
management of our regulatory function; and
manufacturing, sales, marketing and distribution of our product candidates.
Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme
targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our product development efforts
would suffer. Similarly, if the contract research organizations that conduct our initial or late-stage clinical trials, conduct our toxicology studies,
manufacture our starting materials, drug substance and drug products or manage our regulatory function breached their obligations to us, this
would delay or prevent the development of our product candidates.
Our development of both intravenous and intramuscular dosing of peramivir for avian flu is subject to all disclosed drug development and
potential commercialization risks and numerous additional risks. Any potential revenue benefits to us are highly speculative.
Further development and potential commercialization of peramivir is subject to all the risks and uncertainties disclosed in our other risk
factors relating to drug development and commercialization. In addition, potential commercialization of peramivir is subject to further risks,
including the following:
•
•
•
•
•
•
•
•
the injectable versions of peramivir are at an early stage of development and have been tested in a limited number of humans,
primarily healthy volunteers, and may not be safe or effective;
necessary government or other third party funding and clinical testing for further development of peramivir may not be available
timely, at all, or in sufficient amounts;
the avian flu prevention or treatment concerns may not materialize at all, or in the near future;
advances in flu vaccines could substantially replace potential demand for an antiviral such as peramivir;
any substantial demand for avian flu treatments may occur before peramivir can be adequately developed and tested in clinical
trials;
numerous large and well-established pharmaceutical and biotech companies will be competing to meet the market demand for avian
flu drugs and vaccines;
regulatory authorities may not make needed accommodations to accelerate the drug testing and approval process for peramivir; and
in the next few years, it is expected that a limited number of governmental entities will be the primary potential customers for
peramivir and if we are not successful at marketing peramivir to these entities for any reason, we will not receive substantial
revenues.
If any or all of these and other risk factors occur, we will not attain significant revenues or gross margins from peramivir and our stock price
will be adversely affected.
Because we have limited manufacturing experience, we depend on third-party manufacturers to manufacture our drug product candidates
and the materials for our product candidates. If we cannot rely on third-party manufacturers, we will be required to incur significant costs
and potential delays in finding new third-party manufacturers.
22
Table of Contents
We have limited manufacturing experience and only a small scale manufacturing facility. We currently rely upon third-party manufacturers
to manufacture the materials required for our drug product candidates and most of the preclinical and clinical quantities of our product
candidates. We depend on these third-party manufacturers to perform their obligations in a timely manner and in accordance with applicable
governmental regulations. Our third-party manufacturers may encounter difficulties with meeting our requirements, including problems
involving:
•
•
•
•
•
•
•
inconsistent production yields;
difficulties in scaling production to commercial and validation sizes;
interruption of the delivery of materials required for the manufacturing process;
scheduling of plant time with other vendors or unexpected equipment failure;
potential catastrophes that could strike their facilities;
poor quality control and assurance or inadequate process controls; and
lack of compliance with regulations and specifications set forth by the FDA or other foreign regulatory agencies.
These contract manufacturers may not be able to manufacture the materials required or our drug product candidates at a cost or in quantities
necessary to make them commercially viable. We also have no control over whether third-party manufacturers breach their agreements with us
or whether they may terminate or decline to renew agreements with us. To date, our third party manufacturers have met our manufacturing
requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the
location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with
the FDA’s cGMPs, and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the
launch of a product. The FDA or similar foreign regulatory agencies at any time may also implement new standards, or change their
interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are
unable to comply, we or they may be subject to regulatory action, civil actions or penalties.
If we are unable to enter into agreements with additional manufacturers on commercially reasonable terms, or if there is poor manufacturing
performance on the part of our third party manufacturers, we may not be able to complete development of, or market, our product candidates.
Our raw materials, drug substances, and drug products are manufactured by a limited group of suppliers and some at a single facility. If any
of these suppliers were unable to produce these items, this could significantly impact our supply of drugs for further preclinical testing and
clinical trials.
If the clinical trials of our drug product candidates fail, our product candidates will not be marketed, and we will not realize product related
revenue.
To receive the regulatory approvals necessary for the sale of our product candidates, we or our partners must demonstrate through
preclinical studies and clinical trials that each product candidate is safe and effective. If we or other third party partners are unable to
demonstrate that our product candidates are safe and effective, our product candidates will not receive regulatory approval and will not be
marketed, and we will not realize product related
23
Table of Contents
revenue. The clinical trial process is complex and uncertain. Because of the cost and duration of clinical trials, we may decide to discontinue
development of product candidates that are unlikely to show good results in the trials, unlikely to help advance a product to the point of a
meaningful collaboration, or unlikely to have a reasonable commercial potential. Positive results from preclinical studies and early clinical
trials do not ensure positive results in clinical trials designed to permit application for regulatory approval, called pivotal clinical trials. We may
suffer significant setbacks in pivotal clinical trials, even after earlier clinical trials show promising results. Any of our product candidates may
produce undesirable side effects in humans. These side effects could cause us or regulatory authorities to interrupt, delay or halt clinical trials
of a product candidate. These side effects could also result in the FDA or foreign regulatory authorities refusing to approve the product
candidate for any targeted indications. We, our partners, the FDA or foreign regulatory authorities may suspend or terminate clinical trials at
any time if we or they believe the trial participants face unacceptable health risks. Clinical trials may fail to demonstrate that our product
candidates are safe or effective.
We negotiated a special protocol assessment, or SPA, with the FDA for the recently initiated pivotal clinical trial of our lead anti-cancer
compound, Fodosine™. An SPA is an agreement between an applicant and the FDA on the design and the size of clinical trials that is intended
to form the basis of a New Drug Application (“NDA”). Once the FDA and an applicant reach an agreement on an SPA, the SPA cannot be
changed after the clinical trial begins, except in limited circumstances such as a change in the science or clinical knowledge about the
conditions being studied. Any significant change to the protocols for a clinical trial subject to an SPA would require prior FDA approval, which
could delay implementation of such a change and continuation and completion of the related clinical trial. Receipt of the SPA does not ensure
that Fodosine™ will receive FDA approval or that the process will be accelerated.
Clinical trials are lengthy and expensive. We or our partners incur substantial expense for, and devote significant time to, preclinical testing
and clinical trials, yet cannot be certain that the tests and trials will ever result in the commercial sale of a product. For example, clinical trials
require adequate supplies of drug and sufficient patient enrollment. Delays in patient enrollment can result in increased costs and longer
development times. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file
the required regulatory submissions in a timely manner and may not receive regulatory approval for the product candidate.
If we or our partners do not obtain and maintain governmental approvals for our products under development, we or our partners will not
be able to sell these potential products, which would significantly harm our business because we will receive no revenue.
We or our partners must obtain regulatory approval before marketing or selling our future drug products. If we or our partners are unable to
receive regulatory approval and do not market or sell our future drug products, we will never receive any revenue from such product sales. In
the United States, we or our partners must obtain FDA approval for each drug that we intend to commercialize. The FDA approval process is
typically lengthy and expensive, and approval is never certain. Products distributed abroad are also subject to foreign government regulation.
Neither the FDA nor foreign regulatory agencies have approved any of our drug product candidates. We have several drug products in various
stages of preclinical and clinical development; however, we are unable to determine when, if ever, any of these products will be commercially
available. Because of the risks and uncertainties in biopharmaceutical development, our product candidates could take a significantly longer
time to gain regulatory approval than we expect or may never gain approval. If the FDA delays regulatory approval of our product candidates,
our management’s credibility, our company’s value and our operating results may suffer. Even if the FDA or foreign regulatory agencies
approve a product candidate, the approval may limit the indicated uses for a product candidate and/or may require post-marketing studies.
The FDA regulates, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We
currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate
copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose
important data if our facility incurs damage. If we get approval to market our potential products, whether in the United States or internationally,
we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:
•
adverse drug experience reporting regulations;
24
Table of Contents
•
•
•
product promotion;
product manufacturing, including good manufacturing practice requirements; and
product changes or modifications.
Our failure to comply with existing or future regulatory requirements, or our loss of, or changes to, previously obtained approvals, could
have a material adverse effect on our business because we will not receive product or royalty revenues if we or our partners do not receive
approval of our products for marketing.
In June 1995, we notified the FDA that we submitted incorrect data for our Phase II studies of BCX-34 applied to the skin for CTCL and
psoriasis. In November 1995, the FDA issued a List of Inspectional Observations, Form FDA 483, which cited our failure to follow good
clinical practices. The FDA also inspected us in June 1996. The focus was on the two 1995 Phase II dose-ranging studies of topical BCX-34 for
the treatment of CTCL and psoriasis. As a result of the investigation, the FDA issued us a Form FDA 483, which cited our failure to follow
good clinical practices. We are no longer developing BCX-34; however, as a consequence of these two investigations, our ongoing and future
clinical studies may receive increased scrutiny, which may delay the regulatory review process.
If our drug product candidates do not achieve broad market acceptance, our business may never become profitable.
Our drug product candidates may not gain the market acceptance required for us to be profitable even if they successfully complete initial
and final clinical trials and receive approval for sale by the FDA or foreign regulatory agencies. The degree of market acceptance of any
product candidates that we or our partners develop will depend on a number of factors, including:
•
•
•
•
•
•
our clinical evidence of safety and efficacy;
cost-effectiveness, convenience and ease of use of our product candidates;
their safety, availability and effectiveness relative to alternative treatments;
the actual and potential side effects or other reactions;
reimbursement policies of government and third-party payers; and
the effectiveness of marketing and distribution support for our product candidates.
Physicians, patients, payers or the medical community in general may not accept or use our product candidates even after the FDA or
foreign regulatory agencies approve the drug candidates. If our product candidates do not achieve significant market acceptance, we will not
have enough revenues to become profitable.
We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may be reduced.
The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. We face,
and will continue to face, competition in the licensing of desirable disease targets, licensing of desirable drug product candidates, and
development and marketing of our product candidates from academic institutions, government agencies, research institutions and
biotechnology and pharmaceutical companies. Competition may also arise from, among other things:
•
•
•
other drug development technologies;
methods of preventing or reducing the incidence of disease, including vaccines; and
new small molecule or other classes of therapeutic agents.
25
Table of Contents
Developments by others may render our product candidates or technologies obsolete or noncompetitive.
We and our partners are performing research on or developing products for the treatment of several disorders including T-cell mediated
disorders (T-cell cancers, psoriasis, transplant rejection, and rheumatoid arthritis), oncology, influenza, hepatitis C and cardiovascular
disorders. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that complete
clinical trials, obtain required regulatory approvals and commence commercial sales of their products before their competitors may achieve a
significant competitive advantage. Such is the case with GSK’s Arranon for T-cell ALL and the current neuraminidase inhibitors marketed by
GSK and Roche for influenza. In addition, several pharmaceutical and biotechnology firms, including major pharmaceutical companies and
specialized structure-based drug design companies, have announced efforts in the field of structure-based drug design and in the fields of PNP,
influenza, hepatitis C, and in other therapeutic areas where we have discovery efforts ongoing. If one or more of our competitors’ products or
programs are successful, the market for our products may be reduced or eliminated.
Compared to us, many of our competitors and potential competitors have substantially greater:
•
•
•
•
•
•
capital resources;
research and development resources, including personnel and technology;
regulatory experience;
preclinical study and clinical testing experience;
manufacturing and marketing experience; and
production facilities.
Any of these competitive factors could reduce demand for our products.
If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights
would diminish.
Our success will depend in part on our ability and the abilities of our partners to obtain patent protection for our products, methods,
processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary
rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly
uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent
and Trademark Office (“USPTO”) nor the courts have a consistent policy regarding the breadth of claims allowed or the degree of protection
afforded under many biotechnology and pharmaceutical patents. The validity, enforceability and commercial value of these rights, therefore, is
highly uncertain.
Our success depends in part on avoiding the infringement of other parties’ patents and proprietary rights as well as avoiding the breach of
any licenses relating to our technologies and products. In the U.S., patent applications filed in recent years are confidential for 18 months, while
older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently
infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if
resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial
damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or
delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe,
unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third
party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain
a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.
26
Table of Contents
If we or our partners are unable to adequately protect or enforce our intellectual property rights for our products, methods, processes and
other technologies, the value of the drug product candidates that we license to derive revenue would diminish. Additionally, if our products,
methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO has
issued to us a number of U.S. patents for our various inventions and we have in-licensed several patents from various institutions. We have
filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign
patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We cannot assure you as to:
•
•
•
the degree and range of protection any patents will afford against competitors with similar products;
if and when patents will issue; or
whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.
If the USPTO upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:
•
•
•
obtain licenses or redesign our products or processes to avoid infringement;
stop using the subject matter claimed in those patents; or
pay damages.
We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including
proceedings before the USPTO. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent
application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such
proceeding may be substantial whether or not we are successful.
Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical
personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that
prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas,
developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other
proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any
of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license our technology and
any such events would significantly impair the value of such a license.
If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our drug product
candidates and the expansion of our business will be delayed or stopped.
We are highly dependent upon our senior management and scientific team, the loss of whose services might impede the achievement of our
development and commercial objectives. Competition for key personnel with the experience that we require is intense and is expected to
continue to increase. Our inability to attract and retain the required number of skilled and experienced management, operational and scientific
personnel, will harm our business because we rely upon these personnel for many critical functions of our business. In addition, we rely on
members of our scientific advisory board and consultants to assist us in formulating our research and development strategy. All of the members
of the scientific advisory board and all of our consultants are otherwise employed and each such member or consultant may have commitments
to other entities that may limit their availability to us.
We may be unable to establish sales, marketing and distribution capabilities necessary to successfully commercialize products we may
develop.
We currently have no marketing capability and no direct or third-party sales or distribution capabilities. If we successfully develop a drug
product candidate and decide to commercialize it ourselves rather than relying on third parties, as we are considering doing in the United States
for Fodosine™, we may be unable to establish marketing, sales and distribution capabilities necessary to commercialize and gain market
acceptance for that product.
If users of our drug products are not reimbursed for use, future sales of our drug products will decline.
The lack of reimbursement for the use of our product candidates by hospitals, clinics, patients or doctors will harm our business. Medicare,
Medicaid, health maintenance organizations and other third-party payers may not authorize or otherwise budget for the reimbursement of our
products. Governmental and third-party payers are increasingly
27
Table of Contents
challenging the prices charged for medical products and services. We cannot be sure that third-party payers would view our product candidates
as cost-effective, that reimbursement will be available to consumers or that reimbursement will be sufficient to allow our product candidates to
be marketed on a competitive basis. Changes in reimbursement policies, or attempts to contain costs in the health care industry could limit or
restrict reimbursement for our product candidates and would materially and adversely affect our business, because future product sales would
decline and we would receive less product or royalty revenue.
The Medicare prescription drug coverage legislation and future legislative or regulatory reform of the healthcare system may affect our
ability to sell our products profitably.
In the United States, there have been a number of legislative and regulatory proposals, at both the federal and state government levels, to
change the healthcare system in ways that could affect our ability to sell our products profitably, if approved. For example, the Medicare
Prescription Drug and Modernization Act of 2003 (“MMA”), went into effect in 2006 and has changed the types of drugs covered by Medicare,
and the methodology used to determine the price for such drugs. Further federal and state proposals and healthcare reforms are likely. Our
business could be harmed by the MMA, by the possible effect of this legislation on amounts that private payors will pay and by other
healthcare reforms that may be enacted or adopted in the future.
There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product liability
claim against us could adversely affect our business.
We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face
even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our clinical trials
in the amount of $10 million. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to
obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse
effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is
claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without
merit, could result in:
•
•
•
•
•
•
•
liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if
available;
an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms,
or at all;
withdrawal of clinical trial volunteers or patients;
damage to our reputation and the reputation of our products, resulting in lower sales;
regulatory investigations that could require costly recalls or product modifications;
litigation costs; and
the diversion of management’s attention from managing our business.
If our computer systems fail or our facility incurs damage, our business will suffer.
Our drug development activities depend on the security, integrity and performance of the computer systems supporting them, and the failure
of our computer systems could delay our drug development efforts. We currently store most of our preclinical and clinical data at our facility.
Duplicate copies of most critical data are stored off-site in a bank vault. Any significant degradation or failure of our computer systems could
cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any
system failure could harm our business and operations.
28
Table of Contents
In addition, we store numerous clinical and stability samples at our facility that could be damaged if our facility incurred physical damage or
in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical
functions, but any loss of these samples could result in significant delays in our drug development process.
If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may
incur substantial costs and expenses in our remediation efforts.
Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are
subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste
products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages
that result and any liabilities could exceed our resources. Compliance with environmental laws and regulations could require us to incur
substantial unexpected costs, which would materially and adversely affect our results of operations.
Risks Relating to Our Common Stock
Our stock price is likely to be highly volatile and the value of your investment could decline significantly.
The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in
the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the
twelve months ended December 31, 2006, the 52-week range of the market price of our stock was from $8.20 to $23.00 per share. The
following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common
stock:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
announcements of technological innovations or new products by us or our competitors;
developments or disputes concerning patents or proprietary rights;
status of new or existing licensing or collaborative agreements and government contracts;
we or our partners achieving or failing to achieve development milestones;
publicity regarding actual or potential medical results relating to products under development by us or our competitors;
publicity regarding certain public health concerns for which we are or may be developing treatments;
regulatory developments in both the United States and foreign countries;
public concern as to the safety of pharmaceutical products;
actual or anticipated fluctuations in our operating results;
changes in financial estimates or recommendations by securities analysts;
changes in the structure of healthcare payment systems, including developments in price control legislation;
announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;
additions or departures of key personnel or members of our board of directors;
sales of substantial amounts of our stock by existing stockholders, including officers or directors;
economic and other external factors or other disasters or crises; and
29
Table of Contents
•
period-to-period fluctuations in our financial results.
Because stock ownership is concentrated, you and other investors will have limited influence on stockholder decisions.
As of December 31, 2006, our directors, executive officers and some principal stockholders and their affiliates beneficially owned
approximately 31.7% of our outstanding common stock and common stock equivalents. As a result, these holders, if acting together, are able to
significantly influence matters requiring stockholder approval, including the election of directors. This concentration of ownership may delay,
defer or prevent a change in our control.
We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.
Our board of directors has the authority to issue up to 4,955,000 shares of undesignated preferred stock and to determine the rights,
preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any
preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock
could make it more difficult for third parties to acquire a majority of our outstanding voting stock.
In addition, our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority
approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate
also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of
Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.
In June 2002, our board of directors adopted a stockholder rights plan and, pursuant thereto, issued preferred stock purchase rights
(“Rights”) to the holders of our common stock. The Rights have certain anti-takeover effects. If triggered, the Rights would cause substantial
dilution to a person or group of persons who acquires more than 15% (19.9% for William W. Featheringill, a Director who owned
approximately 9.58% as of December 31, 2006, but owned more than 15% at the time the Rights were put in place) of our common stock on
terms not approved by the board of directors.
We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.
We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our
business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.
Information Regarding Forward-Looking Statements
This discussion contains forward-looking statements, which are subject to risks and uncertainties. These forward-looking statements can
generally be identified by the use of words such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,”
“predicts,” “potential,” “hope,” the negative of these words or similar expressions. Statements that describe our future plans, strategies,
intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking
statements are principally contained in “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations”, as well as any amendments we make to those sections in filings with the SEC. These forward-looking statements include, but are
not limited to, statements about:
•
•
•
the initiation, timing, progress and results of our preclinical and clinical trials, research and development programs;
the further preclinical or clinical development and commercialization of our product candidates;
the implementation of our business model, strategic plans for our business, product candidates and technology;
30
Table of Contents
•
•
•
•
•
•
•
•
our ability to establish and maintain collaborations with biotechnology or pharmaceutical companies and governmental agencies or
other third parties;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and
technology;
our ability to operate our business without infringing the intellectual property rights of others;
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
the timing or likelihood of regulatory filings and approvals;
our negotiations with the FDA for a special protocol assessment;
our financial performance; and
competitive companies, technologies and our industry.
These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties
which may cause our actual results, performance or achievements to be materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on these
forward-looking statements. We discuss many of these risks in greater detail in “Risk Factors.” Also, these forward-looking statements
represent our estimates and assumptions only as of the date of this document.
You should read this discussion completely and with the understanding that our actual future results may be materially different from what
we expect. We may not update these forward-looking statements, even though our situation may change in the future. We qualify all of our
forward-looking statements by these cautionary statements.
None.
ITEM 1B. UNRESOLVED STAFF COMMENTS
Our administrative offices and principal research facilities are located in 50,150 square feet of leased space in Riverchase
Industrial/Research Park in Birmingham, Alabama. The lease runs through June 30, 2010 with an option to renew the lease for an additional
five years at current market rates. In addition, we currently lease 5,375 square feet of office space in Cary, NC through February 2010 for our
clinical and regulatory operation. We believe that our facilities are adequate for our current operations.
ITEM 2. PROPERTIES
None.
None.
ITEM 3. LEGAL PROCEEDINGS
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
31
Table of Contents
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock trades on the NASDAQ Global Market SM under the symbol BCRX. The following table sets forth the low and high
sales prices of our common stock as reported by NASDAQ Global Market SM for each quarter in 2006 and 2005:
First quarter
Second quarter
Third quarter
Fourth quarter
2006
2005
Low
$ 15.80
10.89
8.20
10.80
High
$ 23.00
18.11
14.94
12.89
Low
$ 4.32
3.68
4.90
9.70
High
$ 6.91
5.25
10.44
18.64
The last sale price of the common stock on March 7, 2007 as reported by NASDAQ Global Market SM was $9.64 per share.
Holders
As of March 7, 2007, there were approximately 263 holders of record of our common stock.
Dividends
We have never paid cash dividends and do not anticipate paying cash dividends in the foreseeable future.
Stock Performance Graph
32
Table of Contents
This performance graph is not “soliciting material,” is not deemed filed with the SEC and is not to be incorporated by reference in any filing by
us under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing. The stock price performance shown on the graph is not necessarily
indicative of future price performance.
PERFORMANCE GRAPH FOR BIOCRYST
Indexed Comparison Since 2001
BioCryst Pharmaceuticals, Inc.
The NASDAQ Stock Market
NASDAQ Pharmaceutical Stocks
Beginning
Investment
12/31/01
$ 100.00
100.00
100.00
Investment
at 12/31/02
$ 24.24
69.13
64.62
Investment
at 12/31/03
$ 172.98
103.36
94.72
Investment
at 12/31/04
$ 145.96
112.49
100.88
Investment
at 12/31/05
$ 422.98
114.88
111.09
Investment
at 12/31/06
$ 291.92
126.22
108.75
The above graph measures the change in a $100 investment in the Company’s common stock based on its closing price of $3.96 on
December 31, 2001 and its year-end closing price thereafter. The Company’s relative performance is then compared with the CRSP Total
Return Indexes for the NASDAQ Stock Market (US) and NASDAQ Pharmaceutical Stocks.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the fiscal year ended December 31, 2006.
33
Table of Contents
ITEM 6. SELECTED FINANCIAL DATA
Statement of Operations Data:
Total revenues
Research and development expenses
2006
$ 6,212
47,083
Years Ended December 31,
(In thousands, except per share data)
2004
2005
2003
$
152
23,642
$
337
18,868
$
653
11,522
2002
$ —
15,473
Net loss
(43,618 )
(26,099 )
(21,104 )
(12,700 )
(16,929 )
Amounts per common share:
Basic and diluted net loss per share
$
(1.50 )
$
(1.01 )
$
(1.00 )
$
(.72 )
$
(.96 )
Weighted average shares outstanding
29,147
25,721
21,165
17,703
17,643
Balance Sheet Data:
Cash, cash equivalents and securities
Total assets
Long-term deferred revenue
Accumulated deficit
Total stockholders’ equity
2006
$ 46,236
68,485
36,596
(195,481 )
21,155
2005
$ 59,988
99,248
29,426
(151,863 )
58,440
December 31,
(In thousands)
2004
$ 28,704
32,469
300
(125,764 )
29,334
2003
$ 25,732
30,096
300
(104,660 )
28,447
2002
$ 36,163
41,300
300
(91,960 )
40,128
34
Table of Contents
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATION
This Annual Report on Form 10-K contains certain statements of a forward-looking nature relating to future events or the future financial
performance of BioCryst. Such statements are only predictions and the actual events or results may differ materially from the results discussed
in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed below as well as those
discussed in other filings made by BioCryst with the Securities and Exchange Commission.
This discussion of our financial condition and results of operations should be read together with Item 1, Business and the financial
statements, including the notes thereto, contained in Item 8 of this Form 10-K .
Overview
Since our inception in 1986, we have been engaged in research and development activities and organizational efforts, including:
•
identifying and licensing enzyme targets;
•
drug discovery;
•
structure-based design of drug candidates;
•
small-scale synthesis of compounds;
•
•
conducting preclinical studies and clinical trials;
establishing collaborative relationships with third parties for contract research related to the development of our drug candidates to
support manufacturing, clinical development and regulatory compliance;
•
establishing collaborative relationships with biotechnology or pharmaceutical companies and governmental agencies or other third
parties for the further development and potential commercialization of our compounds;
•
recruiting our scientific and management personnel;
•
establishing laboratory facilities; and
•
raising capital.
Our revenues have generally been limited to license fees, event payments, research and development fees, and interest income. Revenue is
recognized in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition (“SAB No. 104”) and Emerging Issues Task Force
Issue 00-21, Revenue Arrangements with Multiple Deliverables (“EITF Issue 00-21”). License fees, future event payments, and research and
development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations
or we have completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related
to future performance are deferred and recognized as earned over an estimated period determined by management based on the terms of the
agreement and the products licensed. For example, in the Roche and Mundipharma licenses agreements, we deferred the upfront payments over
the remaining life of the patents which are through 2023 and 2017, respectively. We are currently evaluating the period of deferral for the
upfront payment related to the Shionogi agreement. In the event a license agreement contains multiple deliverables, we evaluate whether the
deliverables are separate or combined units of accounting in accordance with EITF Issue 00-21. Revisions to revenue or profit estimates as a
result of changes in the estimated revenue period are recognized prospectively.
Future event payments are recognized as revenue upon the achievement of specified events if (1) the event is substantive in nature and the
achievement of the event was not reasonably assured at the inception of the agreement and
35
Table of Contents
(2) the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred
revenue.
Under the guidance of EITF Issue 99-19 and EITF Issue 01-14, reimbursements received for direct out-of-pocket expenses related to
research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. For example, the
amounts received from our collaboration with Mundipharma for the reimbursement of clinical trial costs and the costs received from HHS for
reimbursement will be recorded as revenue in the period the related costs were recorded. Significant direct costs incurred upon entering into a
licensing arrangement, such as our sublicense fees to AECOM and IRL, are deferred and charged to expense in proportion to the revenue
recognized.
Royalty revenue is recognized based on estimates of royalties earned during the applicable period and adjusted for differences between the
estimated and actual royalties in the following period. If royalties can not be reasonably estimated, revenue is recognized upon receipt of
royalty statements from the licensee. We have not received any royalties from the sale of licensed pharmaceutical products.
It could be several years, if ever, before we will recognize significant revenue from royalties received pursuant to our license agreements or
revenue directly from product sales. Future revenues, if any, are likely to fluctuate substantially from quarter to quarter.
We have incurred operating losses since our inception. Our accumulated deficit at December 31, 2006 was $195.5 million. We expect to
incur substantial expenditures relating to the development of our current and future drug candidates. During the three years ended
December 31, 2006, we spent 66.0% of our research and development expenses on contract research and development, including:
•
•
•
•
•
•
•
•
•
•
payments to consultants;
funding of research at academic institutions;
toxicology studies on existing and potential drugs;
manufacturing of our raw materials, drug substance and drug products;
large scale synthesis and formulation of compounds;
preclinical studies;
payments of amounts to academic institutions and others as a result of our recent collaborations;
engaging investigators to conduct clinical trials;
hiring contract research organizations for regulatory and clinical functions; and
using statisticians to evaluate the results of clinical trials.
The above expenditures for contract research and development for our current and future drug candidates will vary from quarter-to-quarter
depending on the status of our research and development projects. For example, during the third quarter of 2006, we incurred significant costs
related to the Phase I trials with peramivir and the ongoing validation manufacturing for peramivir drug substance. Results from these Phase I
trials have enabled us to design the Phase II trials beginning in the 2006-2007 flu season. In addition, we initiated a Phase II pivotal trial with
Fodosine™ in January 2007. As these trials progress and additional trials are started in other indications, our costs for clinical studies will
increase significantly. In addition, the costs associated with the manufacturing of Fodosine™ and peramivir will increase as we continue
scaling up to the larger production runs required for clinical development, manufacturing validation and additional toxicology studies for these
programs.
36
Table of Contents
Changes in our existing and future research and development and collaborative relationships also will impact the status of our research and
development projects. For example, in January 2007, we announced a $102.6 million contract with HHS for the full funding of the
development, manufacturing and clinical trials required for licensure of peramivir with both the i.v. and i.m. formulations. In March 2007, we
announced a license agreement with Shionogi for the development and commercialization of peramivir in Japan for an upfront payment of
$14 million. In November 2005 we entered into a license agreement with Roche for the worldwide development and commercialization for our
second PNP inhibitor, BCX-4208. In addition to an upfront payment plus an advance payment for manufacturing we performed, Roche has
taken over the development and is paying all costs associated with this program. In February 2006, we licensed Fodosine™ to Mundipharma
for the development and commercialization of this drug in Europe, Asia and Australasia. In addition to the upfront payment of $10 million,
Mundipharma is paying 50% of the clinical development costs we incur for Fodosine™ on existing and planned clinical trials, but their portion
shall not exceed $10 million.
For the Roche and Mundipharma collaborations, we will owe sublicense payments to AECOM and IRL on all upfront, future event
payments and royalties. For the Shionogi and Green Cross collaborations, we will owe sublicense payments to UAB. For 2006, we paid
approximately $8.2 million related to the Roche and Mundipharma agreements. The revenue from these agreements has been recorded as
deferred revenue on our balance sheet and will be recognized over the remaining patent life of the related drug candidate. The payments to
AECOM and IRL have been recorded as deferred assets on our balance sheet and will be recognized over the period of the related revenue
recognition. Due to the nature of the potential milestones in our collaborations, it is difficult to predict if and when particular milestones will be
achieved by us or our partners.
The contract with HHS is a standard cost-plus-fixed-fee contract which provides for the reimbursement of allowable costs plus an element
of overhead and profit. This is expected to have a significant positive revenue impact on our financial statements. As the costs of our peramivir
program increase for the clinical trials, manufacturing and other expenses we will submit invoices to HHS for reimbursement of expenses
allowable under the contract. The expenses are recorded as R&D expenses and reimbursements are recorded as revenue. In the same way, as
we incur R&D costs for our Fodosine™ program that are reimbursable under the Mundipharma contract or R&D expenses for peramivir that
are related to the Shionogi contract, we will invoice the respective company for those costs. The amounts reimbursable will be recorded as
revenue in the same period the costs are incurred. During January 2007, we initiated a pivotal clinical trial with Fodosine™ in T-ALL, which
triggered a $5 million milestone payment from Mundipharma. The revenues expected from the Mundipharma agreement in 2007 will consist of
continuing reimbursement of R&D expenses in accordance with the contract and the amortization of the upfront and milestone payments. The
primary revenue expected from the Roche agreement for 2007 is the continuing amortization of the upfront payment received.
Although we may, in some cases, be able to control the timing of development expenses, in part by accelerating or decelerating certain
costs, many of these costs will be incurred irrespective of whether we are able to discover drug candidates or obtain collaborative partners for
commercialization. In addition, the achievement of milestones in our collaboration agreements is uncertain and unpredictable and would most
likely have a significant impact on our operating results in the periods they are achieved. As a result, we believe that quarter-to-quarter
comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of future performance. If we
fail to meet the research, clinical and financial expectations of securities analysts and investors, it could have a material adverse effect on the
price of our common stock.
Year Ended December 31, 2006 Compared with the Year Ended December 31, 2005
Collaborative and other research and development revenue was $6,212,000 for the year compared to $152,000 for 2005. The increase for
2006 was primarily due to amounts earned pursuant to our collaboration agreements with Mundipharma and Roche, plus the continuing
amortization of the upfront payments from those agreements.
Research and development expenses for 2006 were $47,083,000, a 99.1% increase from 2005 expenses of $23,642,000, primarily
attributable to the clinical and manufacturing costs of our expanded peramivir and Fodosine™ programs, a $1,549,000 non-cash share-based
compensation charge related to adoption of Statement of Financial Accounting Standards No. 123(R) (“SFAS 123R”) in January 2006,
increases in personnel and related costs to support the clinical development of our pipeline, and increases in consulting and toxicology. As of
December 31, 2006, the Company had incurred approximately $2.3 million of pre-contract costs directly related to the Phase 2 trials for both
the
37
Table of Contents
intravenous and intramuscular peramivir products. These costs were incurred in anticipation of a contract award from HHS and were required
to meet the delivery schedule of the proposed contract. In accordance with the provisions of Federal Acquisition Regulation 31.205-32, the
costs were included in the Company’s request for proposal and are eligible for reimbursement from HHS. The $2.3 million of costs incurred
prior to the contract award date were deferred and are included in other current assets on the Company’s balance sheet at December 31, 2006.
In the first quarter of 2007, the $2.3 million in costs will be billed and expensed. Concurrently, revenue will be recognized for these costs plus
the applicable fixed fee.
General and administrative expenses for 2006 were $6,108,000, an increase of 65.7% over the 2005 expense of $3,686,000, primarily due to
the $1,790,000 non-cash share-based compensation charge related to SFAS 123R, an increase in professional fees, and an increase in personnel
related expenses. These increases were partially offset by an increase in costs allocated to research and development.
Interest income for 2006 was $3,362,000, a 211.9% increase compared to $1,078,000 in 2005. This increase was due to a higher average
cash balance during 2006 and a more favorable interest rate environment as compared to 2005.
The net loss for the year ended December 31, 2006 was $43,618,000, or $1.50 per share, compared to a net loss of $26,099,000, or $1.01
per share in 2005.
Year Ended December 31, 2005 Compared with the Year Ended December 31, 2004
Collaborative and other research and development revenue was $152,000 for the year compared to $337,000 for 2004 due to completion of
work performed under the NIH grant for hepatitis C during 2005. Also, there was an NIH grant during 2004 for our TF/FVIIa program that
totaled approximately $100,000, which was completed in 2004.
Research and development expenses for 2005 were $23,642,000, a 25.3% increase from 2004 expenses of $18,868,000, which is directly
related to the additional contract research, clinical trial and toxicology expenses required for the further development of our lead drug
candidates during 2005 and an increase in personnel costs.
General and administrative expenses for 2005 were $3,686,000, an increase of 14.4% over the 2004 expense of $3,221,000, primarily due to
an increase in legal fees related to the Mundipharma and Roche collaborations and an increase in personnel related expenses.
Interest income for 2005 was $1,078,000, a 66.4% increase compared to $648,000 in 2004. This increase was due to a higher average cash
balance during 2005 and a more favorable interest rate environment as compared to 2004.
The net loss for the year ended December 31, 2005 was $26,099,000, or $1.01 per share, compared to a net loss of $21,104,000, or $1.00
per share in 2004.
Liquidity and Capital Resources
Cash expenditures have exceeded revenues since our inception. Our operations have principally been funded through public offerings and
private placements of equity and debt securities and cash from collaborative and other research and development agreements and to a lesser
extent interest. For example, during December 2005, we raised $30.0 million (approximately $29.9 million net of expenses) through a sale of
2,228,829 shares of our common stock. During 2006, we received cash from collaborative and other research and development agreements
(primarily Roche and Mundipharma) of approximately $31.8 million net of sublicense fees. Based on anticipated cash receipts from the HHS
contract and the collaborations with Shionogi, Mundipharma and Roche we expect such cash receipts to increase significantly. Other sources of
funding have included the following:
•
other collaborative and other research and development agreements;
•
government grants and contracts;
•
equipment lease financing;
38
Table of Contents
•
facility leases;
•
research grants; and
•
interest income.
In addition, we have attempted to contain costs and reduce cash flow requirements by renting scientific equipment and facilities, contracting
with other parties to conduct certain research and development and using consultants. We expect to incur additional expenses, potentially
resulting in significant losses, as we continue to pursue our research and development activities, undertake additional preclinical studies and
clinical trials of compounds which have been or may be discovered and as we increase the manufacturing of our compounds for clinical trials
and for the continuation of the validation process. We also expect to incur substantial expenses related to the filing, prosecution, maintenance,
defense and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical products advance
through later stages of development.
We invest our excess cash principally in U.S. marketable securities from a diversified portfolio of institutions with strong credit ratings and
in U.S. government and agency bills and notes, and by policy, limit the amount of credit exposure at any one institution. These investments are
generally not collateralized and mature within two years. We have not realized any losses from such investments.
We have financed some of our equipment purchases with lease lines of credit. Our lease for our current Birmingham facilities expires on
June 30, 2010. We have an option to renew the lease for an additional five years at the current market rate in effect on June 30, 2010 and a one-
time option to terminate the lease on June 30, 2008 for a termination fee of approximately $124,000. The lease requires us to pay monthly rent
currently at $37,963 per month in December 2006 and escalating annually to a minimum of $41,481 per month in the final year, plus our pro
rata share of operating expenses and real estate taxes in excess of base year amounts.
In August 2006, we opened an office in Cary, North Carolina for the establishment of our clinical and regulatory operation. We currently
have 5,375 square feet under lease through February 2010. This lease requires us to pay $7,391 per month and escalates annually to $7,841 per
month in the final year.
We have not incurred any significant charges related to building renovations since 2001. Our capital costs during 2006 were approximately
$1.4 million and we anticipate capital costs of approximately $2.0 million in 2007.
At December 31, 2006, we had long-term operating lease obligations, which provide for aggregate minimum payments of $549,758 in 2007,
$565,257 in 2008 and $538,351 in 2009. These obligations include the future rental of our operating facilities.
We plan to finance our needs principally from the following:
•
payments under our contract with HHS;
•
•
•
our existing capital resources and interest earned on that capital;
payments under collaborative and licensing agreements with corporate partners; and
lease or loan financing and future public or private financing.
For the year, our cash, cash equivalents and marketable securities balance has decreased from $60 million as of December 31, 2005 to
$46.2 million as of December 31, 2006, primarily due to the monthly cash burn from operations less the cash received from collaborations,
which totaled to approximately $31.8 million net of sublicense fees.
The collaboration with Roche for the worldwide development and commercialization of BCX-4208 provided an upfront payment of
$30 million, which was received in 2006. Roche has taken over the development and is paying all costs associated with this program. The
agreement also provides for future event payments and royalties to be made by Roche upon the achievement of certain clinical, regulatory and
sales events.
39
Table of Contents
In February 2006, we licensed Fodosine™ to Mundipharma for the development and commercialization of this drug in Europe, Asia and
Australasia. In addition to the upfront payment of $10 million, which was received in February 2006, Mundipharma is paying 50% of the
clinical development costs we are incurring for Fodosine™ on existing and planned clinical trials, but their portion shall not exceed
$10 million. In addition, Mundipharma will conduct additional clinical trials at their own cost up to a maximum of $15 million. The agreement
also provides for future event payments and royalties to be made by Mundipharma upon the achievement of certain clinical, regulatory and
sales events. In January 2007, we initiated our pivotal study with Fodosine™ in T-cell leukemia patients, which triggered a $5 million event
payment from Mundipharma.
In January 2007, we announced that HHS had awarded the Company a $102.6 million, four-year contract for the advanced development of
peramivir. Funding from the contract will support manufacturing, process validation, clinical studies and other product approval requirements
for peramivir. The contract is a standard cost plus fixed fee contract, which will have a significant positive impact on our financial position and
cash flow. We will bill our incurred costs to HHS on a monthly basis. Any significant delays in payment or cancellation of this contract by
HHS would have a significant negative effect on our financial position.
In January 2007, we announced the initiation of a pivotal Phase IIb clinical trial with Fodosine™ in patients with T-ALL. This trial is being
conducted under a SPA negotiated with the FDA. In addition, we are in active discussions with the FDA to determine what would be required
to initiate a pivotal clinical trial with Fodosine™ in CTCL patients later in 2007. With the initiation of the pivotal Phase IIb clinical trial, we
achieved one milestone related to our collaboration with Mundipharma, which triggered a $5.0 million payment. In addition, Mundipharma
will reimburse us for our clinical development costs of Fodosine™ up to the $10 million defined in our agreement. In March 2007, we
announced a collaborative agreement with Shionogi for rights to peramivir in Japan. This agreement requires an upfront payment of
$14 million that will be received in 2007.
With the award of the HHS contract to fund the development of peramivir and the current and planned trials for Fodosine™, we expect an
increase in our research and development expenses for 2007. However, with the expected reimbursement from the HHS contract and our other
partners, we are projecting our net cash burn rate to average approximately $3.0 million per month in 2007. We caution that both our expenses
and our cash flows will vary significantly from quarter to quarter due to the nature of the trials in influenza and the reimbursement from HHS.
As our clinical programs continue to grow and patient enrollment increases, our costs will increase. Our current and planned clinical trials
plus the related manufacturing, personnel resources and testing required to support the development of our drug candidates will consume
significant capital resources and will increase our expenses. Our expenses, revenues and burn rate could vary significantly depending on many
factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our drug candidates, the
amount of funding we receive from HHS for peramivir, the amount of funding or assistance, if any, we receive from other governmental
agencies or other new partnerships with third parties for the development of our drug candidates, the progress and results of our current and
proposed clinical trials for our most advanced drug products, the progress made in the manufacturing of our lead products and the progression
of our other programs.
As of December 31, 2006, we had $46.2 million in cash, cash equivalents and marketable securities. With our currently available funds and
amounts to be received from HHS, Shionogi (and our other collaborators), we believe these resources will be sufficient to fund our operations
for at least the next twelve months. However, this is a forward looking statement, and there may be changes that would consume available
resources significantly before such time. Our long-term capital requirements and the adequacy of our available funds will depend upon many
factors, including:
•
•
•
•
our ability to perform under the contract with HHS and receive reimbursement;
the progress and magnitude of our research, drug discovery and development programs;
changes in existing collaborative relationships or government contracts;
our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies
and governmental agencies or other third parties;
40
Table of Contents
•
the extent to which our partners, including governmental agencies will share in the costs associated with the development of our
programs or run the development programs themselves;
•
•
•
•
•
•
•
•
•
•
•
our ability to negotiate favorable development and marketing strategic alliances for our drug candidates;
the scope and results of preclinical studies and clinical trials to identify and evaluate drug candidates;
our ability to enroll sites and patients in our clinical trials;
the scope of manufacturing of our drug candidates to support our preclinical research and clinical trials;
increases in personnel and related costs to support the development of our drug candidates;
the scope of validation for the manufacturing of our drug substance and drug products required for future NDA filings;
competitive and technological advances;
the time and costs involved in obtaining regulatory approvals;
the costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;
our dependence on others for development and commercialization of our product candidates; and
successful commercialization of our products consistent with our licensing strategy.
We expect that we will be required to raise additional capital to complete the development and commercialization of our current product
candidates. Additional funding, whether through additional sales of securities or collaborative or other arrangements with corporate partners or
from other sources, including governmental agencies in general and from the HHS contract specifically, may not be available when needed or
on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more
favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights
of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate
partners. Insufficient funds may require us to delay, scale-back or eliminate certain of our research and development programs.
Off-Balance Sheet Arrangements
As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as structured finance or special purpose entities (“SPEs”), which would have been established for
the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December 31, 2006, we are
not involved in any material unconsolidated SPE or off-balance sheet arrangements.
Contractual Obligations
In the table below, we set forth our enforceable and legally binding obligations and future commitments and obligations related to all
contracts that we are likely to continue regardless of the fact that they are cancelable as of December 31, 2006. Some of the amounts we
include in this table are based on management’s estimates and assumptions about these obligations, including their duration, the possibility of
renewal, anticipated actions by third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the
obligations we will actually pay in future periods may vary from those reflected in the table.
41
Table of Contents
Contractual Obligations
Operating Lease Obligations
Purchase Obligations (1)
Other Long-Term Liabilities Reflected on BioCryst’s
Balance Sheet Under GAAP
Total
Payments due by period
Total
$ 1,909,209
16,174,050
Less than
1 year
$
549,758
14,894,050
1-3 years
$ 1,103,608
460,000
3-5 years
$ 255,843
460,000
More than
5 years
$
—
360,000
300,000
$ 18,383,259
—
$ 15,443,808
—
$ 1,563,608
—
$ 715,843
300,000
$ 660,000
(1) Purchase obligations include commitments related to clinical development, manufacturing and research operations and other significant
purchase commitments.
In addition to the above, we have committed to make potential future “sublicense” payments to third-parties as part of in-licensing and
development programs. Payments under these agreements generally become due and payable only upon achievement of certain developmental,
regulatory and/or commercial milestones. Because the achievement of these milestones is neither probable nor reasonably estimable, such
contingencies have not been recorded on our balance sheet.
Critical Accounting Policies
We have established various accounting policies that govern the application of accounting principles generally accepted in the United States,
which were utilized in the preparation of our financial statements. Certain accounting policies involve significant judgments and assumptions
by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting
policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other
factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by
management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of
assets and liabilities and the results of operations.
While our significant accounting policies are more fully described in Note 1 to our financial statements included in our Annual Report on
Form 10-K for the year ended December 31, 2006, we believe that the following accounting policies are the most critical to aid you in fully
understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the
preparation of our financial statements.
Revenue Recognition
Our revenues have generally been limited to license fees, event payments, research and development fees, and interest income. Revenue is
recognized in accordance with SAB No. 104 and EITF Issue 00-21. License fees, future event payments, and research and development fees
are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations, or we have
completed the performance obligations under the terms of the agreement. Fees received under licensing agreements that are related to future
performance are deferred and recognized as earned over an estimated period determined by management based on the terms of the agreement
and the products licensed. For example, in the Roche and Mundipharma licenses agreements, we deferred the upfront payments over the
remaining life of the patents which are 2023 and 2017, respectively. We are currently evaluating the deferral period for recognizing the upfront
payment from Shionogi. In the event a license agreement contains multiple deliverables, we evaluate whether the deliverables are separate or
combined units of accounting in accordance with EITF Issue 00-21. Revisions to revenue or profit estimates as a result of changes in the
estimated revenue period are recognized prospectively.
Future event payments are recognized as revenue upon the achievement of specified events if (1) the event is substantive in nature and the
achievement of the event was not reasonably assured at the inception of the agreement and
42
Table of Contents
(2) the fees are non-refundable and non-creditable. Any event payments received prior to satisfying these criteria are recorded as deferred
revenue.
Under the guidance of EITF Issue 99-19 and EITF Issue 01-14, reimbursements received for direct out-of-pocket expenses related to
research and development costs are recorded as revenue in the income statement rather than as a reduction in expenses. For example, the
amounts received from our collaboration with Mundipharma for the reimbursement of clinical trial costs and the costs received from HHS for
reimbursement will be recorded as revenue in the period the related costs were recorded. Significant direct costs incurred upon entering into a
licensing arrangement, such as our sublicense fees to AECOM and IRL, are deferred and charged to expense in proportion to the revenue
recognized.
Royalty revenue is recognized based on estimates of royalties earned during the applicable period and adjusted for differences between the
estimated and actual royalties in the following period. If royalties can not be reasonably estimated, revenue is recognized upon receipt of
royalty statements from the licensee. We have not received any royalties from the sale of licensed pharmaceutical products.
Research and Development Expenses
Major components of R&D expenses consist of personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory,
and toxicology services performed by contract research organizations (CRO’s), materials and supplies, and overhead allocations consisting of
various administrative and facilities related costs. We charge these costs to expense when incurred, consistent with Statement of Financial
Accounting Standards No. 2, Accounting for Research and Development Costs . These costs are a significant component of R&D expenses.
Most of our manufacturing and our clinical and preclinical studies are performed by third-party CRO’s. We accrue costs for studies performed
by CRO’s over the service periods specified in the contracts and adjust our estimates, if required, based upon our on-going review of the level
of services actually performed. We expense both our internal and external research and development costs as incurred.
Additionally, we have license agreements with third parties, such as AECOM and IRL that require maintenance fees or fees related to
sublicense agreements. These fees are generally expensed as incurred unless they are related to revenues that have been deferred in which case
the expenses will be deferred and recognized over the related revenue recognition period.
We group our R&D expenses into two major categories: direct external expenses and all other R&D expenses. Direct external expenses
consist of costs of outside parties to conduct laboratory studies, to develop manufacturing processes and manufacture the product candidate, to
conduct and manage clinical trials and similar costs related to our clinical and preclinical studies. These costs are accumulated and tracked by
program. All other R&D expenses consist of costs to compensate personnel, to purchase lab supplies and services, to maintain our facility,
equipment and overhead and similar costs of our research and development efforts. These costs apply to work on our clinical and preclinical
candidates as well as our discovery research efforts. These costs have not been charged directly to each program historically because the
number of product candidates and projects in research and development may vary from period to period and because we utilize internal
resources across multiple projects at the same time.
The following table summarizes our R&D expenses for the periods indicated:
Direct external R&D expenses by program:
PNP Inhibitor (Fodosine™)
PNP Inhibitor (BCX-4208)
Neuraminidase Inhibitor (peramivir)
Hepatitis C Polymerase Inhibitor
Tissue Factor/Factor VIIa Inhibitor
Other
All other R&D expenses:
Compensation and fringe benefits
43
2006
Year ended December 31,
2005
2004
$ 17,667,599
643,605
11,352,737
1,673,480
153,326
52,850
$ 9,256,417
3,563,966
1,454,738
446,828
25,072
21,167
$ 8,031,922
2,815,773
27,059
205,741
472,633
19,451
6,870,194
3,813,281
3,115,231
Table of Contents
Supplies and services
Maintenance, depreciation, and amortization
Overhead allocation and other
2006
3,366,683
975,790
4,327,108
Year ended December 31,
2005
572,056
984,680
3,504,172
2004
88,515
1,227,117
2,864,670
Total R&D expenses
$ 47,083,372
$ 23,642,377
$ 18,868,112
At this time, due to the risks inherent in the clinical trial process and given the stages of our various product development programs, we are
unable to estimate with any certainty the costs we will incur in the continued development of our drug candidates for potential
commercialization. While we are currently focused on advancing each of our development programs, our future R&D expenses will depend on
the determinations we make as to the scientific and clinical success of each drug candidate, as well as ongoing assessments as to each drug
candidate’s commercial potential. As such, we are unable to predict how we will allocate available resources among our product development
programs in the future. In addition, we cannot forecast with any degree of certainty the development progress of our existing partnerships for
our drug candidates, which drug candidates will be subject to future collaborations, when such arrangements will be secured, if at all, and to
what degree such arrangements would affect our development plans and capital requirements.
The successful development of our drug candidates is uncertain and subject to a number of risks. We cannot be certain that any of our drug
candidates will prove to be safe and effective or will meet all of the applicable regulatory requirements needed to receive and maintain
marketing approval. Data from preclinical studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent
regulatory clearance. We, the FDA or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects
participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or
other problems with our products under development. Delays or rejections may be encountered based on additional governmental regulation,
legislation, administrative action or changes in FDA or other regulatory policy during development or the review process. Other risks
associated with our product development programs are described in Risk Factors in Part I, Item 1A of this Annual Report on Form 10-K, as
updated from time to time in our subsequent periodic reports and current reports filed with the SEC. Due to these uncertainties, accurate and
meaningful estimates of the ultimate cost to bring a product to market, the timing of completion of any of our product development programs
and the period in which material net cash inflows from any of our product development programs will commence are unavailable.
Accrued Expenses
As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves reviewing open
contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and
estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise
notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our
accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses
include:
•
•
•
fees paid to contract research organizations in connection with preclinical and toxicology studies and clinical trials;
fees paid to investigative sites in connection with clinical trials;
fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and drug products; and
•
professional service fees.
We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with
multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. The financial terms of
these agreements are subject to negotiation, vary from contract to
44
Table of Contents
contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment
of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be
performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or
overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.
Stock-Based Compensation
At December 31, 2006, we have two stock-based employee compensation plans, the Stock Incentive Plan and the Employee Stock Purchase
Plan. Prior to January 1, 2006, we accounted for these plans under the recognition and measurement provisions of Accounting Principles Board
Opinion No. 25, Accounting for Stock Issued to Employees , and other related Interpretations, as permitted by Statement of Financial
Accounting Standards No. 123, Accounting for Stock-Based Compensation (“Statement No. 123”). No stock-based compensation cost related
to our employees was recognized in the Statements of Operations for any period ending prior to January 1, 2006, as all options granted to our
employees had exercise prices equal to the market value of the underlying common stock on the date of grant. Effective January 1, 2006, we
adopted the fair value recognition provisions of Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment
(“Statement No. 123R”), using the modified prospective transition method. Compensation cost recognized during 2006 included:
(a) compensation cost for all share-based payments granted prior to, but not yet vested as of December 31, 2005, based on the grant date fair
value estimated in accordance with the original provisions of Statement No. 123, and (b) compensation cost for all share-based payments
granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of Statement No. 123R.
Results for prior periods have not been restated.
Under the fair value recognition provisions of Statement No. 123R, stock-based compensation cost is estimated at the grant date based on
the fair value of the award and is recognized as expense over the requisite service period of the award. Consistent with the valuation method we
used for disclosure-only purposes under the provisions of Statement No. 123, we use the Black-Scholes option pricing model to estimate fair
value under Statement No. 123R. Determining the appropriate fair value model and the related assumptions for the model requires judgment,
including estimating the life of an award, the stock price volatility, and the expected term. Compensation cost is recognized on a straight-line
basis over the requisite service period.
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK.
The primary objective of our investment activities is to preserve principal while maximizing the income we receive from our investments
without significantly increasing our risk. We invest excess cash principally in U.S. marketable securities from a diversified portfolio of
institutions with strong credit ratings and in U.S. government and agency bills and notes, and by policy, limit the amount of credit exposure at
any one institution. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause
the principal amount of the investment to fluctuate. To minimize this risk, we schedule our investments to have maturities that coincide with
our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we believe we have no
material exposure to interest rate risk arising from our investments. Therefore, no quantitative tabular disclosure is provided.
45
Table of Contents
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
BALANCE SHEETS
Assets
Cash and cash equivalents
Marketable securities
Receivables from collaborations
Prepaid expenses and other current assets
Total current assets
Marketable securities
Furniture and equipment, net
Patents and licenses, net of accumulated amortization of $32,094 in 2006 and $13,076 in 2005
Deferred collaboration expense
Total assets
Liabilities and Stockholders’ Equity
Accounts payable
Accrued expenses
Accrued vacation
Deferred revenue
Total current liabilities
Deferred revenue
Stockholders’ equity:
December 31,
2006
2005
$
4,417,528 $ 29,156,827
33,040,038 21,103,572
4,556,145 30,000,000
839,662
3,775,975
45,789,686 81,100,061
9,727,501
8,778,020
2,407,954
3,029,271
187,635
290,694
10,597,750
5,825,243
$ 68,485,421 $ 99,248,394
$
5,886,967 $
1,506,712
641,474
2,699,463
8,812,985
1,252,018
442,977
873,786
10,734,616 11,381,766
36,595,796 29,426,214
Preferred stock: shares authorized - 5,000,000 Series B Junior Participating Preferred stock, $.001 par
value; shares authorized - 45,000; shares issued and outstanding — none
Common stock, $.01 par value; shares authorized - 45,000,000; shares issued and outstanding -
—
—
29,248,849 – 2006; 28,813,533 – 2005
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
See accompanying notes to financial statements .
46
32,463
292,488
288,135
216,310,578 210,014,946
—
(195,480,520 ) (151,862,667 )
21,155,009 58,440,414
$ 68,485,421 $ 99,248,394
Table of Contents
Revenues
STATEMENTS OF OPERATIONS
2006
Years Ended December 31,
2005
2004
Collaborative and other research and development
$ 6,211,936 $
151,867 $
336,901
Expenses
Research and development
General and administrative
Total expenses
Loss from operations
Interest and other income
Net loss
47,083,372
6,108,373
53,191,745
23,642,377
3,686,323
27,328,700
18,868,112
3,220,655
22,088,767
(46,979,809 )
(27,176,833 )
(21,751,866 )
3,361,956
1,078,065
647,745
$ (43,617,853 ) $ (26,098,768 ) $ (21,104,121 )
Basic and diluted net loss per common share
$
(1.50 ) $
(1.01 ) $
(1.00 )
Weighted average shares outstanding
29,147,397
25,721,031
21,165,311
See accompanying notes to financial statements.
47
Table of Contents
STATEMENTS OF STOCKHOLDERS’ EQUITY
Common
Stock
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stock-
holders’
Equity
Comprehensive
Income
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$ (104,659,778 ) $ 28,447,143
(21,104,121 )
(21,104,121 ) $ (21,104,121 )
—
—
—
$ (21,104,121 )
—
20,279,850
—
1,080,336
—
—
(125,763,899 )
(26,098,768 )
118,577
512,427
29,334,212
(26,098,768 ) $ (26,098,768 )
—
—
—
$ (26,098,768 )
—
52,563,855
—
2,477,902
—
—
(151,862,667 )
(43,617,853 )
136,821
26,392
58,440,414
(43,617,853 ) $ (43,617,853 )
Balance at December 31, 2003
Net loss
Unrealized gain on marketable
securities available-for-sale
Comprehensive income
Sale of common stock, 3,571,667
shares
Exercise of stock options, 283,636
shares
Employee stock purchase plan sales,
31,695 shares
Stock-based compensation expense
Balance at December 31, 2004
Net loss
Unrealized gain on marketable
securities available-for-sale
Comprehensive income
Sale of common stock, 6,578,829
$ 178,713 $ 132,928,208 $
—
—
—
—
35,717
20,244,133
2,836
1,077,500
317
—
217,583
—
118,260
512,427
154,880,528
—
—
—
shares
65,788
52,498,067
4,507
2,473,395
257
—
288,135
—
136,564
26,392
210,014,946
—
Exercise of stock options, 450,717
shares
Employee stock purchase plan sales,
25,700 shares
Stock-based compensation expense
Balance at December 31, 2005
Net loss
Unrealized gain on marketable
securities available-for-sale
Comprehensive income
Exercise of stock options, 409,328
shares, net
Employee stock purchase plan sales,
25,988 shares
Stock-based compensation expense
Balance at December 31, 2006
See accompanying notes to financial statements.
48
—
—
32,463
—
32,463
32,463
$ (43,585,390 )
4,093
2,765,801
—
—
2,769,894
260
—
191,070
3,338,761
$ 292,488 $ 216,310,578 $
—
—
32,463
191,330
3,338,761
$ (195,480,520 ) $ 21,155,009
—
—
Table of Contents
STATEMENTS OF CASH FLOWS
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment
Gain on disposal of furniture and equipment
Impairment of furniture and equipment
Amortization of patents and licenses
Impairment of patents and licenses
Stock-based compensation expense
Changes in operating assets and liabilities:
Receivables from collaborations
Prepaid expenses and other current assets
Deferred collaboration expense
Accounts payable
Accrued expenses
Accrued vacation
Deferred revenue
Net cash used in operating activities
Investing activities
Acquisitions of furniture and equipment
Purchases of patents and licenses
Purchases of marketable securities
Maturities of marketable securities
Net cash used in investing activities
Financing activities
Sale of common stock, net of issuance costs
Exercise of stock options
Employee stock purchase plan sales
Net cash provided by financing activities
(Decrease) increase in cash and cash equivalents
Cash and equivalents at beginning of year
Cash and cash equivalents at end of year
See accompanying notes to financial statements .
49
2006
Years Ended December 31,
2005
2004
$ (43,617,853 ) $ (26,098,768 ) $ (21,104,121 )
802,177
(25,180 )
—
19,018
14,295
3,338,761
854,269
—
52,215
10,298
101,437
26,392
955,548
—
10,922
2,979
8,339
512,427
25,443,855
(2,936,313 )
(4,772,507 )
(2,926,018 )
254,694
198,497
8,995,259
(15,211,315 )
(30,000,000 )
(140,378 )
(5,825,243 )
6,842,542
688,057
143,022
30,000,000
(23,346,157 )
—
(23,377 )
—
1,330,094
96,271
59,583
—
(18,151,335 )
(1,398,314 )
(136,372 )
(42,870,522 )
31,916,000
(12,489,208 )
(497,284 )
(50,784 )
(29,695,358 )
18,729,368
(11,514,058 )
(275,919 )
(80,443 )
(18,879,234 )
16,398,629
(2,836,967 )
—
2,769,894
191,330
2,961,224
52,563,855
2,477,902
136,821
55,178,578
20,279,850
1,080,336
118,577
21,478,763
490,461
20,318,363
(24,739,299 )
29,156,827
8,348,003
8,838,464
$ 4,417,528 $ 29,156,827 $ 8,838,464
Table of Contents
Note 1 – Significant Accounting Policies
The Company
NOTES TO FINANCIAL STATEMENTS
BioCryst Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, is a biotechnology company that designs, optimizes, and
develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The
Company integrates the necessary disciplines of biology, crystallography, medicinal chemistry, and computer modeling to effectively use
structure-based drug design to discover and develop small molecule pharmaceuticals. The Company has multiple research projects in different
stages of development from early discovery to a pivotal Phase II trial of the Company’s most advanced drug candidate, Fodosine™. While the
prospects for a project may increase as the project advances to the next stage of development, a project can be terminated at any stage of
development. Until the Company generates revenues from either a research project or an approved product, the Company’s ability to continue
research projects is dependent upon its ability to raise funds through the sale of equity securities or through collaborative arrangements with
government agencies or third-party partners.
Cash and Cash Equivalents
The Company generally considers cash equivalents to be all cash held in money market accounts or investments in debt instruments with
maturities of three months or less at the time of purchase in accordance with Statement of Financial Accounting Standards No. 95, Statement of
Cash Flows (“Statement No. 95”).
Marketable Securities
The Company is required to classify securities as trading, available-for-sale, or held-to-maturity. The appropriateness of each classification
is assessed at the time of purchase and at each reporting date. At December 31, 2006, the Company had $41,818,058 marketable securities of
which $15,276,235 is classified as available-for-sale and $26,541,823 is classified as held-to-maturity. Securities available-for-sale consisted of
U.S. Agency securities carried at estimated fair values. The estimated fair value of these securities was based on independent quoted market
prices. At December 31, 2006, the amortized cost of securities available-for-sale was $15,243,772. Unrealized gains and losses on securities
available-for-sale are recognized in other comprehensive income. Securities held-to-maturity consisted primarily of U.S. Agency securities
carried at amortized cost. The estimated fair value of securities held-to-maturity at December 31, 2006 was $26,459,243 based on independent
quoted market prices. While this represents an unrealized loss position, the loss does not represent an other-than-temporary impairment, as the
Company has the ability and intent to hold the securities until maturity, at which time the cost of the investments will be recovered. At
December 31, 2006, all of the non-current portions of marketable securities mature in 2008.
Included in held-to-maturity securities, is a U.S. Treasury security in the amount of $132,000. This security is held in escrow for the
payment of rent and performance of other obligations specified in the Company’s lease on the facilities in Birmingham, Alabama. The amount
deposited in escrow decreases $65,000 annually throughout the term of the lease.
Receivables from Collaborations
The Company records amounts due from partners for amounts related to up-front payments, event payments, and research and development
fees. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date. To date, the
Company has not established a reserve and has never had any default of amounts from partners.
Furniture and Equipment
Furniture and equipment are recorded at cost. Depreciation is computed using the straight-line method with estimated useful lives of five
and seven years. Laboratory equipment, office equipment, leased equipment, and software are depreciated over a life of five years. Furniture
and fixtures are depreciated over a life of seven years. Leasehold improvements are amortized over their estimated useful lives or the remaining
lease term, whichever is less. In accordance with Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or
Disposal of Long-Lived Assets (“Statement No. 144”), the Company periodically reviews its furniture and equipment for impairment when
events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is
based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such
cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair
values. Furniture and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
50
Table of Contents
Patents and Licenses
Patents and licenses are recorded at cost and amortized on a straight-line basis over their estimated useful lives or 20 years, whichever is
less. The Company periodically reviews its patents and licenses for impairment in accordance with Statement No. 144 to determine any
impairment that needs to be recognized. During each of the last three preceding years, the Company identified certain patents and licenses that
no longer met its strategic objectives, which were determined to be unrecoverable, and for which the Company had no alternative future uses.
Accordingly, the Company recorded impairment losses for such patents and licenses totaling $14,295, $101,437, and $8,339 for the years
ended December 31, 2006, 2005, and 2004, respectively. These impairment losses are included in general and administrative expenses in the
statements of operations.
Accrued Expenses
The Company records all expenses in the period incurred. In addition to recording expenses for invoices received, the Company estimates
the cost of services provided by third parties or materials purchased for which no invoices have been received as of each balance sheet date.
Accrued expenses as of December 31, 2006, 2005, and 2004 consisted primarily of development and clinical trial expenses payable to contract
research organizations in connection with the Company’s research and development programs.
Income Taxes
The liability method is used in accounting for income taxes in accordance with Statement of Financial Accounting Standards No. 109,
Accounting for Income Taxes (“Statement No. 109”). Under this method, deferred tax assets and liabilities are determined based on differences
between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect
when the differences are expected to reverse.
Comprehensive Income
Accumulated other comprehensive income is comprised of unrealized gains and losses on securities available-for-sale and is disclosed as a
separate component of stockholders’ equity. The Company had $32,463 of unrealized gains on its securities that are included in accumulated
other comprehensive income at December 31, 2006.
Revenue Recognition
The Company’s revenues have generally been limited to license fees, event payments, research and development fees, and interest income.
Revenue is recognized in accordance with Staff Accounting Bulletin No. 104, Revenue Recognition (“SAB No. 104”) and Emerging Issues
Task Force Issue 00-21, Revenue Arrangements with Multiple Deliverables (“EITF Issue 00-21”). License fees, future event payments, and
research and development fees are recognized as revenue when the earnings process is complete and the Company has no further continuing
performance obligations, or the Company has completed the performance obligations under the terms of the agreement. Fees received under
licensing agreements that are related to future performance are deferred and recognized over an estimated period determined by management
based on the terms of the agreements and the products licensed. In the event a license agreement contains multiple deliverables, the Company
evaluates whether the deliverables are separate or combined units of accounting in accordance with EITF Issue 00-21. Revisions to revenue or
profit estimates as a result of changes in the estimated revenue period are recognized prospectively.
Future event payments are recognized as revenue upon the achievement of specified events if (1) the event is substantive in nature and the
achievement of the event was not reasonably assured at the inception of the agreement and (2) the fees are non-refundable and non-creditable.
Any event payments received prior to satisfying these criteria are recorded as deferred revenue.
51
Table of Contents
Significant direct costs incurred upon entering into a licensing arrangement are deferred and charged to expense in proportion to the revenue
recognized. Under the guidance of Emerging Issues Task Force Issue 99-19, Reporting Revenue Gross as a Principal Versus Net as an Agent
(“EITF Issue 99-19”), and Emerging Issues Task Force Issue 01-14, Income Statement Characterization of Reimbursements Received for “Out-
of-Pocket” Expenses (“EITF Issue 01-14”), reimbursements received for direct out-of-pocket expenses related to research and development
costs are recorded as revenue in the income statement rather than as a reduction in expenses.
Royalty revenue is recognized based on estimates of royalties earned during the applicable period and adjusted for differences between the
estimated and actual royalties in the following period. If royalties can not be reasonably estimated, revenue is recognized upon receipt of
royalty statements from the licensee. The Company has not received any royalties from the sale of licensed pharmaceutical products.
Research and Development Expenses
In accordance with Statement of Financial Accounting Standards No. 2, Accounting for Research and Development Costs , the Company
expenses research and development costs as incurred. Research and development expenses include, among other items, personnel costs,
including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by contract research organizations
(“CRO’s”), materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the
Company’s manufacturing and clinical and preclinical studies are performed by third-party CRO’s. Costs for studies performed by CRO’s are
accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company’s
on-going review of the level of services actually performed.
Additionally, the Company has license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University
(“AECOM”) and Industrial Research, Ltd. (“IRL”) that require maintenance fees or fees related to sublicense agreements. These fees are
generally expensed as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and
recognized over the related revenue recognition period.
Stock-Based Compensation
In December 2004, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards No. 123
(revised 2004), Share-Based Payment (“Statement No. 123R”), which revises Statement of Financial Accounting Standards No. 123,
Accounting for Stock-Based Compensation (“Statement No. 123”), supersedes Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees (“APB No. 25”), and amends Statement No. 95. Generally, the approach in Statement No. 123R is similar to the
approach described in Statement No. 123. However, Statement No. 123R requires all share-based payments to employees, including grants of
stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure, allowed by Statement No. 123, is no
longer an alternative.
In March 2005, the Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin No. 107, Share-Based Payment , which
provided further clarification on the implementation of Statement No. 123R. Statement No. 123R originally required adoption no later than
July 1, 2005. In April 2005, the SEC issued a release that delayed the effective date for Statement No. 123R until January 1, 2006.
Statement No. 123R permits companies to adopt its requirements using one of two methods, a “modified prospective” transition method or a
“modified retrospective” transition method. Both methods are similar, except that the modified retrospective transition method permits entities
to restate, based on the amounts previously recognized under Statement No. 123 for purposes of pro forma disclosures, either (a) all prior
periods presented or (b) prior interim periods of the year of adoption.
At December 31, 2006, the Company had two stock-based employee compensation plans, the Stock Incentive Plan (“Plan”), which amended
and restated the Company’s 1991 Stock Option Plan (“1991 Plan”), and the Employee Stock Purchase Plan (“ESPP”). These stock-based
compensation plans are described in more detail below and in Note 7. Prior to January 1, 2006, the Company accounted for those plans under
the recognition and measurement provisions of APB No. 25 and other related Interpretations, as permitted by Statement No. 123. No stock-
based compensation cost related to the Company’s employees was recognized in the Statements of Operations for any period ending prior to
52
Table of Contents
January 1, 2006, as all options granted by the Company had exercise prices equal to the market value of the underlying common stock on the
date of grant. For the year ended December 31, 2005, stock-based compensation cost of $26,392 was recognized by the Company for options
granted to non-employee consultants. For the year ended December 31, 2004, stock-based compensation cost of $512,427 was recognized by
the Company for options granted to non-employee consultants and due to a modification of options outstanding to outside Directors. Effective
January 1, 2006, the Company adopted the fair value recognition provisions of Statement No. 123R, using the modified prospective transition
method. Under that transition method, total compensation cost of $3,338,761 ($3,243,751 of expense related to the Plan and $95,010 of
expense related to the ESPP) was recognized during 2006 and includes: (a) compensation cost for all share-based payments granted prior to,
but not yet vested as of December 31, 2005, based on the grant date fair value estimated in accordance with the original provisions of Statement
No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair value
estimated in accordance with the provisions of Statement No. 123R. In accordance with the modified prospective transition method adopted,
results for prior periods have not been restated. The following table illustrates the pro forma effect on net loss and net loss per share had the
Company applied the fair value recognition provisions of Statement No. 123R for the years ended December 31, 2005 and 2004. For purposes
of the pro forma disclosure, the value of the options was estimated using a Black-Scholes option pricing model and amortized to expense over
the vesting periods of the options using a straight-line expense attribution method.
Net loss as reported
Add stock-based compensation expense for consultants included in reported net loss
Deduct total stock-based compensation expense for employees and consultants as determined under
Statement No. 123
Pro forma net loss
Amounts per common share:
Net loss per share, as reported
Pro forma net loss per share
2005
2004
$ (26,098,768 ) $ (21,104,121 )
512,427
26,392
(1,779,991 )
(2,260,551 )
$ (27,852,367 ) $ (22,852,245 )
$
$
(1.01 ) $
(1.08 ) $
(1.00 )
(1.08 )
As of December 31, 2006, there was approximately $9,386,233 of total unrecognized compensation cost related to non-vested employee
stock option awards granted under the Plan and the ESPP. That cost is expected to be recognized as follows: $3,562,441 in 2007, $2,716,561 in
2008, $2,194,977 in 2009, and $912,254 in 2010.
Statement 123R also requires that the benefits from tax deductions in excess of recognized compensation cost should be reported as a
financing cash flow rather than as an operating cash flow. The Company has never recognized any benefits from such tax deductions, as the
Company has always maintained a loss position.
Net Loss Per Share
The Company computes net loss per share in accordance with Statement of Financial Accounting Standards No. 128, Earnings Per Share .
Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is
equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options and
common shares expected to be issued under the Company’s employee stock purchase plan were anti-dilutive.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the amounts reported in the financial statements. Examples include accrued clinical
and preclinical expenses. Actual results could differ from those estimates.
Note 2 – Furniture and Equipment
Furniture and equipment consisted of the following at December 31:
53
Table of Contents
Furniture and fixtures
Office equipment
Software
Laboratory equipment
Leased equipment
Leasehold improvements
Construction-in-progress
Less accumulated depreciation and amortization
Furniture and equipment, net
Note 3 – Concentration of Credit and Market Risk
$
2006
406,869
685,204
516,281
4,802,481
62,712
4,731,401
309,001
11,513,949
(8,484,678 )
$ 3,029,271
$
2005
339,635
589,702
485,554
4,013,708
62,712
4,624,324
—
10,115,635
(7,707,681 )
$ 2,407,954
The Company invests its excess cash principally in U.S. marketable securities from a diversified portfolio of institutions with strong credit
ratings and in U.S. government and agency bills and notes and, by policy, limits the amount of credit exposure at any one institution. These
investments are generally not collateralized and mature within less than three years. The Company has not realized any losses from such
investments. At December 31, 2006, $2,445,758 was invested in the Merrill Lynch Premier Institutional Fund, a money market mutual fund
that invests in near cash securities with weighted average maturities of less than 90 days. The Merrill Lynch Premier Institutional Fund is not
insured.
The Company’s raw materials, drug substances, and drug products are manufactured by a limited group of suppliers and some at a single
facility. If any of these suppliers were unable to produce these items, this could significantly impact the Company’s supply of drugs for further
preclinical testing and clinical trials.
Note 4 – Accrued Expenses
Accrued expenses were comprised of the following at December 31:
Accrued clinical trials
Accrued professional fees
Stock purchase plan withholdings
Other
Accrued expenses
Note 5 – Lease Obligations and Other Contingencies
The Company has the following lease obligations at December 31, 2006:
2007
2008
2009
2010
Total minimum payments
54
2006
$ 1,155,847
177,951
106,670
66,244
$ 1,506,712
2005
$ 877,882
256,051
81,460
36,625
$ 1,252,018
Operating
Leases
$ 549,758
565,257
538,351
255,843
$ 1,909,209
Table of Contents
Rent expense for operating leases was $566,524, $560,322, and $583,969 in 2006, 2005, and 2004, respectively. The commitment for
operating leases is primarily related to building leases in Birmingham, Alabama and Cary, North Carolina. The lease for the building in
Birmingham, Alabama expires in June 2010. This lease, as amended effective December 1, 2005 for a reduction in occupied space, currently
requires monthly rents of $37,963 in December 2006 and escalates annually to a minimum of $41,481 per month in the final year. The
Company has an option to renew the Birmingham, Alabama lease for an additional five years at the current market rate on the date of
termination and a one-time option to terminate the lease on June 30, 2008, subject to a reasonable termination fee. The lease for the building in
Cary, North Carolina expires in July 2009. This lease, as amended effective October 1, 2006 for an increase in occupied space, requires
monthly rents of $4,500 beginning in October 2006 and escalates annually to a minimum of $4,774 per month in the final year. The lease was
subsequently amended in February 2007 for an additional 2,000 square feet requiring monthly rents of $7,391 beginning in March 2007 and
ending in February 2010. The Company has an option to twice renew the Cary, North Carolina lease for an additional three years at the current
market rate prior to lease termination.
On August 5, 2002, at the request of the compensation committee, the Company’s Board of Directors approved a reduction in salary of 25%
for Dr. Charles E. Bugg, Chairman and Chief Executive Officer and Dr. J. Claude Bennett, President, Chief Operating Officer and Medical
Director, effective August 1, 2002. In the event of any change of control of the Company, any cumulative salary reductions up to the date of the
change of control would become due and payable. The monthly amount of the reduction was $14,677 combined. On December 8, 2003, the
Board of Directors approved the recommendation of the compensation committee to restore their salaries to their previous amounts effective
January 1, 2004, leaving the cumulative reduction of $249,509 outstanding in the event of a change in control.
As of December 31, 2006, the Company has an unused letter of credit of $1.8 million. This letter of credit was originally obtained for a
customs bond that was required in order to import certain compound into the country that was manufactured abroad. The Company does not
anticipate drawing any funds against this letter of credit in the future, but it could remain in force for up to one year or until customs closes the
file on the particular receipt of goods for which the bond was required.
Note 6 – Income Taxes
The provision for income taxes differs from the amounts computed by applying the statutory federal income tax rate to income before
income taxes. The sources and tax effects of the differences are as follows:
Federal tax benefit at statutory rate on income before income taxes
State tax benefit, net of federal income tax benefit
Increase in valuation allowance
Permanent items (federal effect)
R&D credit
Other-net
Total tax expense
2006
$ (15,266,249 )
(1,931,360 )
21,011,952
2,338,857
(6,561,953 )
408,753
—
$
2005
$ (9,134,569 )
(1,120,784 )
12,706,721
1,488,588
(4,237,250 )
297,294
—
$
2004
$ (7,386,442 )
(917,879 )
9,786,925
882,830
(2,514,344 )
148,910
—
$
The Company has not had taxable income since incorporation and, therefore, has not paid any income taxes. Significant components of the
Company’s deferred tax assets and liabilities are as follows:
Deferred tax assets:
Net operating losses
General business credits
Fixed assets
Accrued expenses
Reserve for doubtful accounts
55
2006
2005
$ 66,146,993
23,098,886
696,822
252,327
—
$ 51,727,869
16,536,933
594,432
168,386
—
Table of Contents
Deferred revenue
Other
Total deferred tax assets
Total deferred tax liabilities
Net deferred tax asset
Valuation allowance
Net deferred tax assets
2006
113,400
—
90,308,428
—
90,308,428
(90,308,428 )
$
2005
113,400
—
69,141,020
—
69,141,020
(69,141,020 )
—
— $
Because the majority of the deferred tax assets relate to net operating loss (“NOL”) carryforwards that can only be realized if the Company
is profitable in future periods and because the Company has never been profitable in the past, it is uncertain whether the Company will realize
any tax benefit related to the NOL carryforwards. Accordingly, the Company has provided a valuation allowance against the net deferred tax
assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax asset until
it is more likely than not that the related tax benefits will be realized.
As of December 31, 2006, the Company had net operating loss and research and development credit carryforwards of approximately
$171,096,000 and $23,099,000, respectively, which expire at various dates from 2007 through 2025.
Use of the carryforward tax benefits will be subject to a substantial annual limitation due to the change of ownership provisions of the Tax
Reform Act of 1986. The annual limitation is expected to result in the expiration of a portion of the carryforward tax benefits before utilization.
The ownership change which occurred in 1996 has been considered by the Company in its computations under Statement No. 109. Due to
recent stock issuances, it is possible that additional limitations could currently apply. The Company has not performed a detailed analysis to
determine if an additional ownership change has occurred under the tax code or to determine its impact on its ability to use these net operating
loss and research credit carryforwards. However, it is not anticipated that any such analysis would have a material impact on the balance sheet
as a result of offsetting changes in the deferred tax valuation allowance.
Note 7 – Stockholders’ Equity
On December 14, 2005, the Company entered into a stock purchase agreement with Kleiner Perkins Caufield & Byers Holdings, LLC,
KPTV, LLC and TPG Biotechnology Partners, L.P. in connection with a registered direct offering of 2,228,829 shares of its common stock at
an offering price of $13.46 per share. The common stock was issued pursuant to prospectus supplements filed with the Securities and Exchange
Commission pursuant to Rule 424(b)(2) of the Securities Act of 1933, as amended (“the Securities Act”), in connection with a shelf takedown
from the Company’s registration statement on Form S-3 (333-111226), which was filed on December 16, 2003 and which became effective on
January 5, 2004, and the Company’s registration statement on Form S-3 (333-128087), which was filed on September 2, 2005 and which
became effective on September 20, 2005. On December 16, 2005, the Company issued the total 2,228,829 shares of common stock to the
aforementioned investors and received total proceeds of approximately $30 million (approximately $29.9 million net of expenses).
On February 9, 2005, the Company entered into a Placement Agency Agreement with Leerink Swann & Company in connection with a
registered direct offering of 4,350,000 shares of its common stock at an offering price of $5.50 per share. The common stock was issued
pursuant to a prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(2) of the Securities Act in
connection with a shelf takedown from the Company’s registration statement on Form S-3 (333-111226), filed on December 16, 2003 and
which became effective on January 5, 2004.
On February 17, 2005, the Company entered into stock purchase agreements with a number of institutional investors for an aggregate of
4,350,000 shares of common stock at a gross purchase price of $5.50 per share or approximately $23.9 million (approximately $22.7 million
net of expenses). One of these agreements was with Baker Brothers Investments, L.P., Baker Brothers Investments II, L.P., Baker Biotech Fund
I, L.P., Baker Biotech Fund II, L.P., Baker Biotech Fund II (Z), L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund III (Z), L.P.,
Baker/Tisch Investments, L.P., and 14159, L.P., or the Baker investors, for a total of 1,454,545 shares.
56
Table of Contents
On February 4, 2004, the Company entered into a Placement Agency Agreement with Leerink Swann & Company in connection with a
registered direct offering of 3,571,667 shares of its common stock at an offering price of $6.00 per share. The common stock was issued
pursuant to a prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(2) of the Securities Act in
connection with a shelf takedown from the Company’s registration statement on Form S-3 (333-111226), filed on December 16, 2003 and
which became effective on January 5, 2004.
On February 17, 2004, the Company entered into a Stock Purchase Agreement with Caduceus Private Investments II, LP, Caduceus Private
Investments II (QP), LP and UBS Juniper Crossover Fund, L.L.C. As part of this agreement, the Company granted these investors the right to
appoint a member to its board of directors effective as of the closing of the offering. On February 18, 2004, the Company completed a
$21.4 million registered direct offering of 3,571,667 shares of its common stock to a group of institutional investors.
In June 2002, the Board of Directors adopted a stockholder rights plan and, pursuant thereto, issued preferred stock purchase rights
(“Rights”) to the holders of the Company’s common stock. The Rights have certain anti-takeover effects. If triggered, the Rights would cause
substantial dilution to a person or group of persons who acquires more than 15% (19.9% for William W. Featheringill, a Director who owned
approximately 9.58% at December 31, 2006, but owned more than 15% at the time the Rights were put in place) of the Company’s common
stock on terms not approved by the Board of Directors. The rights are not exercisable until the distribution date, as defined in the Rights
Agreement by and between the Company and American Stock Transfer & Trust Company, as Rights Agent. The Rights will expire at the close
of business on June 24, 2012, unless that final expiration date is extended or unless the rights are earlier redeemed or exchanged by the
Company.
Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series B Junior Participating
Preferred Stock (“Series B”), par value $0.001 per share, at a purchase price of $26.00, subject to adjustment. Shares of Series B purchasable
upon exercise of the Rights will not be redeemable. Each share of Series B will be entitled to a dividend of 1,000 times the dividend declared
per share of common stock. In the event of liquidation, each share of Series B will be entitled to a payment of 1,000 times the payment made
per share of common stock. Each share of Series B will have 1,000 votes, voting together with the common stock. Finally, in the event of any
merger, consolidation, or other transaction in which shares of common stock are exchanged, each share of Series B will be entitled to receive
1,000 times the amount received per share of common stock. Effective in December 2005, we increased the authorized shares available under
these rights to 45,000 to match the authorized common shares of 45,000,000. In addition, our Board of Directors has the authority to issue up to
4,955,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without
further vote or action by our stockholders.
In November 1991, the Board of Directors adopted the 1991 Stock Option Plan (“1991 Plan”) for key employees and consultants of the
Company and reserved 500,000 shares of common stock for issuance. The 1991 Plan was approved by the stockholders in December 1991. The
original term for options granted under the 1991 Plan was for ten years and included provisions for issuance of both incentive stock options and
non-statutory options. The exercise price of the options granted under the 1991 Plan is not to be less than the fair market value of common
stock on the grant date. Options granted under the 1991 Plan generally vest 25% after one year and monthly thereafter on a pro rata basis over
the next three years until fully vested after four years and expire ten years after the grant date. Options are generally granted to all full-time
employees. The vesting and exercise provisions of options granted under the Plan are subject to acceleration in the event of certain stockholder-
approved transactions, or upon the occurrence of a Change in Control as defined by the Plan.
The 1991 Plan was amended and restated in February 1993 to effect the following changes: (i) divide the 1991 Plan into two separate
incentive programs: the Discretionary Option Grant Program and the Automatic Option Grant Program (for outside Directors), (ii) increase the
number of shares of the Company’s common stock available for issuance by 500,000 shares and (iii) expand the level of benefits available. The
Board amended the 1991 Plan in December 1993 to increase the number of shares issuable by 500,000 shares and subsequently amended and
restated the 1991 Plan in its entirety in February 1994. In March 1995, the Board authorized another 500,000 shares for issuance under the
1991 Plan. The 1991 Plan was subsequently amended and restated in March 1997, which increased the number of shares issuable by 1,000,000
shares. The 1991 Plan (as so amended and restated) was further amended in March 1999 to increase the share reserve by 400,000 shares. The
Board amended and restated the 1991 Plan in its
57
Table of Contents
entirety in March 2000, increasing the reserved shares by 1,200,000 and extending the term of the 1991 Plan for ten years from the date of the
amendment. This restatement was approved by the Company’s stockholders in May 2000. The 1991 Plan was amended in March 2004 to
increase the number of shares reserved for issuance by 1,000,000 and to amend the automatic option grant program related to initial grants,
vesting, and option terms. The automatic option grant program grants options to purchase 10,000 shares to new non-employee Board members,
prorated from their initial appointment to the next Annual Meeting, and an additional 10,000 shares annually over such period of continued
service (all of which vest one-twelfth per month). Directors receiving options under the automatic option grant program will have the full term
of the original option to exercise all options vested at the time of their cessation from service. This amendment was approved by the
Company’s stockholders in May 2004.
Most recently, the 1991 Plan was amended and restated by the Company’s Stock Incentive Plan (“Plan”), which increased the number of
shares reserved for issuance by 1,500,000 shares; increased the amounts of the initial automatic option grants to non-employee Board members
from 10,000 shares to 20,000 shares; increased the amounts of the annual automatic option grants to non-employee Board members from
10,000 shares to 15,000 shares; and allow the Company to make discretionary stock issuances. The Plan was subsequently approved by the
Company’s stockholders in May 2006.
For option awards granted under the Plan during 2006, 2005, and 2004, the fair value of the award was estimated on the date of grant using
a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of the options
granted under the Plan during 2006, 2005, and 2004 was $8.64, $3.48, and $6.83, respectively. The fair value expense of options granted is
amortized to expense over the vesting periods of the options using a straight-line expense attribution method.
Weighted Average Assumptions for Options Granted
Expected Life
Expected Volatility
Expected Dividend Yield
Risk-Free Interest Rate
2006
5.9
82.6 %
0.0 %
5.0 %
2005
5.0
96.6 %
0.0 %
3.9 %
2004
5.0
103.1 %
0.0 %
4.0 %
The following explanations describe the assumptions used by the Company to value the options granted during 2006. The expected life is
based on the average of the assumption that all outstanding options will be exercised at full vesting and the assumption that all outstanding
options will be exercised at the midpoint of the valuation date and the full contractual term. The expected volatility represents an average of the
implied volatility on the Company’s publicly traded options, the volatility over the most recent period corresponding with the expected life, and
the Company’s long-term reversion volatility. The Company has assumed no expected dividend yield, as dividends have never been paid to
stock or option holders and will not be for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently
available on zero-coupon government issues with a remaining term equal to the expected term.
Related stock option activity under the Plan is as follows:
Balance December 31, 2003
Options plan amended
Options granted
Options exercised
Options canceled
Balance December 31, 2004
Options granted
Options exercised
Options canceled
Balance December 31, 2005
Options plan amended
Options granted
Options exercised
Options canceled
Balance December 31, 2006
Options
Available
500,819
1,000,000
(499,197 )
—
34,149
1,035,771
(653,801 )
—
61,077
443,047
1,500,000
(1,222,154 )
—
99,861
820,754
Options
Outstanding
2,917,932
—
499,197
(283,636 )
(34,149 )
3,099,344
653,801
(450,717 )
(61,077 )
3,241,351
—
1,222,154
(411,076 )
(99,861 )
3,952,568
Weighted
Average
Exercise Price
7.29
$
—
8.76
3.81
4.10
7.88
4.66
5.50
5.96
7.60
—
12.35
6.82
15.91
8.94
58
Table of Contents
The total intrinsic value of options exercised under the Plan during 2006 was $4,697,366. The intrinsic value represents the total proceeds
(fair market value at the date of exercise, less the exercise price, times the number of options exercised) received by all individuals who
exercised options during the period.
The following table summarizes, at December 31, 2006, by price range: (1) for options outstanding under the Plan, the number of options
outstanding, their weighted average remaining life and their weighted average exercise price; and (2) for options exercisable under the Plan, the
number of options exercisable and their weighted average exercise price:
Range
$0 to 3
3 to 6
6 to 9
9 to 12
12 to 15
15 to 18
18 to 21
21 to 24
24 to 27
27 to 30
$0 to 30
Outstanding
Exercisable
Number
466,953
707,140
1,143,949
226,953
1,170,966
6,667
6,200
204,120
13,620
6,000
3,952,568
Life
6.0
7.6
4.9
9.6
8.0
9.1
9.2
2.9
3.3
3.4
6.6
Price
$ 1.15
4.18
7.79
10.90
12.85
15.92
19.34
22.84
25.75
29.29
8.94
Number
449,625
408,930
949,094
9,953
259,479
4,167
—
204,120
13,620
6,000
2,304,988
Price
$ 1.16
4.05
7.71
9.88
13.53
15.45
—
22.84
25.75
29.29
7.96
The weighted average remaining contractual life of options exercisable under the Plan at December 31, 2006 is 4.9 years. There were
2,199,129 and 2,220,583 options exercisable at December 31, 2005 and 2004, respectively. The weighted-average exercise price for options
exercisable was $8.81 and $8.94 at December 31, 2005 and 2004, respectively.
The aggregate intrinsic value of options outstanding under the Plan at December 31, 2006 is $14,557,736. The aggregate intrinsic value of
options currently exercisable under the Plan at December 31, 2006 is $11,417,547. The aggregate intrinsic value represents the value (the
period’s closing market price, less the exercise price, times the number of in-the-money options) that would have been received by all option
holders under the Plan had they exercised their options at the end of the period.
The following table summarizes, at December 31, 2006 the number of non-vested options under the Plan and their weighted average grant
date fair value:
Balance December 31, 2005
Options granted
Options canceled
Options vested
Balance December 31, 2006
Number
1,042,181
1,222,154
(2,526 )
(614,229 )
1,647,580
Weighted
Average Grant
Date Fair Value
$ 3.82
8.64
8.59
4.03
7.31
The total fair value of the options vested under the Plan during 2006 was $2,473,986.
As of December 31, 2006, the number of options vested and expected to vest under the Plan is 3,703,671. The weighted average exercise
price of these options is $8.94 and their weighted average remaining contractual life is 6.5 years.
59
Table of Contents
Note 8 – Employee Benefit Plans
In January 1991, the Company adopted an employee retirement plan (“401(k) Plan”) under Section 401(k) of the Internal Revenue Code
covering all employees. Employee contributions may be made to the 401(k) Plan up to limits established by the Internal Revenue Service.
Company matching contributions may be made at the discretion of the Board of Directors. The Company made matching contributions of
$252,735, $205,524, and $171,601 in 2006, 2005 and 2004, respectively.
In May 1995, the stockholders approved the ESPP effective February 1995. In May 2002, the stockholders approved an amendment to the
ESPP to reserve an additional 200,000 shares and eliminate the January 2005 termination date. The Company has reserved a total of 400,000
shares of common stock under the ESPP, of which 99,613 shares remain available for purchase at December 31, 2006. Eligible employees may
authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during the six-
month purchase intervals. No more than 3,000 shares may be purchased by any one employee at the six-month purchase dates and no employee
may purchase stock having a fair market value at the commencement date of $25,000 or more in any one calendar year.
There were 25,988, 25,700, and 31,695 shares of common stock purchased under the ESPP in 2006, 2005, and 2004, respectively, at a
weighted average price per share of $7.36, $5.06, and $3.82, respectively. Expense of $95,010 related to the ESPP was recognized during 2006,
while expense of $73,381 and $60,759 related to the ESPP would have been recognized during 2005 and 2004, respectively, had the Company
not followed the guidance of APB No. 25. For all periods, expense was determined using a Black-Scholes option pricing model. The weighted
average grant date fair values of options granted under the ESPP during 2006, 2005, and 2004 were $4.57, $2.55, and $2.37, respectively.
Note 9 – Collaborative and Other Research and Development Contracts
Green Cross Corporation (“Green Cross”). In June 2006, the Company entered into an agreement with Green Cross to develop and
commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and
commercialization costs in Korea. The Company received a one-time license fee and may also receive future event payments as well as
royalties on product sales of peramivir. In addition, the Company will share in any profits resulting from the sale of peramivir to the Korean
government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for
development and any future marketing of peramivir products in Korea.
Mundipharma International Holdings Limited (“Mundipharma”). In February 2006, the Company entered into an exclusive, royalty
bearing right and license agreement with Mundipharma for the development and commercialization of the Company’s lead PNP inhibitor,
Fodosine™, for use in oncology. Under the terms of the agreement, Mundipharma obtained rights to Fodosine™ in markets across Europe,
Asia, and Australasia in exchange for a $10 million up-front payment. Mundipharma will share 50% of the documented out of pocket
development costs incurred by the Company in respect of the current and planned trials as of the effective date of the agreement provided that
Mundipharma’s maximum contribution to these trials shall be $10 million. In addition, Mundipharma will conduct additional clinical trials at
their own cost up to a maximum of $15 million. The license provides for future event payments for achieving specified development,
regulatory and commercial events (including certain sales level amounts following a product’s launch) for certain indications. In addition, the
Company will receive royalties based on a percentage of net product sales, which varies depending upon when certain indications receive NDA
approval in a major market country and can vary by country depending on the patent coverage or sales of generic compounds in a particular
country. Generally, all payments under the agreement are nonrefundable and non-creditable, but they are subject to audit. The Company
licensed Fodosine™ and other PNP inhibitors from AECOM and IRL and will owe sublicense payments to these third parties on the upfront
payment, future event payments, and royalties received by the Company from Mundipharma.
For five years, Mundipharma will have a right of first negotiation on existing backup PNP inhibitors the Company develops through Phase
IIb in oncology, but any new PNP inhibitors will be exempt from this agreement and the Company will retain all rights to such compounds.
The Company retained the rights to Fodosine™ in the U.S. and Mundipharma is obligated by the terms of the agreement to use commercially
reasonable efforts to develop the licensed product in the territory specified by the agreement. The agreement will continue for the commercial
life of the licensed products, but may be terminated by either party following an uncured material breach by the other party or in the event
60
Table of Contents
the pre-existing third party license with AECOM and IRL expires. It may be terminated by Mundipharma upon 60 days written notice without
cause or under certain other conditions as specified in the agreement and all rights, data, materials, products and other information would be
transferred back to the Company at no cost. In the event the Company terminates the agreement for material default or insolvency, the
Company could have to pay Mundipharma 50% of the costs of any independent data owned by Mundipharma in accordance with the terms of
the agreement.
In accordance with SAB No. 104 and EITF Issue 00-21, the Company deferred the $10 million up-front payment that was received from
Mundipharma in February 2006. This deferred revenue began to be amortized to revenue February 2006 and will end in October 2017, which is
the date of expiration for the last-to-expire patent covered by the agreement. In accordance with EITF Issue 99-19 and EITF Issue 01-14, the
costs reimbursed by Mundipharma for the current and planned trials of Fodosine™ are recorded as revenue when the expense is incurred up to
the $10 million limit stipulated in the agreement.
Roche. In November 2005, the Company entered into an exclusive license with Roche for the development and commercialization of the
Company’s second generation PNP inhibitor, BCX-4208, for the prevention of acute rejection in transplantation and for the treatment of
autoimmune diseases. Under the terms of the agreement, Roche obtained worldwide rights to BCX-4208 in exchange for a $25 million up-front
payment and a $5 million payment as reimbursement for a limited supply of material during the first 24 months of the collaboration. According
to the terms of the license, there could also be future event payments for achieving specified development, regulatory and commercial
milestones (including sales level milestones following a product’s launch) for certain indications. In addition, the Company will receive
royalties based on a percentage of net product sales, which varies depending upon when certain indications receive NDA approval in a major
market country and can vary by country depending on the patent coverage or sales of generic compounds in a particular country. The Company
licensed this compound and other PNP inhibitors from AECOM and IRL and will owe sublicense payments to these third parties on the upfront
payment, future event payments, and royalties received by the Company for the sublicense of these inhibitors.
Roche will have a right of first negotiation, under certain conditions, on existing backup PNP inhibitors the Company develops through
Phase IIb in transplant rejection and autoimmune diseases, but any new PNP inhibitors will be exempt from this agreement and the Company
will retain all rights to such compounds. The Company retains the right to co-promote BCX-4208 in the U.S. for several indications. Roche has
certain obligations under the terms of the agreement to use commercially reasonable efforts to develop, manufacture and commercialize the
licensed product. The agreement may be terminated by either party following an uncured material breach by the other party or may be either
fully or partially terminated by Roche without cause under certain conditions and all rights, data, materials, products and other information
would be transferred to the Company at no cost.
At December 31, 2005, the Company recorded a receivable of $30 million due from Roche for the $25 million up-front payment and the
$5 million payment as reimbursement for supply. These amounts were received from Roche in January 2006. In accordance with SAB No. 104
and EITF Issue 00-21, the Company also recorded deferred revenue of $30 million related to the Roche collaboration at December 31, 2005.
This deferred revenue began to be amortized to revenue in October 2006, when the IND was transferred to Roche, and will end in August 2023,
which is the date of expiration for the last-to-expire patent covered by the agreement.
In June 2006, the Company further agreed to perform specific research and clinical activities on behalf of Roche aside from the license
agreement described above. Based on EITF Issues 99-19 and 01-14, the Company has recorded revenues for the reimbursements received and
expected to be received from Roche related to the direct out-of-pocket expenses incurred for these research and clinical activities.
Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. In June 2000, the Company licensed a series of
potent inhibitors of PNP from AECOM and IRL. The lead drug candidates from this collaboration are Fodosine™ and BCX-4208. The
Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, drug candidates that might arise
from research on these inhibitors. The Company has agreed to pay certain milestone payments for future development of these inhibitors,
certain royalties on sales of any resulting product, and to share in future payments received from other third-party partners, if any. In addition,
the Company agreed to pay an annual license fee that is non-refundable, but is creditable against actual royalties and other payments due to
AECOM and IRL. This agreement may be terminated by the Company at any time by giving 60 days advance notice or in the event of material
uncured breach by AECOM and IRL.
61
Table of Contents
Upon completion of the collaborations with Mundipharma for BCX-1777 and Roche for BCX-4208, the Company was obligated to pay
AECOM/IRL approximately $8.4 million. These payments were capitalized as a deferred expense and will be amortized into expense in
proportion to the revenue recognized from the respective agreements.
The University of Alabama at Birmingham (“UAB”). The Company currently has agreements with UAB for influenza neuraminidase and
complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research
payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by
UAB or jointly developed with the Company. The Company has agreed to pay royalties on sales of any resulting product and to share in future
payments received from other third-party partners. The Company has completed the research under the UAB agreements. These two
agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent and are terminable
by the Company upon three months notice and by UAB under certain circumstances. There is currently no activity between the Company and
UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross agreements, or
commercialize products related to these programs, we will owe sublicense fees or royalties on amounts we receive.
Emory University (“Emory”). In June 2000, the Company licensed intellectual property from Emory related to the hepatitis C polymerase
target associated with hepatitis C viral infections. Under the original terms of the agreement, the research investigators from Emory provided
the Company with materials and technical insight into the target. The Company has agreed to pay Emory royalties on sales of any resulting
product and to share in future payments received from other third party partners, if any. The Company can terminate this agreement at any time
by giving 90 days advance notice.
3-Dimensional Pharmaceuticals, Inc. (“3DP”). In December 2003, the Company transferred to 3DP, a wholly owned subsidiary of
Johnson & Johnson, certain rights related to complement system inhibitors discovered during the Company’s collaborative research agreement
with 3DP, which was terminated by the Company on October 18, 2003. BioCryst received an initial payment from 3DP, and will receive
royalties on any future sales of complement inhibitors covered under the assignment.
Novartis Corporation (“Novartis”). The Company granted Novartis, formerly Ciba-Geigy Corporation, an option in 1990 to acquire
exclusive licenses to a class of inhibitors arising from research performed by the Company by February 1991. The option was exercised and a
$500,000 fee was paid to the Company in 1993. Milestone payments are due upon approval of a new drug application. The Company will also
receive royalties based upon a percentage of sales of any resultant products. Up to $300,000 of the initial fee received is refundable if sales of
any resultant products are below specified levels and has been recorded as deferred revenue. This agreement has been inactive for several
years.
Note 10 – Subsequent Events
In January 2007, the Company announced that it had been awarded a four-year contract from the U.S. Department of Health and Human
Services (“HHS”) to develop its influenza neuraminidase inhibitor, peramivir, for the treatment of seasonal and life-threatening influenza,
including avian flu. The contract commits $102.6 million to support the full development of both intravenous and intramuscular formulations
of peramivir. In addition, the contract also funds the validation of U.S. based manufacturing facilities.
The contract with HHS is defined as a cost-plus-fixed-fee contract. That is, the Company is entitled to receive reimbursement for all costs
incurred in accordance with the contract provisions that are related to the development of peramivir plus a fixed fee, or profit. The contract is
effective January 3, 2007. As of December 31, 2006, the Company had incurred approximately $2.3 million of pre-contract costs directly
related to the Phase 2 trials for both the intravenous and intramuscular peramivir products. These costs were incurred in anticipation of a
contract award from HHS and were required to meet the delivery schedule of the proposed contract. In accordance with the provisions of
Federal Acquisition Regulation 31.205-32, the costs were included in the Company’s request for proposal and are eligible for reimbursement
from HHS. The $2.3 million of costs incurred prior to the contract award date were deferred and are included in other current assets on the
Company’s balance sheet at December 31, 2006. In the first quarter of 2007, the $2.3 million in costs will be billed and expensed.
Concurrently, revenue will be recognized for these costs plus the applicable fixed fee.
62
Table of Contents
In March 2007, the Company entered into an exclusive license agreement with Shionogi & Co., Ltd. (“Shionogi”) to develop and
commercialize the Company’s lead influenza neuraminidase inhibitor, peramivir, in Japan for the treatment of seasonal and potentially life-
threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan in
exchange for a $14 million up-front payment. The license provides for future event payments for achieving specified development, regulatory
and commercial events (including certain sales level amounts following a product’s launch) for certain indications. In addition, the Company
will receive royalties based on a percentage of net product sales. Generally, all payments under the agreement are nonrefundable and non-
creditable, but they are subject to audit. The Company developed peramivir under a license from UAB and will owe sublicense payments to
them on the upfront payment and any future event payments and/or royalties received by the Company from Shionogi. The Company retains all
rights to commercialize peramivir in North America, Europe, and other countries outside of Korea and Japan.
Note 11 – Recent Accounting Pronouncements
In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157, Fair Value Measurements (“Statement
No. 157”). The standard provides enhanced guidance for using fair value to measure assets and liabilities and also responds to investors’
requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to
measure fair value, and the effect of fair value measurements on earnings. While the standard applies whenever other standards require (or
permit) assets or liabilities to be measured at fair value, it does not expand the use of fair value in any new circumstances. Statement No. 157 is
effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years.
Management of the Company is evaluating the impact of this standard, but does not anticipate that it will have a significant impact on its
financial statements.
In July 2006, the FASB issued Financial Accounting Standards Board Interpretation No. 48, Accounting for Uncertainty in Income Taxes,
an Interpretation of FASB Statement No. 109, Accounting for Income Taxes (“FIN No. 48”). This interpretation creates a single model to
address uncertainty in tax positions. FIN 48 clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax
position is required to meet before being recognized in the financial statements. The interpretation also provides guidance on derecognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for years
beginning after December 15, 2006. Management of the Company is evaluating the impact of this pronouncement, but does not anticipate that
it will have a significant impact on its financial statements.
Note 12 – Quarterly Financial Information (Unaudited) (In thousands, except per share)
2006 Quarters
Revenues
Net loss
Net loss per share
2005 Quarters
Revenues
Net loss
Net loss per share
First
Second
Third
Fourth
$ 771
(7,882 )
(.27 )
$
41
(5,645 )
(.24 )
$ 1,558
(10,083 )
(.35 )
58
$
(5,648 )
(.22 )
$ 1,790
(15,603 )
(.53 )
32
$
(7,645 )
(.29 )
$ 2,092
(10,050 )
(.34 )
$
21
(7,161 )
(.27 )
Net loss and net loss per share each year may differ from the total of the individual quarters due to rounding.
63
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON FINANCIAL STATEMENTS
The Board of Directors and Shareholders
BioCryst Pharmaceuticals, Inc.
We have audited the accompanying balance sheets of BioCryst Pharmaceuticals, Inc. as of December 31, 2006 and 2005, and the related
statements of operations, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2006. These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform an audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of BioCryst
Pharmaceuticals, Inc. at December 31, 2006 and 2005, and the results of its operations and its cash flows for each of the three years in the
period ended December 31, 2006, in conformity with U.S. generally accepted accounting principles.
As discussed in Note 1 to the financial statements, in 2006, the Company changed its method of accounting for stock-based compensation
upon adoption of Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment .
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the
effectiveness of BioCryst Pharmaceuticals, Inc.’s internal control over financial reporting as of December 31, 2006, based on criteria
established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
and our report dated March 12, 2007 expressed an unqualified opinion thereon.
Birmingham, Alabama
March 12, 2007
/s/ Ernst & Young LLP
64
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL CONTROL
The Board of Directors and Shareholders
BioCryst Pharmaceuticals, Inc.
We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control Over Financial
Reporting, that BioCryst Pharmaceuticals, Inc. maintained effective internal control over financial reporting as of December 31, 2006, based on
criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (“the COSO criteria”). BioCryst Pharmaceuticals, Inc.’s management is responsible for maintaining effective internal control over
financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an
opinion on management’s assessment and an opinion on the effectiveness of the company’s internal control over financial reporting based on
our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial
reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting,
evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such
other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of
management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, management’s assessment that BioCryst Pharmaceuticals, Inc. maintained effective internal control over financial reporting
as of December 31, 2006, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, BioCryst Pharmaceuticals,
Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2006, based on the COSO
criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the 2006
financial statements of BioCryst Pharmaceuticals, Inc. and our report dated March 12, 2007 expressed an unqualified opinion thereon.
Birmingham, Alabama
March 12, 2007
/s/ Ernst & Young LLP
65
Table of Contents
None.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to BioCryst Pharmaceuticals,
Inc. required to be disclosed in our periodic filings under the Securities Exchange Act is recorded, processed, summarized and reported in a
timely manner under the Securities Exchange Act of 1934. We carried out an evaluation, under the supervision and with the participation of
management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of
December 31, 2006, our disclosure controls and procedures are effective to ensure that information required to be disclosed by BioCryst in the
reports filed or submitted by it under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the Securities and Exchange Commission, and include controls and procedures
designed to ensure that information required to be disclosed by BioCryst in such reports is accumulated and communicated to our management,
including the Chairman and Chief Executive Officer and Chief Financial Officer of BioCryst, as appropriate to allow timely decisions
regarding required disclosure.
Management’s Report on Internal Control Over Financial Reporting
Management of BioCryst Pharmaceuticals, Inc. (the “Company”) is responsible for establishing and maintaining adequate internal control
over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined by the Securities and
Exchange Commission, internal control over financial reporting is a process designed by, or under the supervision of our principal executive
and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of the consolidated financial statements in accordance with U.S. generally
accepted accounting principles.
Our internal control over financial reporting is supported by written policies and procedures that (1) pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of the consolidated financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of BioCryst are being made only in accordance with authorizations of our
management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of our assets that could have a material effect on the consolidated financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.
In connection with the preparation of our annual financial statements, management has undertaken an assessment of the effectiveness of our
internal control over financial reporting as of December 31, 2006, based on criteria established in Internal Control — Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO Framework). Management’s assessment
included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of those
controls.
Based on this assessment, management has concluded that as of December 31, 2006, our internal control over financial reporting was
effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with U.S. generally accepted accounting
66
Table of Contents
principles.
Ernst & Young LLP, the independent registered public accounting firm that audited our financial statements included in this report, have
issued an attestation report on management’s assessment of internal control over financial reporting, a copy of which appears on page 65 of this
annual report.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2006 that
have materially affected, or are reasonably likely to materially affect, BioCryst’s internal control over financial reporting.
None
ITEM 9B. OTHER INFORMATION
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
PART III
The directors and executive officers of BioCryst are as follows:
Name
Jon P. Stonehouse
J. Claude Bennett, M.D.
W. James Alexander
Michael A. Darwin
Jonathan M. P. Nugent
Randall B. Riggs
Charles E. Bugg, Ph.D.
Stephen R. Biggar, M.D., Ph.D. (1)
William W. Featheringill (1)
Carl L. Gordon, CFA, Ph.D. (2)
John L. Higgins (2)
Zola P. Horovitz, Ph.D.
Beth C. Seidenberg, M.D. (1)
Joseph H. Sherrill, Jr. (2)
William M. Spencer, III
Randolph C. Steer, M.D., Ph.D. (2)
Age
Position(s) with the Company
46 Chief Executive Officer and Director
73 President, Chief Operating Officer, and Director
57
Senior Vice President, Clinical and Regulatory Operations and Chief
Medical Officer
45 Chief Financial Officer, Secretary, and Treasurer
39 Vice President, Corporate Communications
40 Senior Vice President, Business Development
65 Chairman and Director
36 Director
64 Director
42 Director
37 Director
72 Director
49 Director
66 Director
86 Director
57 Director
(1) Member of the Compensation Committee (“Compensation Committee”).
(2) Member of the Audit Committee (“Audit Committee”).
Jon P. Stonehouse joined BioCryst in January 2007 as Chief Executive Officer and he was also appointed to the Board in January 2007.
Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA since July 2002. His
responsibilities included corporate mergers & acquisitions, global licensing and business development, corporate strategy and alliance
management. In March of 2002, Mr. Stonehouse was appointed Vice President of Global Licensing and Business Development and Integration
where he was responsible for the
67
Table of Contents
worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined
EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business
Development — Strategy & Integration and IT. Prior to joining Merck KGaA, he held a variety of roles at Astra Merck/AstraZeneca including:
Customer Unit Director, Director, Marketing & Sales — IT, National Sales Manager, National Sales Director — Managed Healthcare, and
Product Director — Omeprazole (the world’s most widely prescribed prescription drug-at that time). Mr. Stonehouse started his career in the
pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. Mr. Stonehouse
earned his BS in Microbiology at the University of Minnesota.
J. Claude Bennett, M.D. was named President and Chief Operating Officer in December 1996 and elected a Director in January 1997.
Dr. Bennett also served as the Medical Director from 2001 to 2006. Prior to joining us, Dr. Bennett was President of The University of
Alabama at Birmingham (“UAB”) from October 1993 to December 1996 and Professor and Chairman of the Department of Medicine of UAB
from January 1982 to October 1993. Dr. Bennett served on our Scientific Advisory Board from 1989-96. He is a former co-editor of the Cecil
Textbook of Medicine and former President of the Association of American Physicians. He is a past chair of the Scientific Advisory Committee
of the Massachusetts General Hospital, a post-member of the Scientific Advisory Board of Zycogen, LLC, and continues to hold the position of
Distinguished University Professor Emeritus at UAB, a position he has held since January 1997.
W. James Alexander, M.D., M.P.H joined BioCryst in June 2006 as Senior Vice President, Clinical and Regulatory Operations and Chief
Medical Officer. Prior to joining the Company, Dr. Alexander was Senior Vice President, Product Development at POZEN from
November 2003 to June 2006. Dr. Alexander was Chief Medical Officer of Inveresk Research Group from July 2003 to October 2003. From
1998 to 2003, Dr. Alexander was Chief Medical/Regulatory Officer at PharmaResearch Corporation, with global responsibilities for medical
and regulatory operations and he also served as President from 1998-1999, Chief Executive Officer from 1999-2000 and was Chairman of the
Board of PharmaReseach Corporation from 2000 to 2003. From 1996 to 1998, he served as Vice President and Director, Worldwide Product
Safety and Pharmacovigilance at GlaxoWellcome, Inc. Dr. Alexander received a B.S. from Mississippi State University, his M.D. from the
University of Mississippi and his M.P.H. from the University of Alabama at Birmingham. He is board certified in internal medicine and
infectious diseases.
Michael A. Darwin joined BioCryst in June 2000 as Controller. Effective November 1, 2002, Mr. Darwin was appointed Chief Financial
Officer, Secretary and Treasurer. Prior to joining BioCryst, from June 1990 to June 2000, Mr. Darwin was Chief Financial Officer of a
privately held company in the food services industry. He began his career at Ernst & Young and spent six years in public accounting practice.
Jonathan M. P. Nugent joined BioCryst in May 2005 as Vice President, Corporate Communications. Mr. Nugent served as Senior Vice
President at Burns McClellan, Inc., Investor Relations Division, since April 1999, except for a period from August 2003 to December 2003
when he served as Director of Investor Relations for Eyetech Pharmaceuticals, Inc. and from January 2004 to March 2004 when he was
performing volunteer services. He also served as Account Supervisor from April 1996 to April 1999, Account Manager from April 1994 to
April 1996, and Senior Account Executive from April 1993 to April 1994 at Burns McClellan.
Randall B. Riggs joined BioCryst in February 2005 as Vice President, Business Development and was promoted to Senior Vice President,
Business Development effective January 2006. Mr. Riggs served as Vice President, Business Development at TransMolecular, Inc. an
emerging oncology company from September 2004 to February 2005. Before joining TransMolecular, he served as a Corporate Licensing and
Business Development consultant for TRUBION Pharmaceuticals, Inc. from March 2004 to August 2004. Mr. Riggs was previously Senior
Vice President, Corporate Licensing and Business Development at Lexicon Genetics Incorporated from February 2000 to March 2004 and
served as Vice President, Business Development from December 1998 to February 2000. Prior to joining Lexicon Genetics, Mr. Riggs was
Director of Business Development for the Infectious Disease Unit of GeneMedicine, Inc. Mr. Riggs began his pharmaceutical and
biotechnology business development career with Eli Lilly and Company; starting as a District Sales Manager and advancing to Manager,
Corporate Business Development.
Charles E. Bugg, Ph.D. was named Chairman of the Board, Chief Executive Officer and Director in November 1993 and President in
January 1995. He relinquished the position of President in December 1996 when Dr. J. Claude Bennett joined us in that position and resigned
as Chief Executive Officer in January 2007. Prior to joining us, Dr. Bugg had been a member of the faculty of the University of Alabama at
Birmingham (“UAB”) since 1968, having served as
68
Table of Contents
Professor of Biochemistry, Director of the Center for Macromolecular Crystallography, and Associate Director of the Comprehensive Cancer
Center. He was a founder of BioCryst and served as our first Chief Executive Officer from 1987-1988 while on a sabbatical from UAB.
Dr. Bugg also served as Chairman of our Scientific Advisory Board from January 1986 to November 1993. He continues to hold the position of
Professor Emeritus in Biochemistry and Molecular Genetics at UAB, a position he has held since January 1994.
Stephen R. Biggar, M.D., Ph.D. was appointed to the Board in October 2005. Dr. Biggar has served as a Partner at Baker Brothers
Investments, a family of long-term investment funds for major university endowments and foundations, which is focused on publicly traded life
sciences companies, since October 2006, served as Principal from April 2002 to October 2006 and served as an Associate from April 2000 to
April 2002. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University. He attended
the University of Rochester where he achieved a B.S. degree in Genetics. Dr. Biggar serves as a director of one private biotechnology
company.
William W. Featheringill was elected a Director in May 1995. Mr. Featheringill is President, Chief Executive Officer and director, since
1973, of Private Capital Corporation, a venture capital company. He currently serves as Chairman of Electronic Healthcare Systems, Inc., a
system solutions provider to the ambulatory care industry, since June 1995, and Momentum Business Solutions, Inc., a telecom and VoIP
company, since May 2001. Mr. Featheringill is a Director of Altec Industries, Inc., Southern Research Institute and the Birmingham Museum
of Art, and serves as a Trustee of Vanderbilt University. Mr. Featheringill received a BE in Mechanical Engineering from Vanderbilt
University and a J.D. degree from the Columbia University School of Law and a M.B.A. from the Columbia University Graduate School of
Business.
Carl L. Gordon, CFA, Ph.D . was elected a Director in March 2004. Dr. Gordon is a founding General Partner of OrbiMed Advisors LLC,
an asset management firm focused on the global healthcare industry, and has served in such capacity since 1998. Dr. Gordon was previously a
senior biotechnology analyst at Mehta and Isaly, the predecessor firm to OrbiMed, from 1995-1997. Dr. Gordon received a Bachelor’s degree
from Harvard College, a Ph.D. in molecular biology from the Massachusetts Institute of Technology, and was a Fellow at the Rockefeller
University.
John L. Higgins was elected a Director in May 2004. Mr. Higgins is President and Chief Executive Officer of Ligand Pharmaceuticals Inc.,
a publicly traded biotech company, since January 2007 and has served as a director since February 2007. He was most recently Chief Financial
Officer at Connetics, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development since
January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive
management team at BioCryst. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read &
Co. Inc., an investment banking firm. He received his A.B. from Colgate University.
Zola P. Horovitz, Ph.D. was elected a Director in August 1994. Dr. Horovitz was Vice President of Business Development and Planning at
Bristol-Myers Squibb from 1991 until his retirement in April 1994 and previously was Vice President of Licensing at the same company from
1990 to 1991. Prior to that he spent over 30 years with The Squibb Institute for Medical Research, most recently as Vice President Research,
Planning, & Scientific Liaison. He has been an independent consultant in pharmaceutical sciences and business development since his
retirement from Bristol-Myers Squibb in April 1994. He serves as non executive Chairman on the Board of Directors of Avigen, Inc. and
GenVec, Inc., and also serves on the Boards of Directors of Genaera Pharmaceuticals, Inc., Palatin Technologies, Inc., DOV Pharmaceuticals,
NitroMed, Inc. and Immunicon Corporation.
Beth C. Seidenberg, M.D. was appointed to the Board in December 2005. Dr. Seidenberg has served as Partner of Kleiner Perkins Caufield
and Byers (“KPCB”) since May 2005. Prior to joining KPCB, Dr. Seidenberg served as Amgen’s Chief Medical Officer and Senior Vice
President, Global Development from January 2002 to December 2004, at Bristol-Myers Squibb Company as Senior Vice President, Global
Development from September 2001 to January 2002, Senior Vice President, Clinical Development & Life Cycle Management from May 2000
to September 2001 and Vice President, Clinical Immunology/Pulmonary/Dermatology from April 2000 to May 2000 and at Merck/Merck
Research Laboratories as Vice President, Pulmonary-Immunology from July 1998 to March 2000, Executive Director from March 1996 to
June 1998, Senior Director from September 1993 to February 1996 and also served as both Director and Associate Director of Clinical
Pharmacology from September 1991 to August 1993 and from June 1989 to August 1991, respectively. She received her M.D. from University
of Miami; completed post-doctoral training at Johns Hopkins Medical Center and specialty training in immunology and infectious diseases at
the National Institutes of
69
Table of Contents
Health. Dr. Seidenberg also has a B.S. degree in Biology and Anthropology from Barnard College. Dr. Seidenberg was appointed to the Board
as a designee of KPCB under a Nomination and Observer Agreement with the Company dated December 16, 2005.
Joseph H. Sherrill, Jr. was elected a Director in May 1995. Mr. Sherrill served as Chief Executive Officer and President of R. J. Reynolds
(“RJR”) Asia Pacific, based in Hong Kong, where he oversaw RJR operations across Asia, including licensing, joint ventures and a full line of
operating companies from August 1989 to his retirement in October 1994. Prior management positions with RJR include Senior Vice President
of Marketing for R.J. Reynolds International, President and Chief Executive Officer of R.J. Reynolds Tabacos do Brazil, and President and
General Manager of R.J. Reynolds Puerto Rico. Mr. Sherrill received his M.B.A. from Columbia University.
William M. Spencer, III has been a Director of BioCryst since our inception. Mr. Spencer, who is retired, is also a private investor in
Birmingham, Alabama. Mr. Spencer is a Founder of BioCryst, and served as our Chairman of the Board from our founding in 1986 until
April 1992. He co-founded and operated Motion Industries from 1946 through its merger into Genuine Parts Company in 1976. He has founded
several businesses and has served on the Board of Directors of numerous public and private corporations.
Randolph C. Steer, M.D., Ph.D. was elected a Director in February 1993. He is currently President and Chief Operating Officer of
OrthoLogic Corp., an Arizona-based biotechnology firm, since April 2006. Dr. Steer has been an independent pharmaceutical and
biotechnology consultant since 1989, and has a broad background in business development, medical marketing and regulatory affairs. He was
formerly Chairman, President and CEO of Advanced Therapeutics Communications International, a leading drug regulatory group, and served
as associate director of medical affairs at Marion Laboratories, and medical director at Ciba Consumer Pharmaceuticals. Dr. Steer serves on the
Board of Directors of Techne Corporation and several privately held companies and is trained as a clinical and chemical pathologist.
In accordance with the terms of our Certificate of Incorporation, the Board of Directors has been divided into three classes with members of
each class holding office for staggered three-year terms. In accordance with our By-Laws, a director elected to fill a vacancy shall be elected
for the unexpired term of his predecessor in office, and a director chosen to fill a position resulting from an increase in the number of directors
shall hold office until the annual meeting of stockholders of the Corporation at which term of the class of directors for which he has been
chosen expires. Dr. Bugg’s, Dr. Gordon’s, Mr. Higgins’s, and Dr. Seidenberg’s terms expire at the 2007 annual meeting. Mr. Featheringill’s,
Mr. Sherrill’s, Mr. Spencer’s and Mr. Stonehouse’s terms expire at the 2008 annual meeting. Dr. Bennett’s, Dr. Biggar’s, Dr. Horovitz’s and
Dr. Steer’s terms expire at the 2009 annual meeting (in all cases, subject to the election and qualification of their successors or to their earlier
death, resignation or removal). At each annual stockholder meeting, the successors to the directors whose terms expire are elected to serve from
the time of their election and qualification until the third annual meeting of stockholders following their election and until a successor has been
duly elected and qualified. The provisions of our Certificate of Incorporation governing the staggered director election procedure can be
amended only by a shareholder’s vote of at least 75% of the eligible voting securities. There are no family relationships among any of our
directors and executive officers. The Board has by resolution established the number of directors of BioCryst at twelve (12) commencing
January 5, 2007. Currently, the Board has determined that nine of our directors (Biggar, Featheringill, Gordon, Higgins, Horovitz, Seidenberg,
Sherrill, Spencer and Steer) are independent as defined by the current NASDAQ SM rules.
We have an Audit Committee, consisting of Directors Gordon, Higgins, Sherrill, and Steer, which is responsible for the review of internal
accounting controls, financial reporting and related matters. The Audit Committee also recommends to the Board the independent accountants
selected to be our auditors and reviews the audit plan, financial statements and audit results. The Board has adopted an Amended and Restated
Audit Committee Charter that meets all the applicable rules of the NASDAQ Stock Market LLC (“NASDAQ SM” ”) and the SEC. The Audit
Committee Charter can be found on our website at www.biocryst.com. The Audit Committee members are “independent” directors as defined
by NASDAQ SM listing standards in effect as of the date hereof and meet NASDAQ SM ‘s financial literacy requirements for audit committee
members. The Board of Directors has determined that Mr. Higgins qualifies as the “audit committee financial expert”.
We also have a Compensation Committee consisting of Directors Biggar, Featheringill, and Seidenberg. The
70
Table of Contents
Compensation Committee is responsible for the annual review of officer compensation and other incentive programs and is authorized to award
options under our Stock Option Plan. The Board has adopted a Compensation Committee Charter that meets all the applicable rules of the
NASDAQ SM and the SEC. The Charter can be found on our website at www.biocryst.com. The Compensation Committee members are
“independent” directors as defined by the NASDAQ SM listing standards in effect as of the date hereof.
We have a Corporate Governance and Nominating Committee comprised of all independent directors with terms not expiring in the current
year. The current members of the committee are Directors Biggar, Featheringill, Horovitz, Sherrill, Spencer and Steer. The Committee
nominates persons for election or re-election as directors. The Board has adopted a Corporate Governance and Nominating Committee Charter
that meets all the applicable rules of NASDAQ SM and the Securities and Exchange Commission and is available on our website at
www.biocryst.com. The Committee has established procedures/qualifications for selecting nominees and will consider nominees recommended
in writing, including biographical information and personal references, by stockholders. All submissions by shareholders should be sent
directly to the Chairman of the Board, Dr. Bugg at the corporate address.
We have adopted a Code of Business Conduct (the “Code”) applicable to all employees, including executive officers, and all Board
members. The Code is publicly available on our website at www.biocryst.com. Any waivers of the Code will be disclosed through a Form 8-K
filing with the Securities and Exchange Commission.
Section 16(a) Beneficial Ownership Reporting Compliance
Incorporated by reference from our definitive Proxy Statement to be filed in connection with the solicitation of proxies for our 2007 Annual
Meeting of Stockholders.
Incorporated by reference from our definitive Proxy Statement to be filed in connection with the solicitation of proxies for our 2007 Annual
Meeting of Stockholders.
ITEM 11. EXECUTIVE COMPENSATION
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT
Incorporated by reference from our definitive Proxy Statement to be filed in connection with the solicitation of proxies for our 2007 Annual
Meeting of Stockholders.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Incorporated by reference from our definitive Proxy Statement to be filed in connection with the solicitation of proxies for our 2007 Annual
Meeting of Stockholders.
Incorporated by reference from our definitive Proxy Statement to be filed in connection with the solicitation of proxies for our 2007 Annual
Meeting of Stockholders.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
71
Table of Contents
(a) Financial Statements
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
The following financial statements appear in Item 8 of this Form 10-K:
Balance Sheets at December 31, 2006 and 2005
Statements of Operations for the years ended December 31, 2006, 2005 and 2004
Statements of Stockholders’ Equity for the years ended December 31, 2006, 2005 and 2004
Statements of Cash Flows for the years ended December 31, 2006, 2005 and 2004
Notes to Financial Statements
Report of Independent Registered Public Accounting Firm on Financial Statements
Report of Independent Registered Public Accounting Firm on Internal Control
Page in
Form 10-K
46
47
48
49
50 to 63
64
65
No financial statement schedules are included because the information is either provided in the financial statements or is not required under the
related instructions or is inapplicable and such schedules therefore have been omitted.
(b) Exhibits
Number
Description
3.1
3.2
4.1
Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed
December 22, 2006.
Bylaws of Registrant as amended December 15, 2005. Incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed
December 16, 2005.
Rights Agreement, dated as of June 17, 2002, by and between the Company and American Stock Transfer & Trust Company, as
Rights Agent, which includes the Certificate of Designation for the Series B Junior Participating Preferred Stock as Exhibit A and
the form of Rights Certificate as Exhibit B. Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-A dated June 17,
2002.
10.1&
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, (formerly the 1991 Stock Option Plan), as amended and restated effective
March 7, 2006. Incorporated by reference to Appendix A to the Company’s definitive proxy statement filed April 10, 2006.
10.2#
License Agreement dated April 15, 1993 between Ciba-Geigy Corporation (now merged into Novartis) and the Registrant.
Incorporated by reference to Exhibit 10.40 to the Company’s Form S-1 Registration Statement (Registration No. 33-73868).
10.3&
Employee Stock Purchase Plan. Incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 Registration Statement dated
June 14, 2002 (Registration No. 333-90582).
10.4
Warehouse Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the Registrant for
office/warehouse space. Incorporated by reference to Exhibit 10.8 to the Company’s Form 10-Q for the second quarter ending
June 30, 2000 dated August 8, 2000.
10.5&
Employment Agreement dated March 17, 2004 between the Registrant and Charles E. Bugg, Ph.D. Incorporated by reference to
Exhibit 10.9 to the Company’s Form 10-Q for the first quarter ending March 31, 2004 dated May 11, 2004.
10.6&
Employment Letter Agreement dated February 1, 2005 between the Registrant and Randall B. Riggs. Incorporated by reference to
Exhibit 10.1 to the Company’s Form 8-K dated February 7, 2005.
10.7&
Employment Letter Agreement dated May 4, 2005 between the Registrant and Jonathan M. Nugent. Incorporated by reference to
Exhibit 10.1 to the Company’s Form 8-K dated May 10, 2005.
10.8#
License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and
BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second
Amendment Agreement dated as of April 15, 2005. (Portions omitted pursuant to request for confidential treatment.) Incorporated
by reference to Exhibit 10.1 to the Company’s Form 8-K dated November 30, 2005.
10.9#
Development and License Agreement dated as of November 29, 2005, by and between BioCryst Pharmaceuticals, Inc. and
F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Portions omitted pursuant to request for confidential treatment.)
Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K/A dated November 30, 2005.
72
Table of Contents
Number
10.10
Stock Purchase Agreement, dated as of December 14, 2005, by and among BioCryst Pharmaceuticals, Inc., Kleiner Perkins
Caufield & Byers, Texas Pacific Group Ventures and KPTV, LLC. Incorporated by reference to Exhibit 4.1 to the Company’s
Form 8-K dated December 16, 2005.
Description
10.11
Nomination and Observer Agreement, dated as of December 16, 2005, by and between BioCryst Pharmaceuticals, Inc. and Kleiner
Perkins Caufield & Byers. Incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K dated December 16, 2005.
10.12& Amended and restated Employment Letter Agreement dated February 14, 2007 between Registrant and Jon P. Stonehouse.
23
Consent of Ernst & Young, Independent Registered Public Accounting Firm.
31.1
Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#
&
*
Confidential treatment granted.
Management contracts.
Confidential treatment requested.
73
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized on this 14th day of March, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed by the following persons on behalf of the
registrant and in the capacities indicated on March 14, 2007:
BIOCRYST PHARMACEUTICALS, INC.
By: /s/Jon P. Stonehouse
Jon P. Stonehouse
Chief Executive Officer
Signature
/s/Jon P. Stonehouse
(Jon P. Stonehouse)
/s/J. Claude Bennett
(J. Claude Bennett, M.D.)
/s/Michael A. Darwin
(Michael A. Darwin)
/s/Charles E. Bugg
(Charles E. Bugg, Ph.D.)
/s/Stephen R. Biggar
(Stephen R. Biggar, M.D., Ph.D.)
/s/William W. Featheringill
(William W. Featheringill)
/s/Carl L. Gordon
(Carl L. Gordon, CFA, Ph.D.)
/s/John L. Higgins
(John L. Higgins)
/s/Zola P. Horovitz
(Zola P. Horovitz, Ph.D.)
/s/Beth C. Seidenberg
(Beth C. Seidenberg, M.D.)
/s/Joseph H. Sherrill, Jr.
(Joseph H. Sherrill, Jr.)
/s/William M. Spencer
(William M. Spencer, III)
/s/Randolph C. Steer
(Randolph C. Steer, M.D., Ph.D.)
Chief Executive Officer and Director
Title(s)
President, Chief Operating Officer, and Director
Chief Financial Officer (Principal Financial and Accounting
Officer), Secretary, and Treasurer
Chairman and Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
74
Table of Contents
INDEX TO EXHIBITS
Number
Description
Sequentially
Numbered
Page
3.1
3.2
4.1
10.1&
10.2#
Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the
Company’s Form 8-K filed December 22, 2006.
Bylaws of Registrant as amended December 15, 2005. Incorporated by reference to Exhibit 3.1 to the Company’s
Form 8-K filed December 16, 2005.
Rights Agreement, dated as of June 17, 2002, by and between the Company and American Stock Transfer & Trust
Company, as Rights Agent, which includes the Certificate of Designation for the Series B Junior Participating
Preferred Stock as Exhibit A and the form of Rights Certificate as Exhibit B. Incorporated by reference to
Exhibit 4.1 to the Company’s Form 8-A dated June 17, 2002.
BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, (formerly the 1991 Stock Option Plan), as amended and
restated effective March 7, 2006. Incorporated by reference to Appendix A to the Company’s definitive proxy
statement filed April 10, 2006.
License Agreement dated April 15, 1993 between Ciba-Geigy Corporation (now merged into Novartis) and the
Registrant. Incorporated by reference to Exhibit 10.40 to the Company’s Form S-1 Registration Statement
(Registration No. 33-73868).
10.3&
Employee Stock Purchase Plan. Incorporated by reference to Exhibit 99.1 to the Company’s Form S-8 Registration
Statement dated June 14, 2002 (Registration No. 333-90582).
10.4
10.5&
Warehouse Lease dated July 12, 2000 between RBP, LLC an Alabama Limited Liability Company and the
Registrant for office/warehouse space. Incorporated by reference to Exhibit 10.8 to the Company’s Form 10-Q for
the second quarter ending June 30, 2000 dated August 8, 2000
Employment Agreement dated March 17, 2004 between the Registrant and Charles E. Bugg, Ph.D. Incorporated by
reference to Exhibit 10.9 to the Company’s Form 10-Q for the first quarter ending March 31, 2004 dated May 11,
2004.
10.6&
Employment Letter Agreement dated February 1, 2005 between the Registrant and Randall B. Riggs. Incorporated
by reference to Exhibit 10.1 to the Company’s Form 8-K dated February 7, 2005.
10.7&
Employment Letter Agreement dated May 4, 2005 between the Registrant and Jonathan M. Nugent. Incorporated
by reference to Exhibit 10.1 to the Company’s Form 8-K dated May 10, 2005.
10.8#
License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial
Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of
July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005. (Portions omitted pursuant to
request for confidential treatment.) Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K dated
November 30, 2005.
10.9#
Development and License Agreement dated as of November 29, 2005, by and between BioCryst Pharmaceuticals,
Inc. and F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Portions omitted pursuant to request for
confidential treatment.) Incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K/A dated
November 30, 2005.
10.10
Stock Purchase Agreement, dated as of December 14, 2005, by and among BioCryst Pharmaceuticals, Inc., Kleiner
Perkins Caufield & Byers, Texas Pacific Group Ventures and KPTV, LLC. Incorporated by reference to Exhibit 4.1
to the Company’s Form 8-K dated December 16, 2005.
75
Table of Contents
Number
10.11
Description
Sequentially
Numbered
Page
Nomination and Observer Agreement, dated as of December 16, 2005, by and between BioCryst Pharmaceuticals,
Inc. and Kleiner Perkins Caufield & Byers. Incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K
dated December 16, 2005.
10.12&
Amended and restated Employment Letter Agreement dated February 14, 2007 between Registrant and Jon P.
Stonehouse.
23
Consent of Ernst & Young, Independent Registered Public Accounting Firm.
31.1
Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
32.2
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
83
84
85
86
87
#
&
*
Confidential treatment granted.
Management contracts.
Confidential treatment requested.
76
EXHIBIT 10.12
February 14, 2007
Jon Stonehouse
7 Pine Top Place
Durham, NC 27705
Dear Mr. Stonehouse:
This amended and restated letter agreement (the “Agreement”) will serve to confirm our agreement with respect to the terms and conditions
of your employment with BioCryst Pharmaceuticals, Inc. (“BioCryst” or the “Company”). As you know, this Agreement is identical in all
respects to the agreement originally executed on January 5, 2007, except that it reflects the fact that all of the initial equity awards under
Section 3 were issued under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
1. Term of Employment. Subject to the terms and conditions of this Agreement, BioCryst hereby employs Jon Stonehouse (the “Employee”),
effective January 5, 2007, as Chief Executive Officer of BioCryst, and Employee hereby accepts such employment. During the term of this
Agreement, BioCryst shall use its best efforts to provide that the Employee shall be elected as a member of the Board of Directors of BioCryst
(the “Board”). The Employee shall not, during the term of his employment, engage in any other business activity that would interfere with, or
prevent him from carrying out, his duties and responsibilities under this Agreement. Employee represents that he currently serves on the Board
of Directors of River West Health Care, LLC (a start-up company the business of which is not competitive with that of the Company) as well
as on an advisory council at Duke University, and that neither activity will interfere materially with his duties as contemplated hereunder.
BioCryst hereby acknowledges and approves such activities. BioCryst further agrees and acknowledges that any compensation which the
Employee receives from participation in any such allowable activities shall be outside the scope of this Agreement and in addition to any
compensation received hereunder. The term of employment of Employee under this Agreement shall commence as of the effective date set
forth above and shall continue for a period of one year, subject to earlier termination as provided herein; provided, however that the term shall
be automatically extended by one additional year on each anniversary of the effective date of this Agreement, unless one party to this
Agreement provides written notice of non-renewal to the other party at least 30 days prior to the date of such automatic extension.
2. Basic Full-Time Compensation and Benefits.
(a) As basic compensation for services rendered under this Agreement, Employee shall be entitled to receive from BioCryst, a salary of
$33,333 per month ($400,000 per annum) payable in arrears on the first business day of each month during the term of this Agreement,
beginning on February 1, 2007 for the month of January 2007. This salary will be reviewed annually by the Board of Directors and may be
raised at the discretion of the Board.
(b) In addition to the basic compensation set forth in (a) above, Employee shall be eligible to earn a cash bonus of up to $300,000,
payable as soon as reasonably practicable in calendar year 2008, based on the Company’s achievement of performance related goals
proposed by management and approved by the Board for the Company’s fiscal year ending December 31, 2007. The bonus actually earned,
if any, shall be based on a target amount of $200,000 for achievement of the performance goals, and shall be pro-rated or increased, as
applicable, based on the degree to which the performance goals have or have not been achieved or have been exceeded, subject to a
minimum level of achievement proposed by management and approved by the Board. The amount of the bonus earned in accordance with
the achievement of the performance goals, as described above, shall be prorated according to the percentage of the calendar year that
Employee is employed by the Company. The Company shall provide Employee with similar annual bonus opportunities for future fiscal
years during the term of this Agreement, in amounts that are commensurate with the performance of the Company and of Employee.
77
(c) In addition to the basic compensation set forth in (a) and (b) above, Employee shall be entitled to receive benefits and perquisites at
least as favorable as those provided to other executive officers of BioCryst, which benefits shall include, without limitation, reasonable
vacation, sick leave, payment of fees for Employee’s participation in the advisory council at Duke University, medical benefits, $1,000,000
of life insurance during the term of Employee’s employment, and participation in profit sharing or retirement plans. Notwithstanding the
foregoing, the Company’s obligation to provide $1,000,000 of life insurance for Employee shall be subject to Employee’s insurability at
rates customary for an individual of Employee’s age who is in average physical condition. In addition, the Company shall reimburse
Employee for his reasonable attorneys fees incurred in connection with the negotiation of this Agreement.
(d) In addition to the compensation set forth in paragraphs 2(a), (b) and (c) above, the Board of Directors of BioCryst may from time to
time, in its discretion, also grant such other cash or stock bonuses to the Employee either as an award or as an incentive as it shall deem
desirable or appropriate.
3. Initial Equity Awards. In connection with Employee’s execution of this Agreement, Employee shall be issued initial equity incentive
awards as follows:
(a) The Company shall, on the effective date hereof, grant to Employee an option to purchase 450,000 shares of the Company’s common
stock (“Common Stock”), with an exercise price equal to the fair market value of the Common Stock on the date of the grant. The option
shall vest and become exercisable contingent on Employee’s continued provision of services to the Company on each respective vesting
date, over a period of 4 years as follows: one year after Employee’s start date, 25% of the awards will vest; thereafter, the remaining shares
will vest on a monthly schedule of 1/48 of the total number of shares subject to the grants upon the completion of each month of service.
The option will be an “incentive stock option” to the maximum extent allowed by the tax code.
(b) The Company shall grant to Employee 50,000 shares of its Common Stock, which shall vest in two equal installments as follows: the
first installment shall vest two years after the Employee’s start date; the second installment shall vest four years after the Employee’s start
date. Employee understands and acknowledges that prior to vesting, the shares may not be transferred and will be subject to forfeiture.
(c) All awards will be issued under and shall be subject to the terms of the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and
specific award agreements between the Employee and the Company, which award agreements shall provide that Employee be entitled to
exercise any vested incentive stock option or any non qualified stock option for a period of two years subsequent to the termination or
expiration of Employee’s employment with the Company. All shares issuable pursuant to the awards in this Section 3 have been registered
on Form S-8.
4. Termination.
(a) If Employee’s employment is terminated (i) as a result of the Employee’s resignation or non-renewal of the term, (ii) as a result of the
Employee’s death, or (iii) by the Company for Cause, Employee will receive base salary, as well as any accrued but unused vacation (if
applicable) and other compensation, earned through the effective termination date, and no additional compensation; provided, however, that
in the event Employee’s employment is terminated as a result of the Employee’s death, and the Company has failed to procure and maintain
$1,000,000 in life insurance on the life of Employee in violation of its obligation pursuant to paragraph 3(c), the Company shall pay to the
Employee’s personal representative $1,000,000.
For all purposes under this Agreement, a termination for “Cause” shall mean a determination by the Board that Employee’s employment
be terminated for any of the following reasons: (i) a violation of a federal or state law or regulation that materially and adversely impacts the
business of the Company, (ii) conviction or plea of no contest to a felony under the laws of the United States or any state, (iii) a breach of
the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer
that materially and adversely impacts the Company, (iv) fraud or misappropriation of property belonging to the Company or its affiliates, or
(v) willful misconduct or gross negligence in connection with the performance of Employee’s duties; provided, however, that no act or
failure to act on the part of the Employee
78
shall be considered “willful” unless it is done, or omitted to be done, by the Employee in bad faith or without reasonable belief that the
Employee’s action or omission was in the best interests of the Company.
(b) If Employee’s employment is terminated (i) by the Company without Cause, (ii) upon non-renewal of the term by the Company,
(iii) as a result of a Constructive Termination, or (iv) by the Company as a result of Disability, the Company shall provide written notice of
termination to Employee, along with any base salary and accrued but unused vacation or other compensation earned through the effective
termination date.
In addition, and subject to the Employee (a) signing and not revoking a release of any and all claims against the Company, its officers,
directors and employees, (b) resigning from the Board (if applicable) on the date that employment terminates, and (c) returning to the
Company all of its property and confidential information that is in Employee’s possession, the Employee will receive:
(I) severance in an amount equal to the product of (x) two, except in the event the effective date of termination occurs within one year
of the effective date of this Agreement, in which case the severance multiplier shall be one, and (y) the sum of (1) Employee’s annual
base salary in effect immediately prior to the effective date of termination, and (2) Executive’s target bonus in effect for the fiscal year of
termination, which severance amount shall be paid in equal installments over the regularly scheduled payroll periods of the Company for
the two years following the effective date of termination, and
(II) if Employee elects to continue health insurance coverage under COBRA following termination of employment, the Company shall
pay the monthly premium under COBRA until the earlier of (1) twelve months following the effective date of termination, or (2) the date
upon which COBRA continuation coverage ceases.
“Disability” shall mean the inability of Employee to perform his duties hereunder by reason of physical or mental incapacity for ninety
(90) days, whether consecutive or not, during any consecutive twelve (12) month period.
“Constructive Termination” shall mean a resignation of employment within 30 days of the occurrence of any of: (i) a reduction in
Employee’s responsibilities or any change in the status or title of Employee with regard to his employment; (ii) a reduction in Employee’s
base salary, unless such reduction occurs prior to a Change in Control (as defined below) and is made in connection with a fiscal downturn
of the Company pursuant to which the base salaries of all executive officers of the Company are reduced by a comparable percentage; or
(iii) a relocation of Employee’s principal office to a location more than 50 miles from the location of Employee’s then-current principal
office.
(c) If, during Employee’s employment with the Company, there is a Change of Control, all equity awards granted to Employee under
paragraph 3 and otherwise shall vest in full. In addition, if Employee’s employment is terminated following the Change in Control, the
provisions of paragraph (a) or (b) above shall apply, as applicable; provided, however, that in the event the Employee’s employment is
terminated pursuant to paragraph (b) above following a Change in Control and within one year of the effective date of this Agreement, the
severance multiplier in paragraph 4(b)(I) above shall be two as opposed to one.
“Change of Control” shall be defined as (i) a merger or consolidation in which the Company is not the surviving entity, except for a
transaction the principal purpose of which is to change the State of the Company’s incorporation, (ii) the sale, transfer or other disposition of
all or substantially all of the assets of the Company in liquidation or dissolution of the Company, (iii) any reverse merger in which the
Company is the surviving entity but in which securities possessing more than fifty percent (50%) of the total combined voting power of the
Company’s outstanding securities are transferred to a person or persons different from the persons holding those securities immediately prior
to such merger, or (iv) any person or related group of persons (other than the Company or a person that directly or indirectly controls, is
controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of
Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the
79
Company’s outstanding securities pursuant to a tender or exchange offer made directly to the Company’s stockholders.
(d) In the event (i) any payments described in this paragraph 4 would be “deferred compensation” subject to Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”), and (ii) Employee is a “specified employee” (as defined in Code Section 409A(2)(B)(i)),
such payments shall, to the extent required by Code Section 409A, be delayed for the minimum period and in the minimum manner
necessary to avoid the imposition of the tax required by Code Section 409A.
5. Non-Competition; Proprietary Information and Inventions.
(a) Proprietary Information and Inventions Agreement . As a condition precedent to the employment of Employee by the Company,
Employee shall execute the Company’s standard Proprietary Information and Inventions Agreement, attached hereto as Exhibit A.
(b) Non-Competition Agreement . The Employee agrees that for one (1) year following the termination of this Agreement, the Employee
shall not become the Chief Executive Officer or become a key executive of another for-profit business enterprise whose activities are at such
time directly competitive with BioCryst.
(c) Equitable Remedies . Employee acknowledges and recognizes that a violation of this paragraph by Employee may cause irreparable
and substantial damage and harm to BioCryst or its affiliates, could constitute a failure of consideration, and that money damages will not
provide a full remedy for BioCryst for such violations. Employee agrees that in the event of his breach of this paragraph, BioCryst will be
entitled, if it so elects, to institute and prosecute proceedings at law or in equity to obtain damages with respect to such breach, to enforce the
specific performance of this paragraph by Employee, and to enjoin Employee from engaging in any activity in violation hereof.
6. Golden Parachute Provisions. If it is determined that any payment or benefit provided by the Company to or for the benefit of the
Employee, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, including, by example
and not by way of limitation, acceleration by the Company or otherwise of the date of vesting or payment under any plan, program,
arrangement or agreement of the Company would be subject to the excise tax imposed by Code section 4999 or any interest or penalties with
respect to such excise tax (such excise tax together with any such interest and penalties, shall be referred to as the “Excise Tax”), then the
Company shall first make a calculation under which such payments or benefits provided to the Employee are reduced to the extent necessary so
that no portion thereof shall be subject to the Excise Tax (the “4999 Limit”). The Company shall then compare (a) the Employee’s Net After-
Tax Benefit (as defined below) assuming application of the 4999 Limit with (b) the Employee’s Net After-Tax Benefit without application of
the 4999 Limit. The Employee shall be entitled to the greater of (a) or (b). “Net After-Tax Benefit” shall mean the sum of (i) all payments that
Employee receives or is entitled to receive that are contingent on a change in the ownership or effective control of the Company or in the
ownership of a substantial portion of the assets of the Company within the meaning of Code section 280G(b)(2), less (ii) the amount of federal,
state, local, employment, and Excise Tax (if any) imposed with respect to such payments. If the Employee is required to reduce payments to
which he is otherwise entitled such that no portion thereof is subject to the Excise Tax, the Employee shall choose which payments shall be
reduced and the amount of the reduction of each payment.
7. Miscellaneous.
(a) Entire Agreement . This Agreement, including the exhibits hereto, constitutes the entire agreement between the parties relating to the
employment of the Employee by BioCryst and there are no terms relating to such employment other than those contained in this Agreement.
No modification or variation hereof shall be deemed valid unless in writing and signed by the parties hereto. No waiver by either party of
any provision or condition of this Agreement shall be deemed a waiver of similar or dissimilar provisions or conditions at any time.
(b) Assignability . This Agreement may not be assigned without prior written consent of the parties hereto. To the extent allowable
pursuant to this Agreement, this Agreement shall be binding upon and
80
shall inure to the benefit of each of the parties hereto and their respective executors, administrators, personal representatives, heirs,
successors and assigns.
(c) Notices . Any notice or other communication given or rendered hereunder by any party hereto shall be in writing and delivered
personally or sent by registered or certified mail, postage prepaid, at the respective addresses of the parties hereto as set forth below.
(d) Captions . The section headings contained herein are inserted only as a matter of convenience and reference and in no way define,
limit or describe the scope of this Agreement or the intent of any provision hereof.
(e) Taxes . All amounts to be paid to Employee hereunder are in the nature of compensation for Employee’s employment by BioCryst,
and shall be subject to withholding, income, occupation and payroll taxes and other charges applicable to such compensation.
(f) Governing Law . This Agreement is made and shall be governed by and construed in accordance with the laws of the State of
Alabama without respect to its conflicts of law principles.
(g) Date . This Agreement is effective as of January 5, 2007.
(h) Counterparts . This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original copy of
this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. The exchange of copies of
this Agreement and of signature pages by facsimile or other electronic transmission shall constitute effective execution and delivery of this
Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by
facsimile or other electronic means shall be deemed to be their original signatures for all purposes.
81
If the foregoing correctly sets forth our understanding, please signify your acceptance of such terms by executing this Agreement, thereby
signifying your assent, as indicated below.
Yours very truly,
BIOCRYST PHARMACEUTICALS, INC.
COMPENSATION COMMITTEE
By: /s/ Beth C. Seidenberg
Beth C. Seidenberg, MD
Chairman
By: /s/ Steve Biggar
Steve Biggar, MD, PhD
By: /s/ William W. Featheringill
William W. Featheringill
Address:
2190 Parkway Lake Drive
Birmingham, Alabama 35244
AGREED AND ACCEPTED, as of this 14 day of February, 2007.
/s/ Jon Stonehouse
Jon Stonehouse
Address:
7 Pine Top Place
Durham, NC 27705
82
EXHIBIT 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
•
Registration Statements (Form S-8 Nos. 333-120345, 333-39484, 333-30751 and 33-95062) pertaining to the BioCryst
Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated as of March 8, 2004;
•
•
Registration Statement (Form S-8 No. 333-90582) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan;
Registration Statement (Form S-3 No. 333-128087) pertaining to the registration of up to $85,000,000 of BioCryst Pharmaceuticals,
Inc. common stock;
•
Registration Statement (Form S-8 No. 333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, which
amended and restated the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan as of May 17, 2006.
of our reports dated March 12, 2007 with respect to the financial statements of BioCryst Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc.
management’s assessment of the effectiveness of internal control over financial reporting, and the effectiveness of internal control over
financial reporting of BioCryst Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2006.
Birmingham, Alabama
March 12, 2007
/s/ ERNST & YOUNG LLP
83
Exhibit 31.1
I, Jon P. Stonehouse, certify that:
1.
I have reviewed this annual report on Form 10-K of BioCryst Pharmaceuticals, Inc.;
CERTIFICATIONS
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the
equivalent functions):
a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: March 14, 2007
/s/ JON P. STONEHOUSE
Jon P. Stonehouse
Chief Executive Officer
84
Exhibit 31.2
I, Michael A. Darwin, certify that:
1.
I have reviewed this annual report on Form 10-K of BioCryst Pharmaceuticals, Inc.;
CERTIFICATIONS
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under
our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made
known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be
designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the
equivalent functions):
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrant’s internal control over financial reporting.
Date: March 14, 2007
/s/ MICHAEL A. DARWIN
Michael A. Darwin
Chief Financial Officer and Chief Accounting
Officer
85
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending
December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jon P. Stonehouse, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that,
to the best of my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ Jon P. Stonehouse
Jon P. Stonehouse
Chief Executive Officer
March 14, 2007
This certification is furnished with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not,
except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
86
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ending
December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael A. Darwin, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that,
to the best of my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
/s/ Michael A. Darwin
Michael A. Darwin
Chief Financial Officer
March 14, 2007
This certification is furnished with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not,
except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
87